O-001
CRISPR-Cas based synthetic transcription factors: A strategy for improving bioproduction in CHO cells
Si Nga Sou, Dirk-Jan Kleinjan, Susan J. Rosser
Institute of Quantitative Biology, Biochemistry, and Biotechnology, School of Biological Sciences, University of Edinburgh, EH9 3FF, UK
Correspondence: Si Nga Sou (si.sou@ed.ac.uk)

Abstracts from the 25th European Society for Animal Cell Technology Meeting: Cell Technologies for Innovative Therapies
Lausanne, Switzerland. 14-17 May 2017
Published: 15 March 2018

Background
Despite advances in Chinese hamster ovary (CHO) cell bioprocess optimisation, production of large complex proteins remains costly and high degree of variability among final products is problematic. Novel strategies that target molecular pathways for high product yield and consistency are vital. To overcome this bottleneck, we developed a CRISPR-dCas based synthetic transcription factors (sTF) system that modulates expression of endogenous mRNA and miRNA targets involved in protein transport and glycosylation.

Materials and methods
sTF utilises two forms of Cas9 proteins: Endonuclease inactive ‘dead’ Cas9 (dCas9) with trans-activator domain (VPR) attached and native cutting Cas9 for transcriptional activation, or transfecting dCas9 with sgRNAs against their promoter regions for suppression (Vamp4). To lower galactosyltransferase (β1,4-GalT)-associated miRNA expression (cgr-miR-181d-5p, cgr-miR500 & cgr-miR501-5p), CHO cells were co-expressed with dCas9 and sgRNAs against miRNA promoters; or with native Cas9 and sgRNAs against mature miRNA sequences [1]. mRNA and miRNA levels of target genes were quantified by q-rt-PCR, protein level of β1,4-GalTs by western blot, and secreted IgG yield by IgG-ELISA.

Results
The dCas9 approach receives up to 60% increase in IgG expression, along with 1.2 to 2.5-fold rise in Napg, Rab5A and Aprc1b mRNA levels. While repressing Vamp4 transcription leads to a negative effect on IgG yield (Fig. 1b - c). Our results show positive correlation between pathways involved in protein transport and recycling, and recombinant protein (rProtein) yield. Both Cas9 and dCas9 approaches reduce miR-181d-5p, mirS00 & mirS01-5p by around 35-50%, this simultaneously enhances β1,4-GalT1 & 4 expression by up to 2-fold, which could be useful in future engineering of rProtein glycosylation profiles for specific function. This system also provides a platform for concurrent manipulation of multiple mRNA and miRNA with dCas9, where dCas9 expression can be further controlled via AID- or ecDFR-Degron technology [2].

Conclusions
Our works here present the potential of the CRISPRa/i system to easily reengineer or to study CHO cell metabolic pathways for more efficient rProtein production. The chemical inducible Cas9/dCas9 protein expression offers further control over multiple endogenous gene manipulation.

Acknowledgements
Authors thankfully acknowledge the Biotechnology and Biological Sciences Research Council for funding this research work. SNS thanks ESACT 2017 for providing her with the opportunity to present her work at the meeting.

References
1. Chang H, Yi B, Ma R, Zhang X, Zhao H, Xi Y. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Scientific Reports 2016. 6:22312.
2. Kleinjan D, Wardrope C, Sou S, Rosser S. A Toolkit of Tunable, Degron-tagged dCas9/Cpf1 Effectors for Multi-directional Drug-inducible control of Synthetic Gene Regulation. Nat Commun 2017 (In press).

Fig. 1 (abstract O-001). a Schematic representation of CRISPR based synthetic transcription factor technology. b mRNA expression levels of protein transport related genes (Napg, Rab5A and Aprc1b). c Quantification of secreted IgG production when CHO cells were transfected with dCas9-VPR/dCas9 and different sgRNAs.
Degradation of recombinant proteins of diverse formats by CHO host cell proteases is circumvented via knock-out of CHO matriptase

Holger Laux, Sandrine Romand, Joel Tapparel, Sandro Nuciforo, Stine Buechmann-Moller, Guislay Dogrusoz, Sandra Haas, Benjamin Sommer, Edward J. Oakley, Ursula Bodendorf

¹Novartis (BTDM), Basel, 4056, Switzerland; ⁸Novartis (NIBR), Basel, 4056, Switzerland

Correspondence: Holger Laux (holger.laux@novartis.com)

Background
An increasing number of biologics are entering the development pipelines of pharmaceutical companies [1]. Today, the preferred production host for therapeutic proteins is the CHO cell line. However one of the major hurdles, especially for the production of non-antibody glycoproteins, is host cell-related proteolytic degradation which can drastically impact developability and timelines of pipeline projects.

Material and methods
Spike-in: CHO cells were cultivated in a chemically defined culture medium at 36.5°C/10% CO₂ in shake-flasks. When the cells reached their maximum viable density, they were removed by centrifugation and the conditioned medium was collected. A model mAb was spiked into the conditioned medium and incubated at 37°C ± protease inhibitors. The amount of proteolytic degradation was analysed by western blot and LC-MS.

Transcriptomics: Total RNA was extracted after 3 days of cell cultivation. RNA sequencing libraries were constructed and processed on the HiSeq 2000 platform from Illumina.

Generation of matriptase knockout: CHO-K1 cells were transfected with mRNA encoding “transcription activator-like effector nucleases” or “zinc finger nucleases” targeting matriptase exon 2. The transfected cells were subsequently sorted into single cells and analysed for frameshift mutations in both alleles via Sanger sequencing.

Cell cultivation: Fed batch cultivation was performed in 15-mL miniaturized bioreactors (AMBR15).

Results
Approximately 700 proteases are known in rodents. To reduce the number of candidate proteases we showed first that a model mAb (prone to proteolytic degradation) incubated in conditioned medium of CHO-K1 cells resulted in clipping of the mAb, demonstrating the involvement of secreted/shedded S1A trypsin-like serine proteases (Fig. 1a). Broad spectrum inhibitors of the different protease classes revealed that only serine protease inhibitors prevented clipping. Serine protease inhibitors of higher specificity highlighted the group of "S1A trypsin-like proteases" (Fig. 1a).

Comparison of the proteolytic degradation profile of several therapeutic proteins between CHO-K1 with another CHO cell line (CHO-A) revealed less degradation in CHO-A. Therefore expression of the involved protease(s) is likely lower in CHO-A. Gene expression profile analysis of both cell lines showed five secreted/shedded "S1A trypsin-like serine proteases" more than 1.5 fold lower expressed in CHO-A compared to CHO-K1 (Fig. 1b). Surprisingly, siRNA knockdown experiments of these five candidates identified "Matriptase" as the major protease involved in degradation of recombinant proteins expressed in CHO-K1 cells (Fig. 1c upper panel).

Next, we generated a CHO-K1 matriptase knockout (KO) cell line. No proteolytic degradation product was detected when the model mAb was spiked into conditioned medium of the KO cell line (Fig. 1c lower panel). Also, stable expression of the model mAb in the KO cell line resulted in no/significantly less clipping (Fig. 1e). The protein titer and the cell growth behaviour of the matriptase KO cells were similar to the corresponding wildtype (wt) cells (Fig. 1d) as shown by comparative cultivation in AMBR system.

Conclusions
One major challenge for the production of recombinant proteins is CHO host cell mediated proteolytic degradation which can negatively impact or even result in termination of projects [2; 3].

Using a variety of techniques such as applying protease inhibitors, transcriptomics and siRNA mediated knock-down we were able to identify "matriptase" as the major protease involved in degradation of recombinant proteins expressed in CHO-K1 cells. Subsequently we generated a matriptase deficient CHO cell line. Protein candidates of diverse formats, severely degraded in wt CHO-K1 cell line, were not or significantly less cleaved in the matriptase KO cell line. Furthermore cell growth, viability and productivity levels were comparable between the wt and the matriptase KO cell line. In summary, we have generated a superior platform-compatible CHO production host cell line with the same favourable productivity properties as the parental host cell line [4; 6], allowing expression of complex glycoproteins prone to clipping.

Acknowledgements
We would like to thank Moritz Frei for his support for the generation of the NGS transcriptomics data.

References
1. Walsh (2014) Biopharmaceutical benchmarks 2014. nature biotechnology. 32: 11.
2. Dorai, H., J. F. Nemeth, E. Cammaart, Y. Wang, Q. M. Tang, A. Magill, M. J. Lewis, T. S. Raju, K. Picha, K. O’Neil, S. Ganguly, and G. Moore (2009) Development of mammalian production cell lines expressing CNTO736, a glucagon like peptide-1-MIMETBODY: factors that influence productivity and product quality. Biotechnol Bioeng. 103: 162-176.
3. Robert, F., H. Bierau, M. Rossi, D. Agugiaro, T. Soranzo, H. Broly, and C. Mitchell-Logean (2009) Degradation of an Fc-fusion recombinant protein by host cell proteases: Identification of a CHO cathepsin D protease. Biotechnol Bioeng. 104: 1132-1141.
4. Ritter, A., B. Voedsch, J. Wienberg, B. Wilms, S. Geisse, T. Jostock, and H. Laux (2016) Deletion of a telomeric region on chromosome 8 correlates with higher productivity and stability of CHO cell lines. Biotechnol Bioeng. 113: 1084-1093.
5. Ritter, A., T. Rauschert, M. Oertli, D. Pielimaier, P. Mantas, G. Kunzelmann, N. Lageyere, B. Brannetti, B. Voedsch, S. Geisse, T. Jostock, and H. Laux (2016) Disruption of the gene C12orf35 leads to increased productivities in recombinant CHO cell lines. Biotechnol Bioeng. 113: 2433-2442.
6. Ritter, A., S. Nuciforo, A. Schulze, M. Oertli, T. Rauschert, B. Voedsch, S. Geisse, T. Jostock, and H. Laux (2016) Fam60A plays a role for production stabilities of recombinant CHO cell lines. Biotechnol Bioeng.
Matriptase knock-out in CHO cells prevents clipping of recombinant proteins. a Serine protease inhibitors protect model mAbs from proteolytic degradation in CHO-K1 cell derived conditioned medium. The model mAb was incubated in conditioned medium for 0h or 48h at 37°C, subsequently samples were analyzed by western blot. Broad spectrum serine protease inhibitors (Aprotinin, Leupeptin) were added during incubation. Aprotinin and Leupeptin are inhibiting proteolytic degradation. The intact mAb (upper band) and the clipped mAb (lower band) are indicated by arrows. b Gene expression profiling of CHO-K1 versus CHO-A by NGS. Shown is the gene expression profile of “secreted/shedded members of the S1A trypsin-like serine protease family” for CHO-K1 and CHO-A cell lines using next generation sequencing. The gene expression analysis highlights that five proteases were more than 1.5 fold higher expressed in CHO-K1 cells (labelled with a red asterix). The y-axis shows the transcript abundance as RPKM (Reads Per Kilobase of exon model per Million mapped reads). c siRNA knock-down identifies matriptase as major clipping protease and CHO matriptase KO clone shows no detectable clipping activity. Upper figure: siRNAs directed against the five protease genes and scrambled (scr.) siRNA were transfected and conditioned medium was collected three days after transfection. The model mAb was incubated in fresh medium as control (first lane) and conditioned medium from the siRNA transfected cells. Samples were analyzed by western blot. Only siRNA targeting matriptase (ST14) showed reduced proteolytic degradation. The intact mAb (upper band) and the clipped mAb (lower band) are indicated by arrows. Lower figure: The model mAb was incubated for 48h in conditioned medium collected from wt CHO-K1 as well as the matriptase knockout clone. Samples were analyzed by western blot. The intact mAb (upper band) and the clipped mAb (lower band) are indicated by arrows. No proteolytic degradation could be detected in the samples originating from the matriptase KO clone. d Cell growth, viability and productivity of cell culture to meet the rapidly growing demand for antibody biopharmaceuticals through increased cell densities and longer culture times. The downside is the increase of the process related impurities, bringing new challenges for process and harvest development. Among the process related impurities such as host cell proteins (HCPs) or DNA the potential impact of lipids production and release during cell culture is still poorly understood due to the complex nature and diversity of this class of molecules. Thanks to recent advances in analytical tools especially mass spectrometry, the advent of lipidomics offers now the feasibility to study several thousands of lipid species thus unraveling the possibility to understand and potentially control the interactions between high performance bioreactor processes, harvest conditions and purification. e Materials and methods In order to analyze and quantify lipids, we developed a three steps method. In a first step, lipids were extracted with Methyl tert-butyl ether (MTBE) according to Matyash method [1]. Lipids were then separated by liquid chromatography using either HILIC of reverse phase column prior to detection and quantification by mass spectrometry. All lipid classes were detected by ESI-MS/MS except cholesterol (APCI-MS/MS). Finally we applied this method to analyze the lipid content of different cell lines each expressing a different recombinant protein, during a 14 days fed batch process.

Results

Lipid from CHO cells were successfully extracted with a yield between 80% and 95% depending on the different lipid classes. Stable isotope labeled lipids were used as internal standard in order to have comparable results between batches. The obtained results (Fig. 1) show that for a given cell line, lipid distribution is changing over the process. Moreover, this distribution may vary significantly depending on the cell line: CL-1 and in a lower extend, CL-3, show an accumulation of triglycerides from day 6 to the end of the process, while CL-2 doesn’t seem to follow this trend.

Conclusion

Interestingly, in some cell lines/experimental conditions, we highlighted an overproduction of triglycerides and cholesterol leading to the accumulation of lipid droplets known as energy storage sink. At the metabolic level, these findings suggest a relative over-flow of the carbon metabolism. From a process development perspective these findings can be considered on the one hand as a resource waste since the stored energy is not used for protein/biomass biosynthesis and on the second hand as the root cause of additional process challenges especially during the harvest and the first capture steps given the hydrophobic nature of these molecules. Implementation of lipidomics analysis enables us to highlight a new type of process variability and to anticipate potential problems for the downstream steps. The application of this methodology on our platform has helped us to design tailor made solutions (pretreatment selection, filter selection,…) at the clarification step which are now implemented in our harvest development platform approach.

Acknowledgments

Many thanks to Valentine Chevaller for her precious advices, to Stefanos Grammatikos for his support and to the whole Upstream Process Sciences team.
High throughput analysis of antibody glycosylation in cell culture samples

Sebastian Giehring, Kristina Lechner, Christian Meissner, Anna Johann, Christine Wosnitza
PAIA Biotech GmbH, Cologne, D-51105, Germany
Correspondence: Sebastian Giehring (sebastian.giehring@paiabio.com)
BMC Proceedings 2018, 12(Suppl 1):O-020

Background

The glycosylation of therapeutic proteins is a critical quality attribute (CQA) and needs to be analyzed during cell line and bioprocess development. The current methods for analyzing glycosylation are mainly based on the enzymatic release of glycans. They are tedious and offer only limited throughput, which makes them unsuitable for cell line development work. In this study we evaluated a novel PAIA assay for measuring intact glycoproteins with capture beads and fluorescence labeled plant lectins to analyze glycans in a high throughput 384-well plate format.

Material and methods

Analytes: Erbitux®, Mabthera®, Arzerra® and Avastin®. Two glyco-engineered variants of one IgG were kindly provided by Merck (Vevey, Switzerland) for providing the IgG glycan variants and the 2-AB-UPLC glycan data.

Anlayses were spiked into CHO-K1 cell culture supernatant or buffer, diluted 1:1 with a denaturation solution and incubated at 65 or 70°C for 20 minutes to expose the Fc glycans. Erbitux samples were analyzed under denaturing conditions to detect Fab- and Fc-glycosylation and in native conditions for Fab glycosylation only. 10μL of pretreated sample was added to each well of the special 384-well PAIAplate, containing labeled lectin and capture beads. The microplate was incubated for 45 minutes at 1800 rpm on an orbital shaker at room temperature and spun down at 500 xg. The read-out was done on a fluorescence microscope (SytenTec, Elmshorn, Germany) in less than five minutes.

Results

Figure 1a: Lectin binding profiles of different IgGs. The analysis of different IgG results in lectin binding profiles which show the different degrees in glycosylation. High abundance of sugars leads to high binding rates of the lectin for the respective sugar. Avastin has a very low degree of galactosylation and high mannose species compared to Mabthera and Arzerra (Fig. 1a). Only Arzerra is carrying glycans with 2-6 linked sialic acids. These findings are in line with results from literature [1].

Figure 1b: Distinction between Fc and Fab glycosylation in Erbitux. Without denaturation only the Fab glycans are detectable in Erbitux. Denaturation leads to additional exposure of the Fc glycans and thus higher lectin binding rates compared to native Erbitux. GNA and NPL only bind to denatured Erbitux indicating that the high mannose glycans are only present on the Fc part. The equal SNA binding rates for both conditions confirm that the 2-6 linked sialic acids are almost exclusively found on the Fab part. This is in agreement with published data [2].

Figure 1c: Lectin binding rates correlate with the levels of galactosylation and fucosylation. Increasing degrees of glycosylation in the mixtures of the glycan variants from Merck lead to higher lectin binding rates for all galactose and fucose markers proving that quantitative analysis can be performed with these assays. The ConA lectin which binds to the common core mannose glycan motive remains at the same level, suggesting that the Fc glycans were similarly exposed in all samples.

Conclusions

The results demonstrate that PAIA assays are capable of quickly detecting differences in glycan patterns of different antibodies. In addition it was shown that glycan variants of the same IgG can be analyzed quantitatively. And finally we could confirm the differences in Fab and Fc glycosylation in Erbitux. We believe that bead-based assays with lectins have a great potential for monitoring product quality early in the development process.

Acknowledgements

We thank David Bruehlmann and Thomas Vuillemin from Merck (Vevey, Switzerland) for providing the IgG glycan variants and the 2-AB-UPLC glycan data.

References

1. Fuller, S. et al.: Assessing the Variability of an Innovator Molecule N-Glycan Profile. Poster Prozyme Inc. 2012.
2. Ayoub D, et al.: Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. Mabs 2013 Vol 5,5, 699-710.

Table 1 (abstract O-020). Specificity of lectins

| Lectin | Specificity |
|--------|-------------|
| LCA    | Core Fucose |
| PSA    | Core Fucose |
| ECL    | Terminal β-Gal |
| RCA    | Terminal β-Gal |
| GNA    | High Mannose |
| NPL    | High Mannose |
| SNA    | Sia α 2-6 Gal |
| MAL-II | Sia α 2-3 Gal |
| ConA   | Core Mannose |
adventitious agents into the production process. Correspondingly, the PEI transfection reagent must also be sourced from a qualified supplier, and have gone through rigorous testing to ensure reliable transfection efficiencies, and hence reproducible virus production yields.

Here, we present PEIpro® and PEIpro®-HQ, the unique PEI-based transfection reagents suitable for use in process development and in cGMP biomanufacturing, respectively. Unlike commercially available PEIs, PEIpro® benefits from extensive research and development in polymer chemistry and formulation for mammalian cell transfection. We further demonstrate that PEIpro® and PEIpro®-HQ are the reagents of choice for virus production runs in most cell culture systems, hence facilitating the transition from initial optimization during process development up to large-scale therapeutic viral vector production in adherent or suspension cells.

**Materiel and methods**

**Manufacturing process of PEIpro® and PEIpro®-HQ reagents.**

PEIpro® and PEIpro®-HQ are fully synthetic reagents, free of any animal-origin components. In comparison to PEIpro®, a more extensive number of Quality Controls are performed on PEIpro®-HQ to enable its use as a qualified raw material in GMP processes for the manufacturing of clinical batches of therapeutic products.

**Lentivirus and AAV production.**

Irrespective of the cell culture vessel type, transfection using PEIpro® was performed following our recommendations. As an example, HEK-293T (lentivirus) and HEK-293 (AAV) cells were thawed directly into each medium and passaged every 3 to 4 days before going into a 2 L benchtop bioreactor. Cells were resuspended and cultured for 3 days before transfection with PEIpro®. HEK-293T cells were transfected with a third-generation system (four plasmids) for lentivirus production. HEK-293 cells were co-transfected with three plasmids for AAV production. Lentiviral and AAV titers were measured 48 and 72 hours post-transfection (Data kindly provided by Généthon).

**Results**

PEIpro® is the reagent of choice for virus production runs in most adherent and suspension cell culture systems from process development up to large scale clinical-grade virus production. Irrespective of the cell culture-based system and production scale, PEIpro® and PEIpro®-HQ have led to efficient viral vector yields in standard laboratory cell systems, such as in flasks, cell factories, and roller bottles, as well as in multilayers flakes or fixed-bed culture systems that take into account time and space concerns for the scaling-up process (Table 1).

For example, high viral vector yields superior to $10^7$ VG/mL and $10^{11}$, $10^{12}$ VG/mL were obtained respectively for lentiviruses and AAVs in suspension HEK-293T and HEK-293 cells cultured in one of the commercially available synthetic cell culture medium BalanCD® HEK293 (Irvine Scientific®).

**Conclusion**

PEIpro® and its higher quality grade PEIpro®-HQ are the unique PEI reagents suitable for efficient and reproducible production of therapeutic viral vectors. Efficient viral vector production yields can be achieved in most cell culture systems, irrespective of the production scale. With appropriated and advanced quality controls, the highest quality grade PEIpro®-HQ is commercially available to accompany academics and biopharmaceutical companies in terms of qualified raw material for their GMP-grade viral vector production needs.

**Acknowledgments**

Polyplus-transfection would like to thank Généthon for their kindly provided data.

**Reference**

1. Merten et al. Methods & Clinical Development 3:16017 (2016).
Table 1 (abstract P-004). PEIpro®, the reagent of choice for virus production runs in most cell culture systems in both adherent and suspension cells. Irrespective of the cell culture-based system and production scale, PEIpro® and PEIpro®-HQ have led to efficient viral vector yields superior to 10^7 IU/ml and 10^10 VG/ml, respectively for lentiviruses and AAVs.

| Cell culture system                | Vector | Cells   | Titer          |
|-----------------------------------|--------|---------|----------------|
| CS10®/CF10®                       | AAV    | Adherent HEK-293, HEK-293T | 10^10-10^13 IU/ml |
| Fixed-bed bioreactor (iCELLIS®)   | AAV    | Adherent HEK-293T           | 10^14-10^16 VG/ml |
| Shaker Flask                      | AAV    | Suspension HEK-293, HEK-293T| 10^7-10^10 VP/ml  |
| Bioreactor                        | AAV    | Suspension HEK-293, HEK-293T| 0.8-1.5 x10^6-10^9 VG/ml |
| 10 cm dish/75 cm²                 | Lentivirus | Adherent HEK-293, HEK-293T | 1-2 x10^8 TU/ml |
| HYPERflask®                       | Lentivirus | Adherent HEK-293, HEK-293T | 1-2 x10^8 TU/ml |
| HYPERstack®                       | Lentivirus | Suspension HEK-293F, HEK-293T | 2 x 10^7-10^10 VP/ml |
| Shaker Flask                      | Lentivirus | Suspension HEK-293, HEK-293T | 10^7 IU/ml |
| Bioreactor                        | Lentivirus | Suspension HEK-293, HEK-293T | 10^7 IU/ml |

Fig. 1 (abstract P-004). Lentivirus and AAV production in HEK-293T and HEK-293 cells grown in suspension in BalanCD® HEK293 (Irvine Scientific®), HEK-293T (lentivirus) and HEK-293 (AAV) cells were thawed directly into each medium and passaged every 3 to 4 days before going into a 2 Liter benchtop bioreactor. Cells were seeded and cultured for 3 days before being transfected by PEIpro® (Polyplus). For transfection, four plasmids were used for lentivirus and three plasmids were used for AAV. Lentiviral and AAV titer were measured 48 and 72 hours post transfection (Data kindly provided by Généthon).

P-014

Inoculum performance under different culture conditions: “One clone, multiple behaviour”

Chandrashekar K. Nanjegowda, Sasikumar Karunakaran, Kumanar Sivalingavasu, Ritika Lakhota, Sohini Jana, Reetesh P. Mahalinganavar, Dinesh Baskar, Saravanan Desan, Ankur Bhatnagar, Anuj Goel

Cell Culture Lab, Biocon Research Limited, Biocon Special Economic Zone, Plot No. 2 & 3, Bommasandra Jigani Link Road, Bangalore 560 099, India

Correspondence: Chandrashekar K. Nanjegowda (chandrashekar.kuravangi@biocon.com)

BMC Proceedings 2018, 12(Suppl 1):P-014

Background

In mAb manufacturing processes, production bioreactor step is considered to be crucial as the product is produced in this step. However, the cells spend a significant portion of process time in the inoculum stage starting from vial thaw to expansion in shake flasks and seed bioreactors. During these stages, the cells encounter environmental changes in parameters like pH, Osmolality, concentration of nutrients and waste metabolites. These small changes can have a profound impact on the cells when experienced over multiple passages. The effect of this cumulative impact is not apparent during the seed stage(s) but can be evident in the production step.

In this work, we present the data from experiments with cells maintained under different inoculum culture conditions and evaluating its behaviour in terms of growth performance in production bioreactor. The following case studies were conducted where the changes were made in the inoculum step. The cells from the inoculum step which were exposed to these changes over multiple passages were used to run production batches with control conditions and the impact in the production step was observed as a response.

Case Study 1: Effect of incubation at different CO2 levels
Case Study 2: Effect of incubation at different Temperature
Case Study 3: Modification of seed medium buffer composition

Materials and methods

Table 1

Results

Results indicated that when the cells were subjected to various culture conditions for multiple passages (like different temperature, CO2 levels and medium composition), the growth in inoculum stages (doubling time and viability) did not get impacted. However, when these cells were used in the production bioreactor, significant impact was observed on process performance.

As illustrated in the Fig. 1a, the cells which were maintained at higher CO2 levels and lower temperature during inoculum stages showed improved cell concentration in the production bioreactor. However, the cells sub-cultured in higher temperature showed reduced growth performance. When the cells were maintained in the same media with two different buffering components (Fig. 1b), a shift in lactate production was observed in the inoculum stage itself. These effects became predominant in production culture. The ability to modulate the inoculum conditions was exploited to improve cell line stability. In one of the clone, cell growth and viability in the production bioreactor was observed to decrease with the increase in age of inoculum (Fig. 1c & d). However with the use of alternate medium (buffering, medium components and culture conditions) used for sub-culturing, improvement in cell line stability was achieved.

Conclusions

The results of our experiments indicate that cells when maintained under different inoculum culture conditions can behave significantly different when used in the production process. We also identified that these conditions impact the overall cell line stability of a clone. Hence a thorough understanding of the cells and its metabolism is required. The parameters which predict its behavior must be controlled as per the requirement of the process. Manipulation of culture conditions suitably in the early inoculum propagation steps enables improving performance and stability of a cell line, thereby increasing process robustness. Also, we propose that the model to study the inoculum parameters effect should include production run where the impact of the inoculum parameters will be more pronounced.

Acknowledgements

Cell Culture Team, Biocon
Results

Case 1: Comparison between fed-batch and perfusion process

The Perfusion run yielded 5-fold higher titer compared to Fed batch run (Fig. 1a). Considering the number of runs that could be executed in a manufacturing facility within the same calendar days, about 1-fold increase in product output can be achieved with the perfusion process (Fig. 1a). This difference is attributed to higher IVCC, higher PCD and longevity of cells because of decreased level of toxic metabolite concentrations such as lactate and ammonia.

Case 2: Understanding product retention in perfusion process

The new-age perfusion processes utilize hollow fiber filters. This has been observed to cause retention of product within the bioreactor especially towards the end of the production run. Two types of experiments were conducted to study the factors contributing to product retention:

- Spiking studies:
  - Role of product titer: product was spiked into chemically defined media
  - Role of different cell viability: different broths with varying viability spiked with same product titer
  - Evaluation of different hollow fiber membrane (M1, M2 and M3) on product retention.

From spiking studies, it was evident that cell debris and poor quality cell broth (lower viability) were the major factors contributing to product retention (Fig. 1c). From the different membranes experiments, it was identified that at Pilot scale, M1 showed much higher retention from the first perfusion cycle itself and it increased to more than 75% towards the end of the batch. However, with M2 membrane, product retention started only late (after 50% of batch duration) and it remained low (~20-40%). On the contrary, this difference was not observed at 1L scale due to the usage of membranes with larger filter area (2-3 folds higher compared to pilot scale). When the filter area per unit volume of perfusate was decreased by half (M2_Batch 4) for the pilot scale, even M2 showed retention profile similar to M1 (Fig. 1d).

Conclusions

We presented data to show that perfusion process has 5-fold increase in product yield on a per-batch basis and a 3-fold increase when facility throughput is considered. Product retention is a technical challenge that requires optimization (perfusion rates and filter membrane types). We believe it is imperative that labs that develop processes for biologics can now consider both perfusion and fed-batch based processes as both these technologies can now closely compete with each other. The choice of the process format going forward should now solely be dependent on the requirement for the biologic rather than the earlier perception that fed-batch is the preferred choice because of its simplicity.

Acknowledgements

Asmita Mukerji, Reetesh PM, Sasi Kumar K, Pilot plant team

Table 1 (abstract P-015). Material and methods used for the work described

| Parameter | Description |
|-----------|-------------|
| Cell lines | Recombinant CHO cells expressing monoclonal antibody |
| Media | Chemically defined cell culture media |
| Process mode | Fed-batch and Perfusion |
| Analysis | Cell concentration and viability were determined using automated cell counters (Cedex HiRes), Product titer of perfusate and harvest were measured using Protein A HPLC |
Differential analysis of IgG product quality by intact mass analysis for fed-batch-cultivated CHO cells under glucose limitation

Benjamin Müller1, Anica Schmidt2, Christoph Heinrich3, Heino Büntemeyer1
1Biofidus AG, Bielefeld, 33613, Germany; 2Institute of Cell Culture Technology, Bielefeld University, Bielefeld, 33615, Germany; 3Xell AG, Bielefeld, 33689, Germany

Correspondence: Benjamin Müller (benjamin.mueller@biofidus.de)

BMC Proceedings 2018, 12(Suppl 1):P-023

Background

Chinese hamster ovary (CHO) cell culture has been widely used for production of monoclonal antibodies in the pharmaceutical industry. Previous studies have shown that the cell specific productivity in CHO cells can be increased by glucose limitation [1]. Introducing a productivity enhancing effect it is possible that this also affects the quality of the product such as glycosylation or other posttranslational modifications. In this work, we are focusing on the impact of glucose limitation and increased productivity on the product quality of a monoclonal antibody produced in a fed-batch cultivation of CHO cells.

Materials and methods

CHO cells were cultivated both under limiting and non-limiting nutrient conditions in fed-batch. For fed-batch cultivation the reduced range for glucose concentration was chosen between 0.2 and 0.5 g/L. Reference cultivation was performed between 1.5 and 3.0 g/L. Both cultures were fed with similar volumes of a complex nutrient supplement. All cultivations were performed in chemically-defined, animal-component free CHO growth media (Xell AG). Viable cell density and viability were determined using the automated cell counting system CEDEX (Roche Diagnostics), glucose and lactate concentrations were detected via YSI (YSI life sciences). Amino acid were quantified using HPLC-FLD, vitamins were quantified using reversed phase chromatography coupled to a triple quadrupol mass spectrometer (Varian 320, selected reaction monitoring). Amounts of IgG1 were quantified via Protein A HPLC, mAb purified from another CHO cell clone was used as a standard. The analysis of product quality was performed by intact mass analysis using reversed phase chromatography coupled to a microOTOF-Q II mass spectrometer (Bruker Daltonik).

Results

The CHO cell culture cultivated under low nutrient conditions reached a 54% higher viable cell density than the reference culture (Fig. 1a). The product titer was even increased by 109% (Fig. 1b). The spent media analysis shows that some amino acids and vitamins were present at presumably limiting concentrations after day 5/6, mostly in the low nutrient level culture (down to 40 to 190 μM for TYR, GLN, ARG, and ASN, below 1 μM for pyridoxine, data not shown). The product quality showed significant changes for the changed feeding strategy (Fig. 1c and d). As expected, the glycation level decreased from 3% to 1% compared to the reference culture. The truncation level of C-terminal lysine at the heavy chain of the mAb increased from 79% to 88%. The glycosylation was also significantly influenced by the low nutrient level (Fig. 1e): The non-fucosylated variants increased from 3% to 6% (Fig. 1f), the degree of galactosylation increased from 31% to 39% (Fig. 1g).

Conclusions

Cultivation under low nutrient level led to 54% higher viable cell density and a product titer increased by 109% when compared to reference culture grown under non-limiting nutrient conditions. The analysis of product quality reveals 75% less glycation of light chain for CHO cells grown under low nutrient conditions (0.7% vs. 2.7% in reference culture). The truncation of C-terminal lysine decreased by 10% (from 88% to 79%), the degree of galactosylation increased by 23% (from 31% to 39%, also observed by Takuma et al. [2]) and non-fucosylated glycans increased by 105% (from 2.8% to 5.8%) under low nutrient conditions. The product quality analysis by intact mass proved to be highly robust (average CV for four replicates = 2%).

In summary, cultivation with alternative feed led to higher IgG product titer and better product quality (glycation unwanted, higher amount of non-fucosylated glycans leads to higher antibody-dependent cell-mediated cytotoxicity (ADCC), higher amount of galactosylation to higher complement-dependent cytotoxicity (CDC) and ADCC [3, 4]).

References

1. Wingens M, Galtung J, Albaim, S, Büntemeyer, H, Noll, T, Hoffrogge, R: 2D-DIGE screening of high productive CHO cells under glucose limitation – basic changes in the proteome equipment and hints for epigenetic effects. Journal of Biotechnology 2015, 201: 86-97.
2. Takuma, S, Hiroshima, C, Piret, JM: Dependence on Glucose Limitation of the pCO2 Influences on CHO Cell Growth, Metabolism and IgG Production. Biotechnology and Bioengineering 2007, 97, 6: 1479-1488.
3. Thomann, M, Reckermann, K, Reusch, D, Prasser, J, Tejada, M.L: Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Molecular Immunology 2016, 73: 69-75.
4. Reusch, D, Tejada, M.L: Fc glycans of therapeutic antibodies as critical quality attributes. Glyobiology 2015, 25, 12: 1325-1334.
P-031
How cell culture automation benefits upstream process development
Carsten Musmann (carsten.musmann@roche.com)
Roche Diagnostics GmbH, Pharma Biotech Production and Development, Penzberg, 82377, Germany
BMC Proceedings 2018, 12(Suppl 1):P-031

Background
We developed an automated, multiwell plate (MWP) based screening system for suspension cell cultures (Fig. 1a) which is now routinely used in cell culture process development. It is characterized by a fully automated workflow with integrated analytical instrumentation. It uses shaken 6-24 well plates as bioreactors which can be run in batch and fed-batch mode with a capacity of up to 768 reactors in parallel [1-3]. A wide ranging analytical portfolio to monitor cell culture processes and also a cooperation with internal high throughput (HT) analytic groups to characterize product quality are available. In addition the use and the benefits of spectroscopic methods for cell culture automation were shown in the past [4, 5].

Materials and methods
Automated cell culture systems enable broader screening within a shorter time frame for many applications in upstream process development. The higher degree of parallelization and automation helps to screen for most promising parameters in a shorter time. The use of broad DoE screening design allows in addition the identification of parameters that support high titers while keeping high product quality (multiple factors at the same time). The illustration (Fig. 1b) shows an example how this combination can speed up process development steps. Main applications of the cell culture automation are for example the identification of product quality levers and media or feed optimization.

Results
The application of the cell culture automation is shown for two examples. The goal in the first application was to identify levers to reduce trisulfides. A screening of 39 conditions in parallel (in 4-fold replication, 158 wells in sum) the reduction of Trisulfides by 97.5% (normalized to start level) was possible. In addition the levers for trisulfide reduction were identified. The best and start conditions were verified in bioreactor scale (Fig. 1c).
The goal in the second application was to increase product concentration without an impact on product quality. By a screening of 54 conditions in parallel (in 4-fold replication, 216 wells in sum) the increase of titer from 1.5 g/L to 3.7 g/L (> factor 2) was possible by media platform change and media optimization. An impact on product quality could not been shown. The best conditions were also verified in bioreactor scale (Fig. 1d).

Conclusion
The benefits of using cell culture automation in late stage process development were shown based on two examples of current applications. For this purpose the experimental results of the development work of two late state projects using the in-house developed automated cell culture system were shown. The first example shows the capability of the automated cell culture system by reducing trisulfides significantly in just one experiment. For the other project the final product concentration could be increased by factor 2.5 by a media screening and changing to the in-house media platform. These two examples show the potential of cell culture automation as a routine tool in process development.

Acknowledgements
The author would like to thank the cell culture automation team (J. Hoffmann, G. Pechmann, C. Schuster), all internship and diploma students (S. Spielmann, K. Müller, B. Frommeyer, J. Wibauer, A. Gutknecht), former members of the cell culture automation team (K. Joeris, S. Markert), the Roche Penzberg pilot plant team and all Roche Penzberg portfolio project teams.

References
1. Markert, S., Joeris, K.: Development of an automated, multiwell plate based screening system for suspension cell culture, BMC Proc. 2011, 5(Suppl 8), O9.
2. Markert, S., Musmann, C., Joeris, K.: Development and application of an automated, multwell plate based screening system for suspension cell culture, BMC Proc. 2011, 7(Suppl 6), P113.
3. Markert, S., Joeris, K.: Establishment of a fully automated microtiter plate-based system for suspension cell culture and its application for enhanced process optimization, Biotechnol Bioeng. 2017, 114(1):113-121.
4. Musmann, C., Joeris, K., Markert, S.: Spectroscopic tools for an automated suspension cell culture screening system, BMC Proc. 2015.
5. Musmann, C., Joeris, K., Markert, S., Solle, D., Scheper, T.: A review of spectroscopic methods for high-throughput characterization of mammalian cell cultures in automated cell culture systems. Engineering in Life Sciences. 2015.

Fig. 1 (abstract P-031). a Schematic illustration of the automated cell culture system. Only the core system is shown with a robotic plate handler as key device connecting cultivation, processing and analytical parts. b Illustration of an example how cell culture automation can speed up process development steps. c Application in the identification of product quality levers. d Application in titer optimization

P-038
A novel platform for high throughput cell line screening and development
Christoph Freiberg1, Lukasz Gricman1, Gian Andrea Signorelli1, Lukas Flueck-Kabay1, Amanda Fitzgerald2, Maria Wendt1, Yang-Chieh Chou3, Hans Peter Fischer1
1Genedata AG, Basel, Switzerland; 2Genedata Inc., Boston, MA, USA; 3Genedata Inc., San Francisco, CA, USA

Correspondence: Christoph Freiberg (bioprocess@genedata.com)
BMC Proceedings 2018, 12(Suppl 1):P-038

Background
The cell line development process has become faster and is simultaneously generating more clone- and product-related analytical data. In order to select the best producer cell line, extremely heterogeneous data types need to be systematically compared. The timely availability of all data needed to decide which cell line to pursue has become a bottleneck in the cell line development workflow. To ensure sound decision making, new integrated workflow support and data analysis methods are needed.

Materials and Methods
We have developed a new end-to-end platform for bioprocess development, which includes a cell line development workflow system supporting seeding, selection, passages, analyzing, cryo-conservation, and processing in (micro-) bioreactors. This platform, Genedata Bioprocess™, enables partially or fully automated cell line selection and assessment processes, and it increases process efficiency and quality. The system tracks the full history of all clones - from initial transfection all the way to their evaluation in bioreactor runs - and combines this information with analytics data on molecules, clones, and product quality. It can directly integrate with all instruments, such as pipetting robots, bioreactors, and bioanalyzers. The system is designed for a wide range of
biologic molecules, including antibodies (IgGs, novel formats) and other therapeutic proteins (e.g., fusion proteins).

Results and Conclusions

Highlighted use cases describe the identification of top producer cell lines, decision making support, bioreactor data management, and full clone history report documentation (Fig. 1). Genedata Bioprocess, which was developed in collaboration with top pharmaceutical companies, can flexibly support various (non-linear) workflows and structure the collected information in a way that fosters collaboration across an organization. While increasing throughput is crucial to ensure the timely availability of optimal producer cell lines, high-throughput is only possible when automated processes in the laboratory and the resulting data collection and aggregation can be streamlined. Genedata Bioprocess helps to establish more productive processes by offering support and integration for automation stations and measurement devices. Thanks to the comprehensive workflow support and the possibility to integrate results from cell line stability experiments, product quality assessment, and bioreactor suitability tests, Genedata Bioprocess provides a unique way to evaluate cell lines. Comprehensive analysis of all data collected in the process helps to ensure the highest possible quality and minimize the time and resources needed for data analysis and management. Integration of bioreactor data analysis and visualization with other parameters measured in cell line development, streamlines clone evaluation in micro-bioreactors and supports high-throughput operations. Genedata Bioprocess comprehensively tracks the full clone history from the origin of the host cell line to the generation of the validated monoclonal producer cell line. For promising clones, the clone history report can be generated with one click. Besides supporting cell line development, Genedata Bioprocess is a comprehensive platform capable of tracking the complete bioprocess development process.

Acknowledgements

Allison Kurz, Genedata AG, Basel, Switzerland

Fig. 1 (abstract P-038). Scheme of the complete cell line development workflow support in Genedata Bioprocess. Showcasing integration of data from diverse measurement instruments, data visualization for decision making support as well as, tracking of full clone history

P-043

Clarification of Oncolytic Measles Virus suspension using Charged Depth Filters

Daniel Loewe1, Tanja A. Grein1, Hauke Dieken1, Tobias Weidner1, Denise Salzig2, Peter Czermak2,3
1Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstraße 14, 35390 Giessen, Germany; 2Department of Chemical Engineering, Kansas State University, Manhattan, KS, USA; 3Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group Bioresources, Winchesterstr. 3, 35394 Giessen, Germany

Correspondence: Daniel Loewe (daniel.loewe@fz-thm.de)

BMC Proceedings 2018, 12(Suppl 1):P-043

Background

In 2012, 14.1 million people suffered from cancer [1] making it to a major concern of our society. Since common cancer treatment is limited and not effective for late stage carcinoma, alternative methods are needed to reduce the high mortality rate of cancer patients. One alternative approach is the application of the oncolytic Measles virus (OMV), because OMV has a natural affinity against cancer cells. The major drawbacks of OMV is to produce the extremely high amount of at least $10^{11}$ TCID$_{50}$ (50% tissue culture infective dose) per dose [2] which is needed. To solve this problem, a high titer process must be established including an efficient downstream processing (DSP). We developed an appropriate upstream processing and are able to produce $10^{10}$-10$^{11}$ TCID$_{50}$ mL$^{-1}$ in a bioreactor with 0.5 L working volume [3]. Now, we focus on the DSP part. The following study tested the application of charged depth filters for the OMV clarification. In contrast to common DSP schemes, a depletion of virus particles or a loss of infectivity is not desired. The aim is a reduction of protein content and DNA with minimal loss of infective OMV. Further, we investigated the influence of the cell culture medium on the depth filtration process.

Material and Methods

To explore the influence of the surrounding cell culture medium on the depth filtration performance, OMV was either produced in serum-free medium (VP-SFM) or serum-containing medium (DMEM + 10% FCS). The production was done in a STR with a working volume of 0.5 L as described in [3]. Cells and carriers were separated with an Opticap XL 1-module (Polygard-CR, 5 μm; Merck). For the depth filtration Millistak+ CE50 filters (Merck) were used. The filter material was autoclaved and rinsed with 25 mL of 20 mM Tris-HCl (pH=7.4). The virus suspension was filtered with a load of 50 L m$^{-2}$ using a peristaltic pump (SMP931C; I smatec) applying a flux of 150 L m$^{-2}$ h$^{-1}$ (Fig. 1). Samples were collected at the beginning and end of a filtration run.

The OMV titer (TCID$_{50}$ mL$^{-1}$) of the samples was determined according to Kärber and Reed [4, 5]. Protein content was measured with the Pierce BCA protein assay kit (ThermoFisher Scientific) according to the manufacturer’s instructions. DNA was measured by a microtiter assay using Quant-iT PicoGreen dsDNA reagent (ThermoFisher Scientific) according to the manufacturer’s instructions.

Results

We found that positively charged depth filters were suitable to clarify OMV suspensions. The cell culture medium, in which the OMV was produced, influenced the outcome of the depth filtration. A log reduction value (LRV) of 0.87 was determined for OMV present in serum-containing medium (SCM), whereas the titer of OMV in serum-free medium (SFM) was reduced 1.63 log levels. This indicates that without serum in the surrounding liquid, OMV will adsorb to the filter material. However, we must evaluate if the missing serum or other components present in SFM are responsible for this effect. Total protein was not relevantly reduced by the clarification using charged depth filters. For OMV present in SCM, the residual protein content was slightly less compared to OMV present in SFM (Table 1). In contrast, host cell DNA (hcDNA) was bound to the filter material. We achieved a 33% reduction of hcDNA for an OMV suspension in SFM. After clarifying an OMV suspension in SFM, the remaining hcDNA content was even lower being only 42%.

Conclusions

Charged depth filters are suitable for the first clarification step of OMV downstream processing. Residual protein could pass the depth
filter almost unhindered, whereas the hcDNA content was already reduced to 42% at maximum. However, the OMV titer was also reduced by the depth filtration. This undesired effect was stronger for the OMV present in SFM. Because the agencies require avoiding serum in clinical-grade production processes, this is disadvantageous. Nonetheless, because SFM will be soon standard for OMV production, further experiments have to be done preventing the OMV reduction during clarification. One option can be to reduce the adsorption strength of the virus to the filter material by the addition of salt. Moreover, it is important to establish a standardized protocol for the upstream processing. We determined batch-to-batch variations within the clarification indicating a strong impact of upstream processing (USP) on the outcome of the DSP. Therefore, further studies must investigate the influence of USP parameter e.g. time of harvest and pH of the harvest solution on the OMV.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
2. Russell SJ, Federspiel MJ, Peng K-W, Tong C, Dingli D, Monroe WG, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89:26–33. doi:10.1016/j.mayocp.2014.04.003.
3. Grein TA, Schwebel F, Kress M, Loewe D, Dieken H, Salzig D, et al. Screening different host cell lines for the dynamic production of measles virus. Biotechnol Prog. 2017;33:989–97. doi:10.1002/btp2.2432.
4. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv f. experiment. Pathol. u. Pharmakol. 1931;162:480.
5. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology. 1938;27:493–7. doi:10.1093/oxfordjournals.aje.a118408.

Results and discussion
Improvements made at different steps during fed-batch development are shown in Fig. 1. At step 1, all eight Cell Boost supplements were added to CDM4NS0 according to a DoE approach, and batch cultures were performed. This evaluation allowed us to select only those Cell Boost supplements that were beneficial to the overall culture performance. Non-performing Cell Boost supplements were removed and not considered further.

At step 2, the selected Cell Boost supplements were added daily to the cultures at different ratios according to a DoE approach, and fed-batch cultures were conducted. As expected, daily feed additions to replenish consumed nutrients substantially improved mAb and peak cell concentrations as well as viable cumulative cell days (VCCD) compared to batch cultivation. Further, the results enabled us to fine-tune the feed ratio of selected Cell Boost supplements.

At step 3, we further optimized the best performing feed ratio by investigation of static and dynamic feed protocols. Most fed-batch protocols rely on constant feed additions on distinct days. However, these approaches often lead to substantial over- or underfeeding during bioprocessing. To improve such “static” protocols, we investigated three different “dynamic” approaches as shown in Table 1 by applying the selected Cell Boost supplements with the optimized

Table 1 (abstract P-043). Virus titer of OMV present in serum-containing (SCM) or serum-free medium (SFM), before (feed) and after (permeate) depth filtration. Additionally, total protein and host cell DNA (hcDNA) were determined.

| Medium | Sample | Log. virus titer (-) | Residual total protein (%) | Residual hcDNA (%) |
|--------|--------|----------------------|---------------------------|-------------------|
| SCM    | Feed   | 6.39 ± 0.23          | 100 ± 5                   | 100 ± 13          |
|        | Permeate| 5.52 ± 0.48         | 92 ± 4                    | 67 ± 4            |
| SFM    | Feed   | 6.16 ± 0.55          | 100 ± 10                  | 100 ± 9           |
|        | Permeate| 4.53 ± 0.23         | 96 ± 7                    | 42 ± 3            |

P-047
Development of DoE based fed-batch strategies for high-producing CHO cell cultures
David Reinhart1, Andreas Castan*, Lukas Damjanovic1, Barbara Holub3, Renate Kunert1
1Vienna Institute of BioTechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 11, 1190 Vienna, Austria; 2GE Healthcare Bio-Sciences AB, Björkgatan 30, 751 84 Uppsala, Sweden; 3GE Healthcare Bio-Sciences AB, Kremplstraße 5, 4061 Pasching, Austria
BMC Proceedings 2018, 12(Suppl 1):P-047

Background
Fed-batch culture is commonly employed to maximize cell and product concentrations in upstream mammalian cell culture processes. Typical standard platform processes rely on fixed-volume bolus feeding of concentrated feed supplements at regular intervals. However, such static approaches might result in over- or underfeeding. To mimic more closely the dynamics of a fed-batch culture, we developed a dynamic feeding strategy responsive to the actual nutrient needs of a mAb-producing recombinant CHO cell line.

Materials and methods
Model cell line was a mAb-expressing CHO DG44 (licensed from Cellica GmbH) cultivated in HyClone™ CDM4NS0 (GE Healthcare) supplemented with glutamine. Feed media were HyClone Cell Boost™ 1, 2, 3, 4, 5, 6, 7a and 7b feed supplements (all GE Healthcare). Analytics comprised cell concentration, viability, mAb titer, selected metabolites, osmolality and amino acids. For fed-batch development, we applied a Design of experiments (DoE) approach using MODDE™ statistical software (Umetrics AB) combined with a three-step strategy, as follows:

- Step 1: Selection of the best performing Cell Boost supplements (batch)
- Step 2: Fine-tuning of feed ratio of selected Cell Boost supplements (fed-batch)
- Step 3: Feed strategy development: constant vs. dynamic (fed-batch)
- Bioreactor: Verification of the best results (step 3) under controlled conditions (fed-batch)

Results and discussion
Bioreactor: Verification of the best results (step 3) under controlled conditions (fed-batch)

- Step 1: Selection of the best performing Cell Boost supplements (batch)
- Step 2: Fine-tuning of feed ratio of selected Cell Boost supplements (fed-batch)
- Step 3: Feed strategy development: constant vs. dynamic (fed-batch)

Results and discussion
Bioreactor: Verification of the best results (step 3) under controlled conditions (fed-batch)
feed ratio. This investigation allowed us to further improve the bioprocess performance. The best performing approaches, constant and retrospective feed, were further investigated in fully automated bioreactors under controlled conditions. In general, constant cultivation parameters in the bioreactor slightly enhanced mAb titers compared to shake flask cultivation. The retrospective feed strategy yielded 10% higher titers than the constant strategy.

Overall, the established methodology for fed-batch development allowed us to obtain 2.5× higher mAb titers (batch mean: 1.9 g/L vs. fed-batch 4.9 g/L) in a short time and three simple steps. In addition, the product quality was investigated. Compared to the legacy fed-batch process, fed-batches that were conducted with the newly selected basal and feed media altered the distribution of charge and glycan variants. The amount of aggregated product was not altered.

Conclusions
The established methodology for fed-batch development is a rapid protocol to select well-performing feed supplements and optimize their ratio to the culture requirements. In three steps, mAb titers were boosted 2.5× from 1.9 g/L to 4.9 g/L. Product glycosylation and charge variants could be influenced by the newly selected basal and feed media compared to a legacy fed-batch process. The amount of aggregated product was not altered.

Materials and methods
Model cell line was a mAb-expressing CHO DG44 (licensed from Celica GmbH) cultivated either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (GE Healthcare). Both cultures were grown in batch mode using DASGIP™ Cellca GmbH) cultivated either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (GE Healthcare). Both cultures were grown in batch mode using DASGIP™ Cellca GmbH) cultivated either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (GE Healthcare). Both cultures were grown in batch mode using DASGIP™ Cellca GmbH) cultivated either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (GE Healthcare). Both cultures were grown in batch mode using DASGIP™ Cellca GmbH) cultivated either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (Genentech Healthcare). Both cultures were grown in batch mode using DASGIP™ Cellca GmbH) cultivated either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (Genentech Healthcare). Both cultures were grown in batch mode using DASGIP™ Cellca GmbH) cultivated either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (Genentech Healthcare). Both cultures were grown in batch mode using DASGIP™ Cellca GmbH) cultured either in ActiPro basal medium only (Genentech Healthcare) or in ActiPro basal medium feed-spiked with additional supplementation with 7% Cell Boost 7a and 0.7% Cell Boost 7b (Genentech Healthcare).

Both basal and feed-spiked processes lasted for seven days with viability above 95% until Day 6. On day seven, a sharp decline in viability indicated the end of the batch process (Fig. 1a). In feed-spiked medium, cells initially grew slower but reached almost twice as high peak cell concentrations (17.6 × 10^6 c/mL) than in basal medium only (9.79 × 10^6 c/mL). Remarkably, the integral of the viable cell concentration over the total process time (viable cumulative cell days [VCCD]) was similar between both process strategies (Fig. 1c). While mAb production plateaued after Day 4 in basal medium only (final titer 0.8 g/L), a continuous increase to three-fold higher final titers (2.4 g/L) was observed in feed-spiked medium (Fig. 1b). The higher titers could be attributed to generally higher cell-specific productivities (qP), which remained rather constant (~70 pg/cell/day) in feed-spiked cultures. In basal medium, the qP continuously dropped by 20% (Day 0 to 3), 50% (Day 4), and > 90% (Day 5 to 7) from 70 to 10 pg/cell/day in basal medium cultures. In average, the qP was 70% higher in feed-spiked cultures (Fig. 1d).

Transcriptome analysis of differentially expressed genes between cells grown in basal medium or feed-spiked medium were used to identify relevant GO terms that indicated a more active proliferative state for feed-spiked cultures (data not shown). The top GO terms significantly related to cell cycle and primary metabolism, cellular division, as well as nucleobase formation or regulation. Furthermore, GSEA revealed several significantly enriched sets of genes related to gene transcription, DNA replication and repair, cell growth and proliferation, as well as inhibition of apoptosis in feed-spiked cultures. Thus, feed-spiking increased the proliferative activity of cultivated cells. Several of the identified genes appear as promising targets for cell line engineering, but have not yet been described in relation to high-producing recombinant cell lines and will need to be evaluated in future studies.

Conclusions
Feed-spiking of basal medium is a convenient and easy way to considerably increase product concentrations in a simple batch culture. Differential gene expression revealed genes that appear important for high cell-specific production rates, and this knowledge can be leveraged into cell line engineering approaches or the design of high producing CHO cell media. In the latter case, a maximized supply of...
Physicochemical and functional characterization of a candidate adalimumab biosimilar TUR01

A. Emin Atik1, Zeynep Yıldırım Keleş1, Yigit Erdemgil1, Deniz Baycin Hizal1, Özge Can2, R. Serdar Alpan1

1Biotechnology Development Center, Turgut İlaçları, Istanbul, Turkey; 2Department of Medical Engineering, Acıbadem University, Istanbul, Turkey

Correspondence: Deniz Baycin Hizal (dhizal@turgutilac.com.tr)

Background

TUR01 has been developed as a candidate biosimilar of adalimumab (Humira®). A number of originator molecules have been analyzed to determine the ranges of the critical quality attributes (CQAs). In order to obtain high similarity; a variety of upstream and downstream process development strategies were applied to assure that the CQAs fall within the ranges determined from the originator. After drug substance formulation, state-of-art analytical methods have been used to demonstrate the similarity between TUR01 and originator adalimumab.

Materials and methods

TUR01 was produced in a genetically engineered Chinese hamster ovary (CHO) cell lines. All mass spectrometry experiments (intact & reduced mass, peptide mapping, glycan analysis) were carried out on a Xevo G2-XS QToF mass spectrometer equipped with a lock spray ion source (Waters Corp., Milford, MA, USA). The kinetic rate constants and binding of TUR01 to TNFα was measured by Biacore T200 (GE Healthcare). The data were evaluated using the 1:1 fitting model. The charge heterogeneity (acidic and basic variants) and size heterogeneity (aggregate, monomer and fragment levels) were determined by capillary isoelectric focusing (cIEF, PA800 Plus Beckman Coulter) and size-exclusion chromatography (SEC, Waters Corp., Milford, MA, USA), respectively. Additionally, CE-SDS was used for impurity analysis. The secondary structure was obtained by FTIR experiments (Bruker Tensor 27 FTIR, Bruker Optics GmbH, Ettlingen, Germany).

Results

High biosimilarity must be demonstrated by physicochemical and functional characterization for approval requirements of phase I and phase III studies in terms of efficacy, safety and immunogenicity. In this study, rounds of upstream and downstream processes were run to reach the CQA limits of the originator molecule. After conducting many different development strategies, the mirror plot images of the intact deconvoluted mass spectrum were found to be identical corresponding to similar levels of glycoforms. The UV chromatogram of reversed phase ultra-performance liquid chromatography (RP-UPLC) of tryptic peptide mapping demonstrated that the primary structure of TUR01 is identical to the originator as shown in Fig. 1a. Post-translational modifications (PTMs) such as oxidation, deamidation, N-terminal pyroglutamic acid, C-terminal lysine truncation levels were also comparable for two products. The glycosylation site (HC-Asn301) was confirmed by peptide mapping analysis and 100% glycan site occupancy was proven for TUR01 and originator. The glycosylation pattern for two products were highly similar in terms of major glycans (G0F, G1F, G0F-GN and etc.). Man5 level was lower in TUR01 compared to the originator product which may not have any clinical effect on the molecule. The secondary structure was determined by ATR-FTIR spectroscopy. Absorption bands (Amide I and Amide II) were overlapped completely and amounts of α-helix and β-sheet structures were comparable. Furthermore; size-exclusion chromatography (SEC) analysis revealed that both products have the same level of purity (>99%) and aggregate (<1%) levels. The level of impurities were determined as below 4% by CE-SDS. The capillary isoelectric focusing (cIEF) experiments showed that the charge variant profiles of two products are indistinguishable and the isoelectric point of main peak is observed at 8.3 for both products. The association/dissociation rate constants and binding affinity for both TUR01 and originator were highly similar and similarity score was calculated greater than 99%, as shown in Fig. 1b.

Conclusions

In this study, state-of-art analytical techniques were used to assess the biosimilarity of TUR01 to the originator adalimumab. Head-to-head comparison data clearly demonstrated that TUR01 is highly similar to the originator adalimumab in terms of physicochemical and functional characteristics. Based on the analytical similarities, we
believe that TUR01 will have comparable PK/PD, potency, and efficacy results to the originator adalimumab.

Acknowledgements

The authors thank upstream and downstream development teams of Turgut Ilaclar, Merck Life Sciences and Covance.

P-054

Perfusion media development using cell settling in automated cell culture system
Dustin Davis, Jeremiah Riesberg, Delia Lyons
MilliporeSigma, Saint Louis, MO, 63103, USA
Correspondence: Dustin Davis (dustin.davis@sial.com)
BMC Proceedings 2018, 12(Suppl 1):P-054

Background

The expanded interest in intensified continuous bioprocessing has highlighted the need to develop a small scale model for perfusion cell culture. The direction in the industry has been to increase target cell densities to ≥5x10^6 vc/mL and decrease perfusion rates to ≤3vvd. In order to increase the throughput of our perfusion media development capabilities we sought to develop a small scale model of perfusion using the ambr®15 instrument (Sartorious, Germany). We used a modified cell settling model from the previously published by Kreye et. al. to achieve the cell retention necessary to reach perfusion relevant viable cell concentrations [1]. In this work, we will show the application of this small scale model for: (1) Identification of specific productivity performance over a steady-state for tested media, (2) Identification of CSPR_{min} for a specific cell line and medium combination, and (3) Confirmation of consistent product quality profiles between the small scale model and benchtop perfusion (data not shown).

Materials and methods

A CHOZN® cell line producing an IgG1 was evaluated in several proprietary chemically defined media prototypes generated during the development of the catalog EXCELL® Advanced HD Perfusion medium: “Fed Batch Medium”, “Early Prototype”, “Mid Prototype”, “Intermediate Prototype” and “Late Prototype” [2]. Small scale simulation of perfusion experiments were run in ambr®15. Media exchange was performed 3 times per day in equal amounts. Agitation, gassing, and liquid handling were stopped for an optimized period of time to allow cells to settle to the bottom. Spent media was removed in an amount proportional to 1/3rd daily exchange volume. Agitation, gassing, and liquid handling were resumed and fresh media was added back to the vessels. For benchtop perfusion, cells were inoculated in 3L Applikon bioreactors (Applikon, Netherlands). At a concentration of ~6.0x10^6 vc/mL, perfusion was initiated using the ATF2 (Repligen, Massachusetts). Perfusion rate was limited at 1.2vvd during steady-state.

Results

Using the cell settling method described above we have been able to achieve ≥90% cell retention efficiency. All media tested in this work were able to reach and maintain the 30x10^6 vc/mL target cell density at 1vvd (Fig. 1). Performance of each media formulation was ranked based on specific productivity (Table 1). Using “Intermediate Prototype”, minimum steady-state CSPR was determined to be 33.3pL/c/d for this cell line. N-glycan analysis of ambr®15 and bioreactor samples via intact mass spectrometry displayed only slight differences in product quality profile (data not shown).

Conclusions

Our work has shown a clear distinction between various prototype perfusion media and demonstrated a 50% increase in specific productivity over “Fed Batch Medium” used in perfusion. Additionally, we have shown the application to further characterize the process using this model to determine CSPR_{min} for a given medium and cell line.

Acknowledgements

Thank you to the bioreactor team of Irfan Hodzic, Amer Al-Lozi, and Jana Mahadevan.

References
1. Kreye S, Zoro B: Webinar: ambr15 as a sedimentation-perfusion model for cultivation characteristics and product quality prediction. 2016.
2. Riesberg J, Hodzic I, Lyons D: “De novo” high density perfusion medium: increased productivity and reduced perfusion rates. PO083. ESACT 2017.

Table 1 (abstract P-054). Average specific productivity and cell specific perfusion rates for media formulations tested

| Medium                  | Fed Batch | Early Prototype | Mid Prototype | Late Prototype |
|-------------------------|-----------|-----------------|---------------|---------------|
| Average q_p (pg/c/d)    | 19.01±0.65| 22.98±1.29      | 26.26±1.69    | 31.80±1.07    |
| Average CSPR (pL/c/d)   | 35.17±3.90| 31.30±2.34      | 34.51±6.49    | 35.37±1.34    |

Fig. 1 (abstract P-054). Growth and specific productivity at various perfusion rates

P-061

An ‘Industry first’ 500L Bioreactor CHO Transient Culture: Development of large scale transient expression capabilities
Emma Tyzack, Gary Pettman, Lekan Daramola
Biopharmaceutical Development, MedImmune, Cambridge, CB21 6GH, UK
Correspondence: Lekan Daramola (daramola1@medimmune.com)
BMC Proceedings 2018, 12(Suppl 1):P-061
Background
MedImmune has developed a proprietary high yielding, scalable and easy to use Chinese Hamster ovary (CHO) cell based transient expression system. The system is used routinely for early stage material supply of a variety of biologic protein formats for projects within R&D at both AstraZeneca and MedImmune. The transient process has been successfully operated at 500L in a Sartorius Biostat Single Use Bioreactor (SUB), yielding 0.4kg of crude product from a two-week expression culture (Table 1). Successful scale up of the process to 500L creates the potential to supply transiently expressed products to support toxicology studies or even early GMP clinical supply, enabling accelerated biopharmaceutical development project timelines.

The scale up from rocking bioreactors (RBr) to SUB scale identified some scalability issues. Lower specific productivity due to increased cell growth and decreased titres were observed in the SUB (Fig. 1 iii & iv). To improve the predictability of scale up, a new process was developed and evaluated in the SUB vessels utilising a modified transfection method, which resulted in comparable expression levels and specific productivity between RBr and SUB scales.

Materials and methods
Two sets of expression vectors comprising heavy chain and light chain plasmids expressing a human IgG1 kappa mAb, as previously described [1,2] were used in the process optimisation study. The cell line used for transient expression and the PEI mediated transfection method has been described previously [1]. Transfected cultures were run under fed batch conditions for 14 days in 22L GE Healthcare Wave bioreactors (RBr), Hyclone SUB using 50L and 250L Hyclone bioreactor bags (Thermo Scientific).

Results
The transfection process was modified to address the reduced titres and higher viable cell density (VCD) seen in the SUB cultures. Shake flask cultures were used to assess the standard (A) and modified transfection processes (B and C) (Fig. 1, i & ii). Process C was identified as the process to be studied at SUB scale, offering the potential to mitigate the high viable cell densities (VCD) observed. Scaling up process C to 50L and 250L SUB resulted in cultures producing titres exceeding 1g/L with desired cell growth profiles.

Conclusions
Scale up of process A into SUB vessels resulted in decreased productivity compared to the RBr scale. After optimisation, the SUB process C yielded increased specific productivities and expression titres comparable to those seen at RBr scale (Table 1).

MedImmune has successfully completed the first known successful CHO transient culture at 500L scale producing > 800mg/L of mAb at harvest. Process optimisation has subsequently demonstrated reproducible titres at 50L to 250L scale exceeding 1g/L with comparable glycosylation profiles between SUB and RBr cultures across scales.

Acknowledgements
Steve Ruddock, Richard Lugg, Ken Lee, Rob Stedelman, Ruchika Bandekar, Karen Dickson, Faisal Uddin, Jake Warrington, Nick Myatt, Claire Pearce, Andy Smith, Chris Sellick

References
1. Dataramola O, Stevenson J, Dean G, Hatton D, Pettman G, Holmes W, Field R. A high-yielding CHO transient system: Co-expression of genes encoding EBNA-1 and GS enhances transient protein expression. Biotechnol Prog. 2014; 30:132-141; DOI: 10.1002/btpr.1809.
2. Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187:9-18.

Table 1 (abstract P-061). qP and titre benefits of the optimised SUB transfection process C when compared to process A across scales

| Process Scale | Specific productivity (pg/cell/day) | Day 14 Titre mg/L |
|---------------|------------------------------------|------------------|
| 500L SUB Process A | 6.54                              | 831              |
| 250L SUB Process A | 5.52                              | 838              |
| 50L SUB Process A | 3.22                              | 440              |
| 25L RBr Process A | 16.35                             | 1499             |
| 250L SUB Process C | 17.31                             | 1300             |
| 50L SUB process C | 21.70                             | 1402             |
| 5L RBr Process C | 23.64                             | 1614             |

P-064
Comprehensive analysis of the impact of trace elements in media on clone dependent process performance and product quality
Fabian Stiefel1, Melanie Oesterle2, Frederick Rudolph1, Martin Pauers1, Jochen Schaub1, Jan Bechmann3
1Biopharmaceutical Development Biologicals, Boehringer Ingelheim, Germany; 2Pharmaceutical Development Biologicals, Boehringer Ingelheim, Germany
Correspondence: Fabian Stiefel (fabian.stiefel@boehringer-ingelheim.com)

BMC Proceedings 2018, 12(Suppl 1):P-064

Background
State-of-the-art biopharmaceutical processes are accounting concurrently for process performance and product quality. Even though high yielding, robust processes are the cornerstones of any process development, product quality parameters such as structural integrity, charge variances and post-translational modifications are
progressively becoming the focus of the developmental work. In conjunction with host cell line selection and process performance parameters, media components are crucial for the continued progress in rational modulation of product quality attributes affecting biological activity, immunogenicity, half-life or stability. Among media components, trace elements (TE) are of particular interest as they play a pivotal role in various cell metabolism pathways. Based on a comprehensive DOE approach, extensive process performance- and product quality evaluation combined with metabolic flux analysis, the impact of several trace elements on the biopharmaceutical process is assessed.

**Material and methods**

In a comprehensive I-optimal DOE approach (Fig. 1), the effect of six TE in various concentration levels and combinations in serum-free media was studied for four different CHO-K1 cells lines in an ambr® 15 setup. A scrutiny of the process performance parameters such as cellular growth, productivity, amino acids and vitamins consumptions rates for each of the conditions was performed. The process performance evaluation was accompanied by extensive product quality analysis including size and charge variants, glycosylation patterns, oxidation and methylation. Furthermore, a metabolic flux analysis was performed based on the nitrogen balance.

**Results**

Based on extensive analytical data, the obtained response surface model provides a clear insight into the impact of particular TE and their combinations on process performance and product quality. The high model quality enables discriminations between clone dependent and clone independent effects. With an elevation in titer up to 25% in the best condition of the cell lines clearly show, that even state-of-the-art media can be outperformed by trace element combinations up to 25% in the best condition of the cell lines clearly show. In parallel, we have also harnessed a SPR biosensor directly to a bioreactor, which permitted the at-line determination of the concentration of antibodies by hybridoma cells during a bioreactor culture.

**Conclusions**

We now plan on combining both approaches to determine on-line the glycosylation profile of the produced mAbs. Our ultimate goal is to design a unique and highly innovative bioprocess control tool that can be readily applied in an industrial bio-manufacturing setting.

**Acknowledgements**

This work was supported by the Canada Research Chair on Protein-Enhanced Biomaterials and the National Research Council Canada: Human Health Therapeutics portfolio. We thank Gilles Saint-Laurent and Christian Gervais for technical support and fruitful discussions.

**References**

1. Dorion-Thibaudeau, J., C. Raymond, E. Lattova, H. Perreault, Y. Durocher and G. De Crescenzo: Towards the development of a surface plasmon resonance assay to evaluate the glycosylation pattern of monoclonal antibodies using the extracellular domains of CD16a and CD64. Journal of Immunological Methods 2014; 408: 24-34.

2. Dorion-Thibaudeau, J, G. St-Laurent, C. Raymond, G. De Crescenzo and Y. Durocher: Biotinylation of the Fc gamma receptor ectodomains by mammalian cell co-transfection: application to the development of a surface plasmon resonance-based assay. Journal of Molecular Recognition 2016, 29(2): 60-69.

**P-066**

Development and assessment of a robotic highthroughput platform for antibody minipurification

Frédéric Delouvroy, Cyrielle Calmets, Grégory Mathy, Laetitia Malphettes

Upstream Process Sciences, Biotech Sciences, UCB Pharma S.A., Chemin du Forêt, Braine l’Alleud, Belgium

**Correspondence:** Frédéric Delouvroy (frederic.delouvroy@ucb.com)

**BMC Proceedings** 2018, 12(Suppl 1):P-066

**Introduction**

Reducing timelines and costs are key factors for bio-pharmaceutical industries to accelerate process development and drug delivery to patients. Enhancing throughput of bioprocess development has become increasingly important for the screening and optimization of cell culture processes. This challenge requires high throughput tools. In a previous study [1], we showed that ambr® 15, a robotically driven mini-bioreactor system developed by TAP-Sartorius, could be advantageous to accelerate process development. The use of ambr® 15 system allows us to test a large number of experimental conditions in a single experiment. Therefore, the large amount of production samples to be characterized for Product Quality Attributes (PQA) increases as well: the bottleneck has moved from the generation of samples at the production bioreactor step to in-process analysis.
For product quality attribute analysis at lab scale, protein purification is generally carried out on >5ml columns which is incompatible with the size of ambr® 15 bioreactors. Moreover, the applied methods are relatively low throughput. The development of a high binding capacity resin (up to 70 mg/ml) [2], combined with high performing new cell lines which are able to produce up to 5 g/L of recombinant monoclonal antibodies, allow us to carry the development of an efficient and high throughput (HTS) purification method robot. The use of robotic equipment for small scale purification purposes is a great opportunity for us to tackle this bottleneck, by enabling high throughput sample purification at smaller scale (200μL).

Materials and methods
Recombinant monoclonal antibodies were produced by a genetically engineered Dihydrofolate Reductase (DHFR)-/- DG44 Chinese Hamster Ovary (CHO) cell line. Clarified cell culture fluid (CCCF) was obtained from engineered Dihydrofolate Reductase (DHFR)-/- DG44 Chinese Hamster Ovary (CHO) cell line. Cloned cell culture fluid (CCCF) was obtained from two and 2K liter bioreactors after three filtration steps. Minipurifications were performed on Tecan Freedom EVO® robot with Predicator RoboColumns® containing 200μl Mabselect SuRe® resin. Larger scale purification were executed using an AktaXpress using Hitrap column ProtA.

To assess monoclonal antibody purification at small scale, we first tested the repeatability of the minipurification, purifying the samples 8 times on the same columns and using different columns, focusing on the yield of the purification and the impact on Product Quality Attributes, especially the HMWS. Then, we compared those results to those obtained with the AktaXpress at larger scale purification, comparing the yield of the purification and the PQA of the Protein A eluates obtained with both purification systems. Finally, we assessed the capability of the robot to perform HTS of buffer and purification conditions, evaluating three different buffers at different concentrations and pH values, and also testing different loading column capacities.

Results and discussion

In this study we established that the Tecan can be used as a robust platform for purification at small scale. We observed similar purification yields, intra and inter run. The analysis of the PQA1a level showed there is also very high reproducibility. And the pH of the eluate showed as well strong comparability as well. Table 1 shows the coefficient of variation (CV) of the yield, HMWS and eluate pH are low, demonstrating the good reproducibility of the purification. The strong reproducibility obtained between the different purifications showed that the Tecan and the AktaXpress are similar in terms of purification performance and PQA (Fig. 1a, b). The Tecan is a versatile automated liquid handler allowing the screening of huge purification conditions (Fig. 1c), the possibility to purify large quantities of samples, while the samples amount is limited. The Tecan has the potential to purify more than 150 samples/day, reducing timelines and allowing us to deliver faster to the patients.

Table 1 (abstract P-066). Reproducibility data summary

| Bioreactor          | Yield (%) | Average CV (%) | PQA1a (%) | Average CV (%) | pH of the eluate | Average CV (%) |
|---------------------|-----------|----------------|-----------|----------------|-----------------|----------------|
| 2000L Bioreactor    | 76.73     | 0.13           | 1.06      | 0.09           | 3.93            | 0.1            |
| 2L Bio 1 (n=8)      | 66.68     | 0.02           | 1.03      | 0.13           | 4.07            | 0.01           |
| 2L Bio 2 (n=8)      | 65.53     | 1.52           | 1.2       | 0.28           | 3.56            | 1              |
| 2L Bio 3 (n=8)      | 67.69     | 0.05           | 1.05      | 0.28           | 4.1             | 0.03           |
| 2L Bio 4 (n=8)      | 64.3      | 0.06           | 1.09      | 0.23           | 4.07            | 0.04           |
| 2L Bio 5 (n=8)      | 66.49     | 0.06           | 0.59      | 0.11           | 3.94            | 0.04           |
| 2L Bio 6 (n=8)      | 67.99     | 0.03           | 0.63      | 0.05           | 3.94            | 0.02           |
| 2L Bio 7 (n=8)      | 61.62     | 0.04           | 0.68      | 0.05           | 3.95            | 0.02           |
| 2L Bio 8 (n=8)      | 67.18     | 5.35           | 0.65      | 0.06           | 3.93            | 0.03           |

Fig. 1 (abstract P-066). Comparison between both purification systems and the ability of the system to be used as a high throughput tools for buffers screening. a Purification yield (%). b PQA1a (normalized). c Impact of the pH and buffer concentration on the PQA1a

P-067
Viable cell density monitoring in bioreactor with lensless imaging

Geoffrey Esteban1, Martin Pisanesch1, Jérémie Cubeta2, David Sergeant2
1R&D, Iprasense, Clapiers, France; 2R&D; Iraztech, Mons, Belgium

BMC Proceedings 2018, 12(Suppl 1):P-067

Background

Monitoring cell density and viability of mammalian cell culture bioreactors is a necessary task that presents today a number of remaining challenges. The traditional measurement for bioreactor cell count and viability rely on using the Trypan Blue exclusion method once a day. While automatic cell counters have reduced the statistical manual error, sampling the bioreactor remains a contamination risk and is prohibiting process control as the sampled volume becomes significant. Lensless Imaging Technology is a new method for accurately determining cell concentration and viability without staining. This technique directly acquires the light diffraction properties of each individual cells through their holograms images without any objective, lens or focus settings. Living and dead cells have significant holographic patterns that can be distinguished and precisely counted.

Material and method

Lensless imaging technique directly acquires the light diffraction properties of each individual cells through their holograms images without any objective, lens or focus settings. Living and dead cells have significant holographic patterns that can be distinguished and precisely counted. We compare cell counts and viability between the reference method and our Lensless Imaging device, the Cytonote counter. Measures are performed once a day on samples from 12 bioreactors, from the inoculation to the end of the culture. We also assessed the repeatability of our method. Another Lensless Imaging prototype is setup as a measurement chamber directly connected to a perfusion bioreactor, for continuously receiving the bioreactor broth, and therefore reproducing an in situ measure.

Results and discussion

With a concentration range up to 40x10⁶ cells/ml (Fig. 1) and viability range at 75-100%, we obtained a correlation factor of 0.98 between the two compared methods. The large field of view allows the analyze of several thousand cells within a single image, keeping the statistical variability of the measure as low as 3%.

Our measurement chamber prototype has demonstrated its capability for continuous Viable Cell Density and viability monitoring. We are now working at designing a steam sterilizable probe, and we envision Lensless Imaging to become the future method of choice for on-line monitoring of suspension cells cultures.

Conclusion

Lensless Imaging Technology is capable of accurately and precisely monitoring Viable Cell Density and Viability with a combination of significant advantages starting from low sample volume use, label free detection, quick measure, simple device, to high number of cell analyzed which let us think that it is a good candidate for very small
scale bioreactor and high-throughput measures. Its high repeatability is also a key parameter in the effort to narrow batch to batch deviations. In addition we demonstrate that this technique is potentially powerful for in-line and continuous monitoring of a lab bioreactor. We envision Lensless Imaging to become the future method of choice for on-line and in-situ monitoring of suspension cells and a perfect tool for process control in fed-batch or perfusion mode in single-use bioreactors or traditional steam sterilized vessels. It can certainly become the first VCD measurement technique to work from cell line engineering, to process development, pilot scale, and up to manufacturing scale.

Acknowledgements
Acknowledgment to Cedric Allier from CEA Leti, Grenoble, France.

Fig. 1 (abstract P-067). Viable cell count correlation between the lensless imaging technique and the trypan blue reference instrument

P-068
Time-dependent product heterogeneity in mammalian cell fermentation processes
K. Grunwald1, T. Noll1, H. Büntemeyer1
1Cell Culture Technology, Bielefeld University, 33615 Bielefeld, Germany;
2Biofidus AG, 33613 Bielefeld, Germany.
Correspondence: H. Büntemeyer (heino.buentemeyer@uni-bielefeld.de)
BMC Proceedings 2018, 12(Suppl 1):P-068

Background
A consistent product quality is a major goal in the production of biotherapeutics, especially recombinant glycoproteins. Whereas it is unlikely that the polypeptide chain changes during a production process, posttranslational modifications and protein folding are sensitive to fluctuations in parameters and conditions. Here we focus on protein glycosylation as one important indicator for protein quality [1]. During a batch process conditions change continuously. At the beginning, the supply situation for the cell is excellent, but the secreted material stays a long time in the culture fluid. Later during cultivation substrate provision decreases, whereas the exposition time of the protein to the culture fluid is much shorter. Altogether this leads to product heterogeneity of the secreted protein during a batch culture.

Materials and methods
Four different cell lines, two of human origin and two CHO clones, producing four different recombinant glycoproteins were investigated in this study. Together with their respective parental cell line the clones were cultured in three replicates in shakers. Supernatant from the cultures were harvested at four time points. The removed culture volume was replaced by culture supernatant of the identically cultured corresponding parental cell line. The product was isolated from the supernatant and the glycans were released. One part of the released glycans was labeled with 2-AB and separated by HILIC-FLD. The other part of the glycans was permethylated and analyzed by MALDI-ToF mass spectrometry (Fig. 1a). The investigated proteins were Antibody, Antithrombin III from CHO clones and α1-Antitrypsin, C1-Inhibitor from human clones.

Results and conclusions
The antennary of the glycans is quite stable in all production phases. The degree of core fucosylation is very high in all products. A low fucosylation degree of antibodies may be favorable for a higher ADCC performance [2]. Some of the products showed an antennary fucosylation, which seemed to change not very much in different cultivation phases. Nevertheless, this might be an issue due to an antigenic impact in the patient.

The antennary galactosylation changes noticeable for the antibody and α1-Antitrypsin. In both cases the degree is highest in the first phase. An incomplete galactosylation leads to truncated glycans. This leads inevitably to undersialylated antibodies to be seen for α1-Antitrypsin. The sialylation is the highest in the early phases and decreases during cultivation time. Sialylation of a therapeutic protein is important for the half-life in the patient. Therefore highly sialylated products are desired [3].

In further studies the consistency of the galactosylation and the sialylation will be investigated for fed batch and long term continuous cultures in comparison to batch cultures. Due to the feed solution or the fresh media being present during such processes, the supply situation should be excellent for the whole cultivation time.

The differences between the MALDI-ToF and HILIC-FLD data originate from complex and unresolved chromatograms (Fig. 1b, chromatograms not shown). For that reason coupling of HILIC-FLD and MS is very much recommended.

Acknowledgements
We would like to thank A. Schemel and A. Ehrlich for technical assistance.

References
1. Parodi, Armando: Protein Glycosylation and its Role in Protein Folding. Annual Review of Biochemistry, 2000, 69:69-93.
2. Liu, Chalouni, Young, Junttila, Slivkovski, Lowe: Afucosylated antibodies increase activation of FcyRlla-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol Research, 2015, 3(2):173-183.
3. Varki, Schaar, Schauer: Sialic Acids and other Nonulosonic Acids. In Essentials of Glycobiology [internet]. 3rd edition. Edited by Varki. New York, USA:Cold Spring Harbor Laboratory Press; 2017.

Fig. 1 (abstract P-068). a Experimental process, b Overview of glycan appearance. The columns each represent the portion based on all identified glycans in the particular sample. The shown standard deviation results from three biological replicates.
P-071

Efficient protein production by transient gene expression using insect cells

Hideki Yamaji1, Keita Mori1, Hirotugu Hamada1, Yuki Ohmuro-Matsuyama2, Tomohisa Katsuda1
1Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1–1 Rokkodai, Nada, Kobe 657–8501, Japan; 2Present address: Laboratory for Chemistry and Life Science, Institute for Innovative Research, Tokyo Institute of Technology, Yokohama 226–8503, Japan

Correspondence: Hideki Yamaji (yamaji@kobe-u.ac.jp)

BMC Proceedings 2018, 12(Suppl 1):P-071

Background

Novel biologics are often selected from a large library of lead candidates in the initial stage of preclinical and clinical developments. For this selection, there is a demand for high-throughput production of recombinant proteins of high quality and in sufficient quantity. Transient gene expression offers a rapid approach to the production of numerous recombinant proteins for the initial-stage developments of biologics. Mammalian cells are major host cells for transient gene expression, but they have the disadvantages of complicated operations and high cost of culture. Insect cells are easy to handle and can be grown to a high cell density in suspension with a serum-free medium. Insect cells can also produce large amount of recombinant proteins through post-translational processing and modifications of higher eukaryotes. Hence, insect cells have been recognized as an excellent platform for the production of functional recombinant proteins [1,2]. In the present study, the production of an antibody Fab fragment through transient gene expression in lepidopteran insect cells was examined.

Materials and methods

The DNA fragments encoding the heavy chain (Hc) and light chain (Lc) genes of an Fab fragment of mouse anti-bovine RNaseA [3] were respectively cloned into the plasmid vector pHLAneo, which contained the Bombyx mori actin promoter downstream of the B. mori nucleopolyhedrovirus (BmNPV) IE-1 transactivator and the BmNPV HR3 enhancer for high-level expression [4]. Trichoplusia ni BTI-TNb-5B1-4 (High Five) cells were co-transfected with the resultant plasmid vectors using linear polyethyleneimine (PEI) Mw 40,000. Before transfection, the plasmids and PEI were prepared in 150 mM NaCl, pH 7.0 and incubated at room temperature for 5 min. When the transfection efficiency was checked, a plasmid vector encoding the enhanced green fluorescent protein (EGFP) gene was also co-transfected. Transfected cells were incubated with a serum-free medium in a static or shake-flask culture. Culture supernatants were analysed by western blotting and enzyme-linked immunosorbent assay (ELISA). The numbers of green fluorescent cells and total cells in culture broth was determined using a flow cytometer.

Results and discussion

Western blot analysis and ELISA of culture supernatants showed that transfected High Five cells secreted the Fab fragment with antigen-binding activity. In static cultures, transfection and culture conditions, such as Hc:Lc gene ratio, a serum-free medium, DNA:PEI ratio, and DNA amount per cell, were successfully optimized by flow cytometry of EGFP expression in transfected cells and the yield of the secreted Fab fragment measured by ELISA. The effects of culture temperature and initial cell density were also examined by comparing the cell growth and the production of Fab fragments in shake-flask cultures. Under optimal conditions (medium, PSFM-J1 (Wako Pure Chemical Industries, Japan); Hc:Lc gene ratio, 3:7; DNA, 5 μg/106 cells; PEI, 10 μg/106 cells; initial cell density, 1 x 107 cells/cm3; temperature, 24°C), the yield of more than 100 g/(106 cells) of PEI in the serum-free medium PSFM-J1. Transfected cells were incubated at 24°C.

Concentration of Fab fragments in the culture supernatant.

Fig. 1 (abstract P-071), Production of Fab fragment under optimal conditions in a shake-flask culture. Cells at a density of 1 x 106 cells/cm3 were transfected with 5 μg/106 cells/cm3 were transfected with 5 μg/106 cells/cm3 were transfected with 5 μg/106 cells/cm3 were transfected with 5 μg/106 cells/cm3 were transfected with 5 μg/106 cells/cm3 were transfected with 5 μg/106 cells of DNA (Hc:Lc gene ratio = 3:7) using 10 μg/106 cells of PEI in the serum-free medium PSFM-J1. Transfected cells were incubated at 24°C. a Density of viable cells. Density of untransfected cells (open circles) is also shown. b Concentration of Fab fragments in the culture supernatant. Bars represent the means ± S.D. obtained from three different determinations.

References

1. Yamaji H: Production of antibody in insect cells. In Antibody expression and production. Cell engineering, Volume 7. Edited by Al-Rubeai M. Dordrecht, Netherlands: Springer Science + Business Media; 2011 53–76.

2. Yamaji H: Suitability and perspectives on using recombinant insect cells for the production of virus-like particles. Appl Microbiol Biotechnol 2014, 98:1963–1970.

3. Kakubara Y, Kobayashi E, Kurokawa Y, Omasa T, Fujiyama K, Suga K: Cloning of cDNA and characterization of anti-RNase A monoclonal antibody 3A21. J Ferment Bioeng 1996, 82:312–314.

4. Yamaji H, Manabe T, Watakabe K, Murakita M, Fuji I, Fukuda H: Production of functional antibody Fab fragment by recombinant insect cells. Biochem Eng J 2008, 41:203–209.

P-072

Implementation of different culture strategies for increasing cell density and titer in HEK293 bioreactor cultures

Iván Martínez-Monge1, Pere Comas1, Joan Triquell1, Marc Camps1, Jordi Prat1, Antoni Casablancas2, Martí Lecina1, Jordi J. Cairo1
1Department of Chemical, Biological and Environmental Engineering, Autonomous University of Barcelona, Bellaterra (Cerdanyola del Vallès), 08193, Spain; 2Department of Biotechnology, Farmhispания S.A., Montmelò, 08160, Spain

Correspondence: Iván Martínez-Monge (ivan.martinez.monge@uab.cat)

BMC Proceedings 2018, 12(Suppl 1):P-072

Background

The increasing demand for biopharmaceuticals produced in mammalian cells has led industries to increase volumetric productivity of bioprocesses through different strategies [1,2,3]. In this context, fed-batch and perfusion cultures have attracted more interest than conventional batch processes. The efficient application of such alternative processes requires the availability of reliable on-line measuring tools for cell density and cell metabolic activity estimation [4]. The comparison of different culture strategies for HEK293 cell line producing IFN-γ are presented below: batch, fortified batch and fed-batch. In this context, a new robust feeding strategy based on the monitoring of alkali buffer addition was applied for the estimation of nutrient requirements. This method allows to increase cell density and product titer compared with the other strategies assessed.

Materials and methods

Three different culture strategies were carried out in 2-Litre Biostat B-DCU II bioreactor. First, a reference batch and a batch using fortified medium (nutrient enriched medium) were run and assessed in terms of Viable Cell Density (VCD) and product titer, and set as initial references. Then, a fed-batch was performed applying a feeding strategy based on the nutrient requirements estimation by monitoring the alkali buffer addition used for the control of pH.
Results

VCD and product titer achieved for the different culture strategies assessed (batch, fortified-batch and fed-batch) are presented in Table 1. In fortified batch an increase in VCD of 145% and also 350% in product titer were obtained compared with batch.

In the fed-batch culture carried out (Fig. 1), we observed that alkali buffer addition profile matched the VCD evolution trend. Thus, the monitoring of alkali buffer addition was used for estimating the nutrients requirements (i.e. the volume of feeding medium) at any time during the fed batch phase. The feeding strategy based on alkali buffer addition enabled to maintain glucose concentration set point within a narrow range during fed-batch phase (around 20 mM). As a result, higher VCD (1.66·10^6 cells/mL) was obtained when compared with both batch references: VCD was enhanced to 241% and 39% and an increase up to 381% and 7% in product titer in respect to batch and fortified batch respectively.

The results prove that fed-batch strategy based on the alkali buffer addition is a robust on-line monitoring method that enables to optimize the feeding strategy in a fed-batch cultures.

Conclusions

Three different culture strategies have been tested in bioreactor with a HEK293 cell line producing IFN-γ. Results show as the higher VCD is reached, the higher product concentration is achieved. Therefore, from bioprocess development point of view, it is very interesting to implement strategies with higher VCD outcome, such as fed-batch operation mode. In this context, a new robust method for VCD estimation in fed-batch was applied. The alkali buffer addition necessary for maintaining the pH set-point is an on-line reliable and easy measuring variable that provides information about by-products formation (mainly lactic acid). The monitoring of this variable can provide information about the cell concentration, activity and metabolism, to detect changes in culture. Besides that, a relationship between alkali buffer addition and VCD can be established since the first is strongly correlated with cell growth and metabolites consumption/formation. The application of alkali buffer addition measure to implement an optimal feeding strategy in fed-batch permits to enhance VCD and product titer when comparing with batch strategies.

Acknowledgements

The authors would like to mention that this research was supported by the

References

1. Gálvez, J., Lecina, M., Sola, C., Cairó, J. J., & Gódia, F. (2012). Optimization of HEK-293S cell cultures for the production of adenosinarov proteins in bioreactors using on-line OUR measurements. Journal of biotechnology, 157(1), 136-142.
2. Román, R., Miret, J., Scalía, F., Casablanca, A., Lecina, M., & Cairó, J. J. (2016). Enhancing heterologous protein expression and retention in HEK293 cells by means of combination of CMV promoter and IFNα2 signal peptide. Journal of biotechnology, 193, 57-67.
3. Liste-Calleja, L., Lecina, M., & Cairó, J. J. (2014). HEK293 cell culture media study towards bioprocess optimization: animal derived component free and animal derived component containing platforms. Journal of Bioscience and Bioengineering, 117(4), 471-477.
4. Casablanca, A., Gámiz, X., Lecina, M., Sola, C., Cairó, J. J., & Gódia, F. (2013). Comparison of control strategies for fed-batch culture of hybridoma cells based on on-line monitoring of oxygen uptake rate, optical cell density and glucose concentration. Journal of Chemical Technology and Biotechnology, 88(9), 1680-1689.

Table 1 (abstract P-072). Summary of the VCD and product titer for the three culture strategies performed with HEK293 in bioreactor

| Culture Strategy | VCDmax (10^6 cells/mL) | Product titer fold increase (relative to Batch) |
|------------------|-----------------------|-----------------------------------------------|
| Batch            | 4.88                  | 1.00                                          |
| Fortified-Batch  | 12.00                 | 3.50                                          |
| Fed-Batch        | 16.64                 | 3.81                                          |

P-078

A novel approach to high throughput screening for perfusion

Jean-Marc Bielser1, 2*, Jakub Domaradzki1, Jonathan Souquet1, Massimo Mordielli1, Henri Broly1
1 Biotech Process Sciences, Merck KGaA, Courser-sur-Vevey, Switzerland; 2 Institute of Chemical and Bioengineering, ETH Zürich, Zürich, Switzerland

Correspondence: Jean-Marc Bielser (jean-marc.bielser@merckgroup.com)

BMC Proceedings 2018, 12(Suppl 1):P-078

Background

Perfusion systems for suspended mammalian cells raise growing interest in the biomanufacturing industry. Continuous manufacturing is growing in the field and is encouraged by health authorities [1, 2, 3]. This work addresses scale down limitations inherent to continuous media exchange and cell retention by using a semi-continuous system. Data was generated with a set of different clones that were previously studied in fed-batch mode [4].

Materials and methods

4 CHO-K1 cell lines expressing the same monoclonal antibody (mAb) and issued from the same transfection were used as models. 3.5L bioreactors (Sartorius) were used for fed-batch and perfusion production runs. The perfusion bioreactors were run using an alternating tangential flow filtration device (Repligen, XCell™ ATF 2 System). The cell biomass was controlled by removing cells through a bleed line and was controlled using a biocapacitance probe (Hamilton, Incyte). The perfusion rate (D) was fixed to one vessel volume a day (vvd⁻¹). The semi-continuous runs were made in 50 mL shake tube (TPP, Tubofusor Bioreactor 50). Once a day, the tubes were centrifuged (5 min, 200 g), the supernatant removed (to mimic a perfusion rate of 1 vvd⁻¹), replaced with fresh media and cells were re-suspended.

Results

The clone’s growth potential were preserved across the systems (Fig. 1). Clone #3 always reached the highest viable cell density (VCD), followed by clone #1. Clone #2 and #4 showed similar growth characteristics. It is interesting to note that in the perfusion bioreactor different patterns in terms of VCD were observed although the cell biomass signals were similar for all 4 runs. This reflects the fact that the capacitance measures the biomass and not the absolute cell count [5].

To estimate the minimum cell specific perfusion rate (CSPRmin) in the semi-continuous experiment, the perfusion rate was divided by the maximum viable cell density (VCDmax). This value was compared to the CRSP obtained during the 4th set-point (SP4) of the perfusion runs. As expected, the bleed fraction decreased when the capacitance set-point was increased and went down to 5% or less of the total perfusion rate (data not shown). Since the bleed removes the excess biomass, it is an indication of how close to a limitation the system is. Therefore, the CSPR calculated at SP4 was considered as the minimum CSPR. The CSPRmin obtained in both systems were very close (Table 1). The semi-continuous system can therefore be used to identify the CSPRmin before running a continuous bioreactor, it therefore facilitates the decision making early in the development (to define the target cell density for a defined perfusion rate).

Fig. 1 (abstract P-072). VCD, alkali buffer addition, feed volume, glucose and lactate concentration in HEK293 fed-batch performed based alkali buffer addition
The specific productivity (Q_p) of the 4 clones was quantified at the maximum VCD (semi-continuous) or at SP4 (perfusion). Absolute values are not representative since the cell environment is so different in both systems. Nevertheless, a relative ranking proved to be indicative of the respective performances (Table 1). The maximum cell growth in fed-batch, semi-continuous and perfusion were also compared, their ranking was always preserved. Both indications can be used to assess a performance ranking for different clones.

Conclusions

The performance of 4 clones was studied in 3 different cultivation systems: fed-batch/perfusion bioreactors and semi-continuous shake tube. The semi-continuous system was able to precisely predict the CSPR_{min}, an important process parameter for perfusion. Specific productivity and maximum cell density ranking was preserved across the systems, therefore the scale down experiment can be used to assess a performance ranking for perfusion clone screening.

Acknowledgments

The authors want to thank the Biotech Process Sciences team at Merck in Corser-sur-Vervey for their support and also the members of the Morbidelli group at ETH Zürich for their input and collaboration.

References

1. S. S. Farid, B. Thompson, and A. Davidson: Continuous bioprocessing: The real thing this time? mAbs 2014, 6(1):357-361.
2. K. B. Konstantinov, C. L. Cooney: White paper on continuous bioprocessing. J. Pharm. Sci. 2015. J. Pharm. Sci., 104:813-820.
3. S. Chatterjee: FDA Perspective on Continuous Manufacturing. IFPAC Annu. Meet. 2012.
4. Rouiller Y, Bieler J-M, Brühlmann D, Jordan M, Broly H, Stettler M: Screening and Assessment of Performance and Molecule Quality Attributes of Industrial Cell Lines across Different Fed-Batch Systems. Biotechnol. Prog. 2015, 32:160-170.
5. C. F. Opel, J. Li, A. Amanullah: Quantitative modeling of viable cell density, cell size, intracellular conductivity, and membrane capacitance in batch and fed-batch CHO processes using dielectric spectroscopy. Biotechnol. Prog. 2010, 26:1187-1199.

Fig. 1 (abstract P-078). Viable cell density of the 4 clones in a fed-batch bioreactors b semi-continuous shake tubes c perfusion bioreactors and d on-line capacitance signal used to increment the biomass set-point (SP) progressively (SP 1 to 4).

Table 1 (abstract P-078). Summary of CSPR, Q_p (relative to clone #1) and maximum growth in all the systems. Clone #1 was by far the best candidate for perfusion by reaching a productivity of about 1 g/L/day at SP4. The three other clones, despite their different growth and specific productivities all performed a productivity close to 0.5 g/L/day on SP4. The semi-continuous system was able to precisely predict the CSPR_{min}, an important process parameter for perfusion. Specific productivity and maximum cell density ranking was preserved across the systems, therefore the scale down experiment can be used to assess a performance ranking for perfusion clone screening.

| Clone | CSPR_{min} | CSPR_{max} | Q_p | Q_p_{SP4} | VCD_{max} | VCD_{min} | VCD_{SP4} |
|-------|------------|------------|-----|-----------|-----------|-----------|-----------|
| #1    | 23.5       | 21.7       | 1   | 1         | 25.3      | 44.5      | 55.4      |
| #2    | 27.5       | 28.3       | 0.82| 0.67      | 15.4      | 36.4      | 42.7      |
| #3    | 15.2       | 17.3       | 0.28| 0.31      | 31.6      | 70.0      | 72.7      |
| #4    | 27.1       | 24.8       | 0.67| 0.59      | 15.5      | 36.9      | 44.7      |

Background

The production of therapeutic antibodies (Abs) requires high titers and excellent product quality to ensure efficient manufacturing and potent drug efficacy. Glycosylation, or the attachment of sugars to organic molecules, is a critical quality aspect that can significantly alter Ab binding, function, and therapeutic effect [1]. Galactose is a key sugar of interest due to its significant impact on Ab function and the ability to control galactosylation through cell culture medium. Herein, Irvine Scientific assessed the ability of media components to modulate galactose levels on a model therapeutic Ab. Various media compositions were able to modulate galactosylation levels without compromising cell growth and Ab titers. In addition, an in vitro assay was utilized to evaluate the functional ability of Abs to bind and activate complement-dependent cytotoxicity (CDC). Differences in galactosylation significantly altered the Abs’ ability to induce cell cytotoxicity. Furthermore, design of experiment analysis determined the optimal ratio of supplements to maximize galactosylation. This “Optimized Supplement” was verified and evaluated against other suppliers’ galactosylation supplements in terms of growth, titer, glycan analysis, and Ab function. The Optimized Supplement outperformed all other suppliers’ supplements and resulted in the best overall cell growth, titer, galactosylation, and Ab function.

Materials and methods

Fed-batch cultures of Chinese hamster ovary cells expressing an IgG1 Ab against CD20 were grown in BalanCD® CHO Growth A and were fed with BalanCD® CHO Feed 4 on days 3-7 of the cultures. Viable cell density and cell viability were assessed by a Beckman Coulter Vi-Cell XR, Ab titer was assessed by a Pall ForteBio QK®, and glycan analysis was assessed by a PerkinElmer LabChip GXII. For the functional CDC assay, Abs were incubated with Daudi B lymphoblast cells and normal human complement serum. Cell cytotoxicity was assessed with a Promega CytoTox-Glo kit.

Results

Various supplements were evaluated in fed-batch cultures and resulted in 15-45% Ab galactosylation without compromising cell growth and Ab titers. Design of experiment analysis determined an optimal composition, deemed “Optimized Supplement,” which was evaluated against a panel of galactose-modulating supplements from other suppliers. The Optimized Supplement resulted in a similar viable cell density (VCD) and cell viability compared to the fed-batch culture Control which had no supplements (Fig. 1a). Supplements from Supplier 1 resulted in similar to half the VCD of the Control and the 2X Supplier 1 Supplement resulted in over 40% galactosylation. The function of the Abs was further evaluated in a CDC assay (Fig. 1d). Abs from the Optimized Supplement were more effective than the Control Abs and had a significantly lower half-maximal effective concentration (EC_{50} 1.19 μg/mL) than the Control (1.71 μg/mL). Abs from the 2X Supplier 1 Supplement had a similar EC_{50} to the Control which may be due to the higher Man5% of the Abs.

Conclusions

An Optimized Supplement was produced through fed-batch evaluation and design of experiment analysis. The Optimized Supplement outperformed all other supplements from other suppliers and resulted in the best overall cell growth, glycan profile, and functional Ab activity (Table 1).
A semi-automated HTS platform was developed to support media and feed formulation and development for early stage biologics projects. The platform utilizes 24 DWPs, NyONE cell imager, AMBR15, Freedom EVO liquid handler system, and BioHT metabolic analyzer to accelerate the screening process. This screening platform not only improves process throughput, operational precision, and traceability of formulation preparation, but also reduces the labor for the media and feed formulation preparation.

Acknowledgements
Authors would like to thank Dr. Benjamin Youn in Manufacturing Science and Technology (MSAT) at BioMarin for his help on coding the Excel Macro program for AMBR15, and Dr. Donald L. Traul from TAP Biosystems (now part of the Sartorius Stedim Biotech Group) for his assistance on AMBR15 operations.

References
1. Radu C, Adrar HS, Alamir A, Hatherley I, Trinh T, Djaballah H: Journal of laboratory automation. Designs and Concept-Reliance of a Fully Automated High Content Screening Platform. 2012;17(5):359-369.
2. Delouvre F, Sirez G, Tran A-Y, Mukankurayija L, Kochanowski N, Malphettes L: BMC Proceedings. ambr™ Mini-bioreactor as a high-throughput tool for culture process development to accelerate transfer to stainless steel manufacturing scale: comparability study from process performance to product quality attributes. 2015;9(Suppl 9):P78.
A perfusion medium requires high concentrations of specific nutrients while balancing other components to support intensified perfusion processes. Using a combination of design of experiment (DOE), multivariate analysis (MVA), and spent media analysis, we developed a catalog perfusion medium from first principles, de novo. DOE central composite experiments were run and component concentrations were optimized in the selected prototype. In parallel, amino acid specific consumption rates were calculated from bioreactor spent media samples and used to adjust the concentration of amino acids to target a reduced CSPR. Increasing specific amino acids concentrations resulted in a significant reduction of the minimum CSPR across all tested cell lines - for example the CSPR of CHO-S was reduced from 60 to 39pL/cell/day (Table 1). However, even at the lower CSPR, spent media analysis revealed excess concentration of some amino acids, so specific accumulating amino acids were reduced and components were streamlined for the final medium: EXCELL® Advanced HD Perfusion Medium.

Using this medium, a CHO-S and a CHOZN® GS cell line producing a fusion protein were cultured at a CSPR of less than 40pL/cell/day with a VCD of 50*10^6vc/mL. Metabolic profile, productivity, and product quality were constant over the 30 day steady state. The CHOZN® GS cell line was also tested at 80*10^6vc/mL with a CSPR of 33pL/cell/day (Fig. 1). We have developed a catalog perfusion medium from first principles, ensuring broadness of application by using seven cell lines in scaled-down systems and four in perfusion bioreactors. The final catalog medium showed significant improvements in productivity across all cell lines, with reduced CSPRs when compared to enriched fed-batch medium or initial prototypes (Table 1).

**Acknowledgments**

Thanks to the bioreactor team of Dustin Davis, Amer Al-Lozi, and Jana Mahadevan.

**Reference**

1. Davis D, Riesberg J, Lyons D: Perfusion media development using cell settling in automated cell culture system, PO054, ESACT 2017.

---

**Table 1 (abstract P-083).** CSPR and qp, improvements from early prototype to EXCELL® Advanced HD Perfusion Medium with three cell lines. Final catalog perfusion medium requires greatly reduced CSPR with higher specific productivity

| CHO IgG    | 74 | 39 | 8.9 | 10.5 | 50*10^6vc/mL |
|------------|----|----|-----|------|--------------|
| CHOZN GS Fusion | 72 | 39 | 8.7 | 9.6 | 50*10^6vc/mL |
| CHOZN GS IgG | 80 | 59 | 20  | 28.5 | 50*10^6vc/mL |

**Table 1 (abstract P-082).** Comparison of throughput between the traditional and high-throughput screening method

| Condition per Incubator * | Formulation | Cell Preparation | Counting b | Tier Assay |
|---------------------------|-------------|-----------------|-------------|------------|
| HTS platform              | 384 conditions | Fully automated | 0.625 min/sample | 15 min/24 samples |
| Traditional Method        | ~100 conditions | Manual preparation | 3 mins/samplers | 1 hour/24 samples |

*a Based on max capacity of the incubator. **Based on max capacity of the incubator.

**P-083**

"De novo" high density perfusion medium: increased productivity and reduced perfusion rates

Jeremiah Riesberg, Irfan Hodic, Delia Lyons
MilliporeSigma, St. Louis, MO, 63109, USA
Correspondence: Jeremiah Riesberg (jeremiah.riesberg@sial.com)

**Background**

High Throughput Screening (HTS) was performed with seven cell lines, while four were used in bioreactors: CHO-S, DG44, and two CHOZN® GS lines, each producing different monoclonal antibodies and include a fusion protein. For HTS experiments, cells were inoculated at 2.0x10^6vc/mL with a 30 mL working volume in 50 mL TPP® tubes and cultured for 7 days in a Multitron shaken at 200rpm, 37°C, 80% RH, and 5% CO2.

For benchtop perfusion, cells were inoculated at 0.4-2.0x10^6vc/mL in 3L Applikon Bioreactors (Applikon, Netherlands) with a 2L working volume. Bioreactors were operated at 350 rpm, 37°C, 40% DO, and a pH of 6.9 or 7.1±0.05 depending on the cell line. Oxygen was supplied through an L- sparger or microsparger as needed, and Excell® antifoam (MilliporeSigma, Germany) was added at a maximum rate of 0.25% v/v to control foam. At a cell concentration of ~6.0x10^6vc/mL, perfusion was initiated using the ATF2 (Repligen, Massachusetts), with a bleed set to maintain cell concentrations at 50 or 80*10^6vc/mL.

**Results**

Two “de novo” prototype media were developed using DOE and MVA in HTS with TPPs and an ambr®15 [1] and one was chosen for further development after comparing to a basal medium enriched with feed in bioreactors. Eleven components were identified as significant effectors of critical parameters for perfusion processes across evaluated cell lines. DOE central composite experiments were run and component concentrations were optimized in the selected prototype. In parallel, amino acid specific consumption rates were calculated from bioreactor spent media samples and used to adjust the concentration of amino acids to target a reduced CSPR. Increasing specific amino acids concentrations resulted in a significant reduction of the minimum CSPR across all tested cell lines - for example the CSPR of CHO-S was reduced from 60 to 39pL/cell/day (Table 1). However, even at the lower CSPR, spent media analysis revealed excess concentration of some amino acids, so specific accumulating amino acids were reduced and components were streamlined for the final medium: EXCELL® Advanced HD Perfusion Medium.

Using this medium, a CHO-S and a CHOZN® GS cell line producing a fusion protein were cultured at a CSPR of less than 40pL/cell/day with a VCD of 50*10^6vc/mL. Metabolic profile, productivity, and product quality were constant over the 30 day steady state. The CHOZN® GS cell line was also tested at 80*10^6vc/mL with a CSPR of 33pL/cell/day (Fig. 1).

**Conclusions**

We have developed a catalog perfusion medium from first principles, ensuring broadness of application by using seven cell lines in scaled-down systems and four in perfusion bioreactors. The final catalog medium showed significant improvements in productivity across all cell lines, with reduced CSPRs when compared to enriched fed-batch medium or initial prototypes (Table 1).
Improving mammalian cell culture process development by model-assisted design of experiments

Johannes Möller, Tobias Steinmetz, Marius Braakmann, Ralf Pörtner
Institute of Bioprocess and Biosystems Engineering, Hamburg University of Technology, Hamburg, D-21073, Germany
Correspondence: Ralf Pörtner (poertner@tuhh.de)

BMC Proceedings 2018, 12(Suppl 1): P-087

Background
There is a rising demand for accelerated process development, increased efficiency and economics for biopharmaceutical production processes. Furthermore, increased process understanding have evolved from the Process Analytical Tool initiative (PAT) and the Quality by Design (QbD) methodology. In contrast to one-factor-at-a-time methods, statistical Design of Experiment (DoE) methods are widely used to develop biopharmaceutical processes. Even if high-throughput systems can handle these numbers of experiments in parallel, the heuristic restriction of boundaries and the high number of factors results in stepwise iterations with multiple runs. Therefore, the combination of model-based simulations with DoE methods (mDoE) for the development of sophisticated cell culture processes is a novel tool for process development [1]. It is used to reduce the number of experiments during DoE and the time needed for the development of more knowledge-based cell culture processes. This concept was applied to the optimization of the initial glutamine and glucose concentrations of a CHO batch process.

Material and methods
A mechanistic model was adapted and modified from [2] and used to describe the dynamics of cell metabolism and antibody production of an IL-8 antibody producing CHO cell line (see abbreviation of Fig. 1 for cultivation details). Experiments were simulated and compared to a fully experimental DoE. As can be seen from Table 1, user-defined constraints were chosen to get a stable and reproducible process with the aim of maximizing the cell density but decreased lactate and ammonia production.

Results
At first, the experimental space was estimated by simulating the responses for broad concentration ranges and calculating the multiple response desirability function (Fig. 1a). This results in a small area (turquoise) suggested as experimental space. Experiments were planned within these boundaries and responses were either simulated (Fig. 1b, 4 cultivations for fitting the model) or compared with the purely experimental responses (Fig. 1c, 16 cultivations). Optimal concentrations for glutamine and glucose with respect to the constraints are in the lower right corner and similar for both methods (red frame, Fig. 1).

Conclusion
Compared with the fully experimental design, mDoE results in a reduction of 75% in the number of experiments (4 experiments for modelling vs. 16 experiments in experimental DoE). The method is intended to optimize cultivation strategies for mammalian cell lines and evaluated these before experiments have to be performed in laboratory scale. This results in a significant time and cost reduction during process development and process establishment. The strategy is especially intended for the use in multi-single-use-devices to speed up process development.

Acknowledgements
We kindly acknowledge the Cell Culture Technology group (Bielefeld University, Prof. Dr. Thomas Noll) for providing the cell line used in this work and the Federal Ministry of Education and Research for funding (Grant no. 031B0305).

References
1. Möller J and Pörtner R: Model-based Design of Process Strategies for Cell Culture Bioprocesses: State of the Art and New Perspectives. New Insights into Cell Culture Technology, 1st edition, InTech. doi:10.5772/67600, 2017 157-172.
2. Kern S, Platas Barradas O, Pörtner R, Frahm B: Model-based strategy for cell culture seed train layout verified at lab scale. Cytotechnology, 2016 Aug; 68(4):1019-32. doi: 10.1007/s10616-015-9858-9. Epub 2015 Mar 21.

Table 1 (abstract P-087). Constraints for medium optimization

| Constraint       | Constraint Value |
|------------------|------------------|
| Viable cell density | > 10^7 cells/ml  |
| Antibody         | maximize         |
| Lactate          | < 30 mM          |
| Ammonium         | minimize         |

Fig. 1 (abstract P-087). Reduction of experimental space and comparison of simulated and experimental medium optimization, experimental design was done in Design Expert 9 (I-optimal Design, 5 lack-of-fit, 5 replicate points); model was fitted to mean of 4 parallel shaking flask cultivations (80 ml working volume, MATLAB 2011 a), cultivation was done in 16 parallel shaking flasks (40 ml working volume each), Incubator: Kuhner LT-XC (37°C, 5% CO2, 85% humidity, 12.5 mm shaking diameter, 200 rpm), Medium: TC-42, Xell AG.
P-092
Understanding of decreased sialylation of Fc-fusion protein in hyperosmotic recombinant Chinese Hamster Ovary cell culture: N-glycosylation gene expression and N-linked glycan antennary profile
Jong Hyun Lee, Yeong Ran Jeong, Yeon-Gu Kim, Gyun Min Lee
1Biological Sciences, KAIST, Daejeon, 305-701, Republic of Korea; 2Biotechnology Process Engineering Center, KRIIBB, Cheongju, 363-883, Republic of Korea; 3Department of Bioprocess Engineering, UST, Daejeon, 305-350, Republic of Korea

Correspondence: Gyun Min Lee (gyunminlee@kaist.ac.kr)
BMC Proceedings 2018, 12(Suppl 1):P-092

Background
For the large-scale production of therapeutic glycoproteins, fed-batch culture has been widely used for its operational simplicity and high titer. However, repeated feeding of medium concentrates and/or addition of a base to maintain optimal pH during fed-batch culture lead to increase in osmolality. The hyperosmolality affects glycosylation in a protein-specific manner. However, the mechanism behind such osmolality-dependent variations in glycosylation in recombinant Chinese hamster ovary (rCHO) cells remains unclear.

Materials and methods
In this study, to better understand the effect of hyperosmolality on the glycosylation of a protein produced from rCHO cells, we investigated 52 N-glycosylation-related gene expression and N-linked glycan structure in Fc-fusion protein-producing rCHO cells exposed to hyperosmotic conditions. Furthermore, to validate the effect of hyperosmolality on protein glycosylation, we performed hyperosmotic culture supplemented with betaine, an osmoprotectant, and then analyzed the N-linked glycan structure and mRNA levels of N-glycan branching/antennary genes.

Results
After three days of hyperosmotic culture, nine genes (ugp, slc35a3, slc35d2, gcsl, maneba, mgat2, mgat5b, b4galt3, and b4galt4) were differentially expressed over 1.5-fold of the control, and all these genes were down-regulated. N-linked glycan analysis by anion exchange and hydrophilic interaction HPLC showed that the proportion of highly sialylated (di-, tri-, tetra-) and tetra-antennary N-linked glycans was significantly decreased upon hyperosmotic culture. Addition of betaine, an osmoprotectant, to the hyperosmotic culture significantly increased the proportion of highly sialylated and tetra-antennary N-linked glycans (P ≤ 0.05), while it increased the expression of the N-glycan branching/antennary genes (mgat2 and mgat4b). Thus, decreased expression of the genes with roles in the N-glycan biosynthesis pathway correlated with reduced sialic acid content of Fc-fusion protein caused by hyperosmolar conditions.

Conclusions
Taken together, the results obtained in this study provide a better understanding of the detrimental effects of hyperosmolality on N-glycosylation, especially sialylation, in rCHO cells. The identified genes, particularly mgat2 and mgat4b, are potential targets for engineering in CHO cells to overcome the impact of hyperosmolality on glycoprotein sialylation.

Acknowledgements
This research was supported in part by a grant from the Bio & Medical Technology Development Program of the NRF funded by the Korean government (2013M3A9B6075931, 2016R1A2B4014133).

References
1. Pfizenmaier J, Junghans L, Teleki A, Takors R. Hyperosmotic stimulus study discloses benefits in ATP supply and reveals mRNA/mRNA targets to improve recombinant protein production of CHO cells. Biotechnol J 2016; 11(8):1037-1047.
2. Schmelzer AE, Miller WM. Effects of osmoprotectant compounds on NCAM polysialylation under hyperosmotic stress and elevated pCO2. Biotechnol Bioeng 2002; 77(4):359-368.

P-093
Disruptive cost-effective antibody manufacturing platform based on cutting-edge purification process
V. Medvedev, M. Duyck, T. Albano, J. Castillo
Univercells SA, Gosselies, Belgium

Correspondence: V. Medvedev (v.medvedev@univercells.com)
BMC Proceedings 2018, 12(Suppl 1):P-093

Background
Demand for high-quality monoclonal antibodies is growing exponentially, calling for new production capacities. Overcoming current limitations of conventional manufacturing strategies, namely the high capital investment and production cost, can only be achieved through innovative process designs based on the latest technologies. This study presents a process design combining batch-fed technology with continuous multi-column capture. An advanced cell culture clarification method was introduced to simplify downstream operations and increase overall cost-effectiveness of the process, for an optimized production of recombinant proteins.

Materials and methods
This study was performed with CHO cells expressing a monoclonal antibody targeted against the Coronavirus responsible for the Middle East Respiratory Syndrome (MERS), developed by Organic VaccinesSM and the NIH, kindly provided to Univercells.

Upstream process:
- Fed-batch, 12 days culture at 10L scale with CD-CHO chemically defined media and feeds.

Harvest treatment:
- Precipitation of impurities in the production bioreactor using organic compounds (<1% v/v) and flocculation by electropositive organics (<0.1% w/v).
- Acidic pH and physiological conductivity.

Harvest clarification:
- Depth filtration with coarse and fine grade depth filters followed by sterilising-grade filtration.
- Primary depth filters: D0HC, D0SP, Clarisolve 20 (Merck), Sartoclear Dynamics (Sartorius).
- Secondary depth filters: X0HC (Merck), DL20 (Sartorius).
- Sterilizing grade filters: Express SHC (Merck), Sartapore 2 XLG (Sartorius).

Capture of antibody:
- Affinity capture: Captiva PriMab (Repligen), Mab Capture A Select (Thermofisher), Amosphere A3 (SR), Toyopera AF-ProteinA HC-650F (Tosoh).
- Cation exchange capture: Gigacap S-650M (Tosoh).

Results
Upstream processing and harvest treatment: Culture reached 0.5 g/L (8×10^7 cells/mL; 90% viability), harvest treatment was found to be very effective in terms of impurities clearance. Capture: Capture strategies were evaluated from the point of view of simplification of downstream operations, with HCP impurities content monitored as a key performance indicator.
- Protein A affinity chromatography: Advanced harvest clarification enabled major improvements in affinity capture, in terms of eluate purity and reduction of host cell impurities (<35 ppm in all conditions tested). (Fig. 1).
Cation exchange chromatography: CEx allows higher capacities (>100 g/L) than protein A, whilst being more affordable (from 2- to 6-fold cheaper). Low residual HCP (<50 ppm) was observed with all CEx resins tested. Without harvest treatment and clarification preceding the capture studies (either affinity or CEx), results showed a lower binding capacity of the resin, a higher content of HCP in the eluate (up to 2000 ppm), a higher content of HMW species in the elution fraction (up to 3-fold higher) and a significant turbidity of the neutralized eluate.

Continuous multicolumn chromatography: Further options to increase cost efficiency include using a continuous multicolumn setup (Table 1). Two models were assessed based on two different static binding capacities (SBC), demonstrating that 4 to 6 columns of 100ml were able to process a 200L production in less than 24h.

Conclusion
This method provides a great opportunity for designing simplified and low footprint Mabs DSP processes, while maintaining similar or achieving superior quality profile compared to standard approaches:

- Harvests treatments followed by depth filtration proved to be a cost-efficient way to obtain pretreated feed and minimize the burden on downstream operations.
- Protein A resins exhibited advantages of extracting key contaminants during harvest treatment, while CAEX confirmed to be a competitive capture strategy.
- Switching from batch to continuous multicolumn mode allowed to process a complete batch in less than 24 hours, requiring lower media and resins volumes. Followed by a single polishing step, such process set-up strongly supports the reduction of operations required to deliver a high-quality product.

Acknowledgements
Organic Vaccines™ and the NIH, who kindly provided to Univercells.

Table 1 (abstract P-093). Capture results with multicolumn chromatography

|            | 20L Feed at 4g/L | 4 columns | 6 columns |
|------------|------------------|-----------|-----------|
| MW        | Lancs            |           |           |
| 1          | Salticore dynamics + DL20 + MCAS; | Elution fraction (pH 3.6) | |
| 2          | D20P + XHIC + MCAS; | Elution fraction (pH 3.6) | |
| 3          | D20H + B10H + Amphere A3; | Elution fraction (pH 3.8) | |
| MW        | Molecular Weight Marker (Bio-Rad) |           |           |

![Fig. 1 (abstract P-093). Capture on protein A](image)

P-096
Analyses of product quality of complex polymeric IgM produced by CHO cells
Julia Hennicke, David Reinhart, Renate Kunert
University of Natural Resources and Life Sciences, Vienna, 1190, Austria
Correspondence: Julia Hennicke (julia.hennicke@boku.ac.at)
BMC Proceedings 2018, 12(Suppl 1):P-096

Background
Immunoglobulin M (IgM) antibodies are secreted by B cells as the first defense against invading pathogens during primary immune response. Some IgM antibodies already gained the orphan drug status, which shows their unique capability in therapy of rare diseases. Potential fields for applications are discovered with increasing knowledge about these molecules. It seems that the most active forms are pentameric and hexameric IgMs. Unfortunately, recombinant production of IgMs is rather difficult as secretion and correct polymer formation results in low expression yields and mixtures of polymers.

Materials and methods
We established stable producing Chinese hamster ovary (CHO) DG44 cell lines to analyze cellular and extracellular factors that influence quantity and quality of the produced recombinant polymeric IgM in future studies [1]. One quality parameter is polymer distribution, which can be measured directly in cell culture supernatant using densitometric analyses [2]. Additionally, we developed a very efficient single-step-affinity purification strategy using the POROS CaptureSelect IgM Affinity Matrix to analyze pure IgMs. For more precise measurements of the IgM isomeric distribution we separated the purified polymers by high performance liquid size exclusion chromatography (SEC-HPLC).

Results
Our CHO DG44 cell lines grow to peak cell concentration of 4.5x10^6 cells/mL in Erlenmeyer flasks and 4.0x10^6 cells/mL in bioreactors. Similar productivity of approximately 50 mg/L was observed for cells cultivated in both cultivation vessels in a non-optimized batch culture using chemically defined media. Analysing how cultivation conditions affect the fraction of polymers may offer clues about the assembly of polymers and the challenges of IgM production. We quantified polymeric distribution of IgM directly in the supernatant using a densitometric method [2]. Cultivated under standard conditions (37°C, pH 7) IgM102 is produced as 90% pentamers, whereas IgM012_GL only consists of approximately 80% pentamers. The purified IgM012_GL was analysed with SEC-HPLC and contained 81% pentamer and 19% dimer, which is comparable to the results achieved with densitometry. The purification of the IgM antibodies was quite challenging as the manufacturer recommend acidic elution, which led to aggregation and inefficient elution of our model IgMs. Therefore, we screened for different elution buffers that prevent denaturation and aggregation. By combining high salt concentrations with moderate pH reduction we optimized elution conditions to 88-99% IgM recovery, which corresponded to a five to six fold improvement compared to the manufacturers’ conditions. SDS-PAGE analysis and SEC-HPLC showed that our elution strategy resulted in a very pure product after a single chromatographic step. The purification strategy was verified with the IgM103, IgM104 and IgM617.

Conclusions
Our model IgMs were produced in a ratio of approximately 4:1 pentameric to dimeric IgM, measured concordantly with both analytical methods. Process development on IgM purification using the POROS Capture Select human IgM affinity matrix enabled the recovery of highly pure fractions. Through optimization, by combining mild pH and high salt concentrations, the relatively low elution yields were increased by a factor of 5-6. Applying densitometry and SEC-HPLC we will investigate how culture conditions influence polymer formation in future.

Acknowledgements
We thank Polymun Scientific Immunobiologische Forschung GmbH for providing the antibodies IgM103, IgM104 and IgM617 as a kind gift. This
work was supported by the PhD program BioTop (Biomolecular Technology of Proteins) funded by the Austrian Science Fund (FWF Project W1224).

References
1. Chromikova, Mader, Steinfellner, Kunert: Evaluating the bottlenecks of recombinant IgM production in mammalian cells. Cytotechnology 2015, 67:334-356.
2. Vorauer-Uhl, Wallner, Lhota, Katinger, Kunert: IgM characterization directly performed in crude culture supernatants by a new simple electrophoretic method. J Immunol Methods 2010, 359:21-27.

P-097
Development of a high-throughput scale down model for a high cell density PER.C6®-based adenovirus perfusion production process
Julia Meijer, Iris van Hoom, Matthijs van Duijvenboden, Jeroen de Lozanne, Perrine Rouel, Bas Diepenbroek
Vaccine Process and Analytical Development, Janssen Vaccine and Prevention B.V., Leiden, Netherlands
Correspondence: Julia Meijer
BMC Proceedings 2018, 12(Suppl 1):P-097

Background
Currently, no small scale (<0.5L) cell culture system is commercially available for high cell density perfusion cultivations to use in high throughput screening studies. To increase throughput for process characterization activities at Janssen Vaccines and Prevention, a shaker flask-based scale down model was developed. Though, the control possibilities of shaker flask cultures are technically very limited and different compared to a bioreactor controlled process. In addition, the sensitivity of the shaker flask model should allow the detection of the effects of process parameters on critical quality attributes (CQAs) of the vaccine produced at large scale.

Material and methods
Iterative experiments were performed in shake flasks to evaluate the influence of cultivation parameters such as shaking speed, working volume, CO2% in the incubator and daily base additions on cultivation parameters (as cell growth, pH and DO). In addition, a medium exchange was tested to mimic the perfusion mode used in the bioreactor process. The PreSens shake flask reader was implemented to allow for pH and DO monitoring. The conditions for which the performance as reflected in specific virus titer showed the best fit were selected. At these conditions, a series of parallel shaker flask infections were conducted to demonstrate statistical equivalence of performance parameter and CQAs (as cell specific IU titer and VP/IU ratio) between the production scale and reduced scale processes and thus to qualify the shake flask as a scale-down model.

Results
A daily medium exchange by centrifugation was implemented and cultivation parameters for shake flasks were identified. Based on performance parameter (cell specific VP titer) and the CQAs of the vaccine (cell specific IU titer and VP/IU ratio), equivalence between the production-scale and scale down systems was confirmed. The scale down model data fall into the 95% prediction intervals calculated on manufacturing data whereas scale down model data from batch mode experiments (using non optimized cultivation conditions) do not.

Conclusions
The shake flask as a scale down model for the 10L bioreactor perfusion process was qualified. This model is a tool to screen a subset of process parameters at a higher throughput, thereby reducing process characterization timelines.
the optimization of Sartorius Stedim Cellca’s standard cell line development process.

Conclusions

- Signal peptide SP(9) was identified as a promising candidate with an average 2.4-fold titer increase during screening of four signal peptides.
- SP(9) was able to improve production titers up to 354% compared to standard SP.
- SP(9) was able to improve cell-specific productivities up to 290% compared to standard SP.
- Future usage of SP(9) contributes to the further optimization of Sartorius Stedim Cellca’s standard cell line development process.

### Background

More and more experiments are used to assess bioreactor suitability and stability of clones, to evaluate media composition and other process parameters, and to start upscaling campaigns. This has resulted in a major bottleneck due to the increase in data capturing, processing, aggregation, visualization, and statistical analysis. In addition, the association of the data with the experimental context (e.g., fermentation protocols, media recipes, bioreactor control parameters) is not easily accomplished in high throughput. The data generated in the process must not only be analyzed, but also managed and stored to enable easy tracking and relating to historical records. Furthermore, the processes are often developed by global teams interacting in complex enterprise IT ecosystems. Therefore, new and high performing systems for data capture, processing, and analysis need to be integrated in order to enable storage and correlation of experimental context information and various types of time course analytics data.

### Materials and methods

We have developed Genedata Bioprocess™, a new enterprise platform for bioprocess development. The platform enables automatic capture and visualization of all online and offline data (e.g., pH, O2, metabolic data), auto-calculations and aggregations (e.g., IVCD, qP, consumption rates) and multi-parametric assessment of any type of data-series bioreactor data in the context of experimental protocol data (e.g., process parameters, feeds). Genedata Bioprocess comes with dedicated interfaces for integrating with relevant laboratory instruments, control systems, statistical analysis software packages and custom enterprise solutions. It enables the modeling and tracking of complex nonlinear workflows and supports decision making in bioprocess development. The data can be analyzed in the context of upstream process development, and also be correlated to other unit operations. Automation support assists the ever increasing throughput of bioprocess development operations, and the analysis of experimental data and process parameters across unit operations or even different projects. This overall integration enhances process development workflows.

### Results and conclusions

Highlighted use cases describe the selection of the best producer clones (Fig. 1a), the identification of optimized media feeding strategies (Fig. 1b), and the comparison of clone performance across different fermentation scales (Fig. 1c). A special focus is on the analysis of data from micro- and bench-top bioreactors (such as the ambr15™ and DasGip™ systems) operated in parallel. These bioreactors allow for increased throughput of clone selection and process optimization studies, which in turn leads to an increase in data generation. Genedata Bioprocess supports integration with such systems and enables a comparison of data regardless of the instrument provider or scale. Automated bioreactor data analysis allows development groups to take advantage of even richer datasets and, as data management is built-in to the system, the data can be easily tracked and associated to historical records. Another focus is on cross-reactor scale comparisons. Data coming from different bioreactor scales can be easily imported into the platform and analyzed to establish the best conditions for upscaling. Genedata Bioprocess enables the correlation of process parameters (e.g., fermentation protocols, media recipes, bioreactor control parameters), with key performance indicators of the processes (e.g., Titer, qP) and the product quality attributes (e.g., aggregation, glycosylation profiles). Finally, bioreactor time course data can be tracked together with clone analytics and product quality parameters, which makes the platform uniquely able to support end-to-end biopharma development.

### Acknowledgements

Allison Kurz and Gian Andrea Signorelli, Genedata AG, Basel, Switzerland
Fig. 1 (abstract P-108). Example use cases for evaluating Bioreactor results with Genedata Bioprocess. a Identification of top performer cell line. The screenshot highlights interactive user interface, allowing to visualize and select cell lines based on custom criteria. b Tracking of process conditions together with online and offline performance analytics. The system allows to flexibly define tracked parameters and select optimal process conditions. c Comparison of process performance across different reactor scales. The open architecture makes Genedata Bioprocess a provider agnostic system which allows to aggregate and compare data regardless of provider.
Design and evaluation of next-generation biologics for cancer immunotherapy

Maria Wendt1, Guido Cappuccilli1, Carl Bruder1, Chris Smith2, Christoph Freiberg1, Yang-Chieh Chou1, Hans Peter Fischer3

1Biologics, Genedata, Basel, Switzerland; 2Biologics, Genedata, Boston, MA, USA; 3Biologics, Genedata, San Francisco, CA, USA

Correspondence: Maria Wendt (biologics@genedata.com)

BMC Proceedings 2018, 12(Suppl 1):P-123

Background

Bi- and multi-specific antibodies, antibody-cytokine fusion proteins, non-immunoglobulin scaffolds, chimeric antigen receptors (CARs), engineered T-cell receptors (TCRs) and TCR-based bispecific constructs can provide significant advantages for use in cancer immunotherapy. However, as highly engineered molecules they pose new challenges in design, engineering, cloning, expression, purification, and analytics. We have thus implemented an infrastructure that addresses these challenges and enables the industrialization of these various novel therapeutic platforms.

Material and method

In close collaboration with leading biopharmaceutical companies, we implemented a workflow, data management and analysis support system, Genedata Biologics™, enabling the automated design, screening, and expression of large panels of therapeutic candidates using these novel technologies. We have also built tools for developability and manufacturability assessments of these complex molecules. We have ensured that there is a seamless integration of all data generated and that functionalities such as bulk protein and vector generation using our in silico cloning engine, configurable library of template vectors and cloning strategies, fully annotated in silico protein molecules and DNA constructs, and DNA synthesis verification support, can be used for the newest protein formats and molecule topologies.

Results and discussion

We implemented data structures and data handling systems, which mirror how these complex next-generation biologics molecules and cell lines are being designed, screened, and analyzed. The result successfully addresses workflows for TCR optimization and engineering. We exemplified this with the generation and evaluation of a panel of engineered TCRs with an alpha chain CD3 randomization and successfully supported the analysis and selection of beneficial mutations. The system also successfully supported workflows for the design and generation of a panel of TCR-based bispecifics (TCR coupled with anti-CD3) using automated molecule registration and in silico cloning tools and subsequent capture of expression, purification, and functional and analytical characterization data. On the CAR-T cell front, the system is able to provide traceability of the work from antibody generation, optimization, CAR engineering, and sample information, manufacturing process parameters, and process and product quality attributes. Critical quality attributes and developability assessment should be enabled along the whole bioprocess development workflow, including cell line development, upstream and downstream process development, as well as analytical and formulation development.

Materials and methods

We have developed a comprehensive platform, Genedata Bioprocess™, which supports drug candidate developability and manufacturability assessment and bioprocess development. The platform captures and structures the cell line and process parameters together with analytical data for cell lines, processes, and protein products. The protein analytical data being tracked include biological data (such as bioactivity, immunogenicity), and physicochemical properties. These properties include glycosylation, chemical liabilities (such as deamidation and oxidation), aggregation, stability under different conditions (low pH, high temperature), solubility, and impurities. Genedata Bioprocess™ simplifies and streamlines laborious, manual process and supports tools for molecule, clone, and process selection. Furthermore, the platform allows for seamless integration with laboratory instruments, statistical software packages, and custom solutions.

Results and conclusions

Here, we present use cases showing how to identify and annotate liability sites prone to chemical modifications (Fig. 1a) and how to monitor CAR-T molecules allowing to assess developability more efficiently. We show how the analytical data generated in the course of a developability assessment are compiled to select the best drug candidate (Fig 1b). Implemented traffic-light systems indicate where molecules harbor issues such as in case of the antibody TPP-86, which is compromised by low temperature and repeated freeze-thaw operations. The same assessment views can also be applied on batches and cell lines. The underlying data can be visualized graphically. As an example, we show how types of products obtained from different cell line clones generated in a cell line development campaign for the molecule TPP-86 (Fig. 1c). Even though the selected clone CLI-35 meets the glycosylation criteria (e.g., <13% afucosylation, <40% galactosylation, <2% sialylation), the produced...
High glucose concentration and low specific cell growth rate improve specific r-tPA productivity in chemostat culture of CHO cells

Mauricio Vergara1,2, Andrea Müller2, Verónica Avello2, Cristian Acevedo3, Julio Berrios2, Juan G Reyes1, Claudia Altamirano2,4

Correspondence: Claudia Altamirano (claudia.altamirano@pucv.cl)

Acknowledgements

Allison Kurz, Gian Andrea Signorell, Genedata AG

Materials and methods

Chemostat cultures were performed at two dilution rate (D)(0.010 or 0.018(h−1)), two temperatures (33 or 37°C) and three feed glucose concentrations (20, 30 or 40 mM). The response was analysed considering r-protein production, cell growth and key metabolites. r-tPA protein concentration was determined by immunoassay (TrinILIZE tPA KIT); cells were counted using a hemocytometer and cell viability was determined by the method of exclusion using trypan blue (TB154, Sigma, USA); glucose, lactate and glutamate were determined by enzymatic assay using a biochemical analyser YSI (Yellow Spring Instruments). Statistical analysis of the results was performed by ANOVA (Design-Expert 7 for Windows).

Results

A decrease in cell density was observed in response to an increase of glucose feeding concentration, regardless of temperature or specific growth rate (in this case μ=D) evaluated. The maximum cell densities were reached at 20mM, achieving 1.65 and 1.50 x10⁶ cells/ml at 37/33°C and 0.018(h−1); and 1.10 and 1.33 x 10⁶ cells/ml at 37/33°C and 0.010(h−1) respectively (Fig. 1a). The increase in glucose concentration from 20 to 40mM resulted in an qP increase of 3 and 3.3 fold at 33°C/0.018(h−1) and 37°C/0.018(h−1) respectively. A lower increase of 2.4 and 1.8 fold was reached at 33°C/0.010(h−1) and 37°C/0.010(h−1) respectively (Fig. 1b). The highest qS were reached at 37°C and 0.010(h−1). However, a positive effect of MH was not observed, in contrast to that observed in batch culture [1, 2, 3]. This behaviour suggests that low μ is a main factor on increased r-protein production in batch cultures exposed at MH condition.

The specific consumption rate of glucose was significantly increased by the glucose increase from 20 to 40mM and reduced by MH (Fig. 1c). At 0.010 (h−1) the specific production rate of lactate (qLac) was increased by glucose increase, independent of the culture temperature used. While at 33°C/0.018(h−1) the qLac decreased with increasing glucose concentration and at 37°C/0.018(h−1) a maximum consumption was observed at 30 mM glucose (Fig. 1d). The lactate-glucose yield (Fig. 1e) did not showed relevant changes at 0.010(h−1), while at 0.018(h−1) this yield showed a more efficient utilization of glucose, as glucose concentration was increased. However, this last behaviour was not reflected in an increase of r-tPA production.

Conclusions

The concentration of glucose has the greatest impact on the behaviour of the culture, and its increase affects positively the protein productivity. The MH did not improve proteins productivity of CHO cells producing tPA under the different conditions evaluated; low dilution rate and at high glucose concentration impact positively the protein productivity and the metabolism exhibited by the cells.

Acknowledgements

This work was supported by FONDECYT 3150373 and FONDECYT 1161452.

References

1. Yoon SK, Choi SL, Song JY. Effect of culture pH on erythropoietin production by Chinese hamster ovary cells grown in suspension at 32.5 and 37.0°C. Biotechnol Bioeng 2005; 89:345-56.
2. Lin CH, Huang Z, Wen W. Enhancing Protein Expression in HEK-293 Cells by Lowering Culture Temperature. PLoS One. 2015 10:e0123562.
3. Berrios J, Díaz-Barrera A, Bazán C. Relationship between tissue plasminogen activator production and specific growth rate in Chinese Hamster Ovary cells cultured in mannose at low temperature. Biotechnol Lett 2009 31:1493-9.
4. Liu Z, Dai S, Bones J. A quantitative proteomic analysis of cellular responses to high glucose media in Chinese hamster ovary cells. Biotechnol Prog. 2015 31:1026-38.
Mammalian cell cultures are the most commonly used bioprocess for the production of therapeutic recombinant proteins such as monoclonal antibodies (mAbs). Facing to the increasing demand of these biopharmaceuticals, the FDA has initiated the Process Analytical Technology (PAT) framework in order to encourage pharmaceutical industries to use innovative technologies to monitor in real time the critical process parameters (CPPs), and to ensure the final product quality [1].

One of the most important CPPs for cell culture bioprocesses is the specific growth rate (\( \mu \)), which is a direct indicator of cellular physiological state. Indeed, \( \mu \) is sensible to culture conditions and its value decreases when cells are in the unfavourable environment for growth [2], which may greatly influence mAb production and quality. However, until this day, the online monitoring of \( \mu \) remains a great challenge for mammalian cell culture bioprocesses.

Materials and methods

IgG-producing CHO cells were cultured in 2 L stirred bioreactors equipped with an \textit{in situ} dielectric spectroscopy (Hamilton). Operating conditions were fixed at 90 rpm, 50% of air saturation, pH 7.2 and 37°C. Permittivity of cell culture was measured every 12 min, which allowed to calculate in real time the VCD by using a previously established linear correlation. Then, a model of online estimation of \( \mu \) was developed based on VCD prediction and cell mass balance equations. Several signal noise filters and various calculation methods were evaluated to reach better model stability. Cell cultures were performed in both batch and feed-harvest modes. Feed-harvest cultures consisted of sequential renewals of 2/3 volume of the culture medium by following different strategies.

Results

This study proposed an innovative methodology based on dielectric spectroscopy to monitor in real time the cellular physiological state, by online estimating the specific growth rate (\( \mu \)) of cells. Model of online estimation of \( \mu \) was developed from cultures in batch mode, and was validated by comparing online estimated \( \mu \) with the experimental ones calculated at the end of the culture. With this model, the moment when \( \mu \) started to decrease significantly, which indicated that cells were no longer in the exponential growth phase, was identified as the critical moment. To demonstrate the interest of online estimation of \( \mu \), the developed model was applied to a feed-harvest culture, where the medium renewals were performed at the critical moments indicated by the model. This culture was then compared with the traditional feed-harvest culture where medium renewals were performed by following offline measurements of glucose and glutamine. We found that the online strategy allowed to maintain the value of \( \mu \) by renewing the medium at the right time, while the values of \( \mu \) varied a lot when using offline strategy. Moreover, by using the online estimation of \( \mu \), the glycosylation of IgG was kept at a high level (about 95%) throughout the whole culture. However, for the culture using offline strategy, the glycosylation level decreased progressively and was only about 75% at the end of the culture (Fig. 1).

Conclusions

Model of online estimation of \( \mu \) was developed by using dielectric spectroscopy, which allowed to monitor the physiological state of cells in cell culture bioprocesses. Implementation of this model in feed-harvest cell culture led to better mAb glycosylation, which demonstrates clearly the potential of this methodology in mAb production bioprocesses.

References

1. Hinz DC: Process analytical technologies in the pharmaceutical industry: the FDA’s PAT initiative. Anal. Bioanal. Chem. 2006, 384: 1036-1042.
2. Lao MS, Toth D: Effects of ammonium and lactate on growth and metabolism of a recombinant Chinese hamster ovary cell culture. Biotechnol. Prog. 1997, 13: 688-691.
P-135
Solid phase enzymatic re-modelling to produce single glycoform antibodies
Michael Butler1, Venkata S. Tay2
1NIBRT, Dublin, Ireland; 2GlaxoSmithkline, King of Prussia, PA, USA

Background
Monoclonal antibodies are normally synthesised from transfected mammalian cells as heterogeneous mixtures of glycoforms [1]. However, clinical efficacy may depend upon single glycoforms which have been difficult to isolate [2]. We have now developed an efficient method for generating single glycoforms by solid phase re-modelling which is superior to previous methods because it allows a sequential series of enzymatic changes without the need for intermediate purification of the antibody. Solid phase binding exposes the antibody glycans to enable easier access of the transforming glycosylation enzyme.

Materials and methods
The antibodies subjected to modification were a chimeric human/camelid monoclonal antibody (EG2), a humanized monoclonal antibody (IL8), a full size chimeric antibody (Cetuximab) and polyclonal antibodies obtained from pooled human serum. The antibodies were bound to a Protein A column using conditions typical of Mab purification (Fig. 1). After washing out non-bound impurities by a neutral pH elution buffer, each antibody was subjected to enzymatic modification directed to a targeted glycan profile (Table 1). The antibodies were then eluted with a low pH buffer and neutralized. The glycan profiles were analysed following glycan removal with PNGase F, labelling with 2-aminobenzamide and separation on a HILIC-HPLC column [3].

Results
Prior to enzymatic modification, glycan analysis of all 4 antibodies showed variable galactosylation and sialylation typical of human Abs. This included a distribution of FG0, FG1, FG2, FS1 bodies showed variable galactosylation and sialylation typical of human Abs. This included a distribution of FG0, FG1, FG2, FS1 and FS2 with galactosylation indices ranging from 0.22 for IL8 to 0.64 for EG2. There was minimal sialylation in IL8 but up to 11% in EG2. Glycan modifications were made as each antibody was held on a Protein A column in accordance with procedures shown in Table 1. Agalactosylated glycans were enriched by treatment with a single addition of galactosidase and neuraminidase. This resulted in 83-95% of agalactosylated structures in the Mabs and 65% in the polyclonal antibody. Galactosylated antibodies (>95% yield) were produced by a single stage reaction involving sialidase and by galactosyltransferase with UDP-Gal. Breakdown of the glycans to a trimannosyl core was accomplished by treatment of the agalactosylated structures with hexosaminidase. This produced a yield of 76-80% of the FM3 structure with a small remainder of FA1. Sialylated antibodies (>95%) were produced by a 2 stage reaction involving sialidase, galactosyltransferase and finally treatment with 2.6 sialyltransferase in the presence of CMP-NANA. The latter reaction produced equimolar quantities of monosialylated and disialylated Cetuximab and polyclonal antibodies. The results suggest that for human antibodies (150 kDa) there may be a limitation for sialylation given the steric constraints between the two CH2 domains of the dimeric structure. The ability to sialylate the smaller camelid antibody (80 kDa) was greater resulting in a high (>90%) level of disialylated glycans. This suggests that the steric constraints for glycosylation may be lower. These sialylated antibodies have significant potential clinical importance for their anti-inflammatory activities.

Conclusions
We have modified the glycans of antibodies following immobilization on an affinity ligand column. This allows enzymatic transformation in a solid state that has a distinct advantage over the equivalent transformation in solution because the enzymes and buffers can be washed out on completion of the modification leaving the antibody still attached to the affinity ligand. This enables repeated rounds of an enzymatic reaction or sequential reaction steps without the need for intermediate antibody purification. The antibody can be removed eventually from the column by application of an elution buffer once all desired glycan modification have been made. Since affinity ligand purification of antibodies is performed routinely as an initial step of purification after cell culture, the glycan modification can easily be incorporated into this process. The enrichment of the resulting antibody for a targeted glycoform can enhance the potential therapeutic efficacy as it is known that specific glycoforms are required for certain biological effects.

Acknowledgements
Financial support is gratefully acknowledged from Natural Science and Engineering Research Council of Canada (NSERC) through a strategic network program (MabNet).

References
1. Spearman,M. and Butler,M.: Glycosylation in Cell Culture. Chapter 9 of Cell Engineering vol. 9, p237-258: Animal Cell Culture (ed. Al-Rubeai,M) publ. Springer 2015.
2. Lu, J, Sun, P. D., Structural mechanism of high affinity FcgammaRII recognition of immunoglobulin G. Immunological reviews 2015, 268, 192-200.
3. Krahn,N., Spearman,M., Meier,M., Dorion-Thibaudeau, J., McDougall,M., Patel,T.R., De Crescenzo,G., Durocher,Y., Stetefeld,J., Butler,M.: Inhibition of glycosylation on a camelid antibody uniquely affects its FcγRI binding activity. European Journal of Pharmaceutical Sciences 96:428-439 2017.
Table 1 (abstract P-135). Enzymatic reactions were conducted in 25 mM Tris + 50 mM NaCl buffer at the specified pH for 48-72 h. The % yields of the targeted glycans are shown. FG0 = fucosylated agalactosylated; FG2 = fucosylated digalactosylated; FM3 = fucosylated trimannosyl core, FA1 = fucosylated mannosyl core plus one GlcNAc, FS1 = fucosylated monosialylated biantennary, FS2 = fucosylated disialylated biantennary.

| Targeted Modification | Stages | Enzyme Reaction | Antibody | Final Structure | Yield % |
|-----------------------|--------|-----------------|----------|----------------|---------|
| Agalactosylation       | 1 Stage 1: 3 units/μL β(1,4) galactosidase, 3 units/μL neuraminidase at pH 6.6 | EG2 | FG0 | 85 |
| Galactosylation        | 1 Stage 1: 2 milli-units/μL β(1,4) galactosyltransferase, 3 mM UDP-galactose, 10 mM MnCl₂, 3 units/μL neuraminidase at pH 6.6 | EG2 | FG2 | 96 |
|                        | Stage 2: 20 units/μL β-N-acetylglucosaminidase at pH 6.6 | Cetux | FM3 | 80 |
|                        | Stage 2: 200 μg/mL β(1,4) galactosyltransferase, 3 mM UDP-galactose, 10 mM MnCl₂ at pH 7.5 | IL8 | FA1 | 17 |
|                        | Stage 2: 100 μg/mL α(2,6) sialyltransferase, 3 mM CMP-Neu5Ac at pH 7.5 | Polyclonal | FS2 | 43 |

Impact on cell growth and recombinant protein production from CHO cells

Materials and methods

CHO-K1 cells were grown in chemically-defined protein-free culture medium (Life Technologies-1835273) in shake flask (GX-00125P). The different fractions of spent-media (microvesicles and microvesicle-free spent media) were collected using ultracentrifugation method [1,3]. Quality of different fractions was ensured using Western blotting for exosomal marker, CD63 (SC-15363) and coomassie stained gel for loading control (Fig. 1a). To evaluate impact on cell growth, cells were seeded with microvesicles and microvesicle-free fraction collected from log-phase of culture and cell counts were performed by ViCell using trypan-blue dye exclusion method. For impact on productivity, cell-free supernatant, collected from microvesicle-treated human IgG secreting CHO culture from stationary-phase of culture with respective control, was evaluated using ELISA (ab100547). Microvesicles collected from 10% of media (by volume) from routine maintenance cultures compared to working volume for microvesicle-supplementation were used in each experiment.

Results

The growth of microvesicle-supplemented cultures had shorter lag-phase and achieved 1.2 fold higher maximum cell density (1.46x10⁶ viable cells/mL) compared to untreated standard culture (1.21 x 10⁶ viable cells/mL) and maintained higher for the remaining period of batch culture (Fig. 1b). However, microvesicle-free fraction did not had significant impact on growth. The viability of microvesicle-supplemented cultures, similar to microvesicle-free media supplemented, was also higher compared to standard culture suggesting potential use of microvesicles for regulating CHO growth in production cultures. This could be possibly because microvesicles have already been reported to be enriched with cell growth/death-regulating proteins and hence facilitating cell growth [2,3]. We have also observed abundance of cell cycle regulators including cyclin D1 in microvesicle-fraction compared to microvesicle-free spent-media in our laboratory (data not shown); however, further investigation are required to prove the hypothesis. The overall productivity of human IgG secreting CHO cells was also observed to increase by ~4 fold following supplementation of microvesicles to the culture without significantly affecting per-cell productivity. Since microvesicle-supplementation facilitates cell growth, increased number of viable producer cells in the culture could be expected to be the basis of observed increase in the overall productivity of the culture [2,3]. The further work is ongoing to in-depth explore the potential of microvesicles for improving recombinant protein production from CHO cells.

Conclusions

The data indicate that microvesicles secreted from CHO cells can improve cell growth and hence recombinant protein production in culture. Therefore, strategies need to be developed for sterile isolation of CHO microvesicles from routine maintenance cultures and their supplementation into the production culture for improving the performance of CHO-based production process.

Acknowledgements

Translational Health Science and Technology Institute, India; Science and Engineering Research Board, India; Department of Biotechnology, India.

References

1. Chaudhuri S, Maurya P, Kaur M, Tiwari A, Borh N, Bhattachar S, Kumar N: Investigation of CHO Secretome: Potential Way to Improve Recombinant Protein Production from Bioprocess. J Bioprocess Biotech 2015, 2:240-247.
2. Yang L, Wu XH, Wang D, Luo CL, Chen LX: Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro. Mol Med Rep 2013, 8:1272-1278.
3. Kumar N, Gupta DG, Kumar S, Maurya P, Tiwari A, Mathew B, Banerjee S, Haldar S, Pillai J, Bhattachar S, Chaudhuri S: Exploring Packaged Microvesicle Proteome Composition of Chinese Hamster Ovary Secretome. J Bioprocess Biotech 2016, 6:274-285.
Glycan Analysis: IgG was purified from supernatant using POROS MabCapture A resin, then exchanged into 20mM phosphate buffer using Zeba™ Spin Desalting Plates (7K MWCO). N-linked glycans were digested with PNGase F and quantified using 100pmole maltotetraose/maltopentose internal standards labeled with 8-aminopyrene-1,3,6-trisulfonic acid (ATPS) as described by Laroy et al [1] or the user guide for the Glycan Labeling and Analysis Kit (GlycanAssure™ user guide, Thermo Fisher Scientific). All CE separations were performed using the Applied Biosystems™ 3500xl.

Results
The timing of transition from EFC+ to GTC+ made it possible to target specific glycosylation profiles. Modulating G0F from 75% down to 32%, while increasing G1F and increasing G2F (Fig. 1). Transitioning to GTC+ early in culture resulted in a greater shift from G0F to G1F and G2F. Transitioning midway or late in culture resulted in a greater proportion of G0F compared to G1F and G2F.

Conclusions
Supplementation based approaches using glycosylation modulating media components to modify and target specific glycosylation profiles proved to be difficult. These approaches were able to increase terminal galactosylation (G1F and G2F), but lacked the ability to fine tune glycan profiles. This could result in numerous rounds of titration experiments to target specific glycan profiles that would likely remain inconsistent between cell lines, culture media and feeds, and process scale. The development of a unique process made it possible to predictably target specific glycosylation profiles. Transition from standard feeding to GlycanTune allowed for precise targeting of glycan profiles. Transition to GlycanTune early in culture resulted in an increased shift from G0F to G1F and G2F. A transition late in culture resulted in increased G0F and decreased G1F and G2F.

P-151
Understanding the effects of utilizing a complete feeding supplement to modulate glycosylation profiles
Ryan Boniface, Nicole DiNardo, Zofia Kozik, Jaime Goldfuss, Mark Stramaglia, Steve Gorfen
Thermo Fisher Scientific, 3175 Staley Rd., Grand Island, New York, USA, 14072.
Correspondence: Ryan Boniface (ryan.boniface@thermofisher.com)
BMC Proceedings 2018, 12(Suppl 1)P-151

Background
The glycosylation profile of a recombinant protein is one of the most important attributes when defining product quality. Producing a protein with desired characteristics requires the ability to modify and target specific glycosylation profiles. Traditionally the approach to modify the glycosylation profile of a protein involves supplementing a culture with components that can improve galactosylation. Experimentation using this supplemental approach resulted in a dramatic increase in terminal galactosylation, but lacked the ability to easily and repeatedly target specific glycosylation profiles.

Using novel and proprietary technology, we have developed a feed (GlycanTune™) and a unique feeding process that will maximize growth and titer while being able to modulate glycan profiles. This new feed can be added as a standalone process that can result in a significant shift from G0F to G1F and G2F (maximum galactosylation). Using a unique fed-batch process, GlycanTune can also be used with a standard feed to dial in targeted glycosylation profiles. Through process development, we created a method where a transition point is used to switch from a standard feed to a glycan modulating feed. The timing of the transition point will determine the specificity of the glycan profile.

Materials and methods
(All materials were from Thermo Fisher Scientific unless otherwise indicated)

Cell culture: CHO DG44 derived recombinant cells expressing an IgG molecule were grown in Dynamis™ media supplemented with 4mM L-glutamine and 1:100 Anti-Clumping Agent. Culture conditions were maintained at 37°C, 8.0% CO2, 125 rpm. Cell densities and viabilities were measured using a Vi-CCELL® counter (Beckman Coulter). Metabolites (glucose, ammonia, and lactate) and IgG were measured using a Cedex® BioHT Analyzer (Roche). 250mL flasks with 60mL starting volume inoculated at 0.3x10⁵ viable cells/mL in Dynamis™ medium. 2X EfficientFeed™ C+ AGT Supplement (EFC+) and/or 2X GlycanTune™ C+ Total Feed (GTC+) were supplemented at 1.7% on days 4 through 15 (20% total). Glycan modulation conditions involved transitioning from EFC+ to GTC+ on culture days 4, 5, 7, 9, 11, 13 and 15. Glucose was supplemented as required to maintain a concentration above 3g/L.

References
1. Laroy W, Contreras R, Callewaert N: Glycome mapping on DNA sequencing equipment. Nature Protocols, 206, 1(1), 397

P-153
Surfactants in cell culture media: Impact on HEK and CHO cells in cultivation and transfection
Sandra Klausing¹, Ekaterina Rudisova², Falk Gronemeier¹, Anica Schmidt¹, Anja Träger¹, Tanja Bus³, Anne-Kristin Trützschler³, Tim F. Beckmann¹, Christoph Heinrich¹
¹Keli AG, Bielefeld, Germany; ²Institute of Cell Culture Technology, Bielefeld University, Bielefeld, Germany; ³Laboratory of Organic and Macromolecular Chemistry (IOMC), Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Jena, Germany
Correspondence: Anica Schmidt (anica.schmidt@kelliag.de)
BMC Proceedings 2018, 12(Suppl 1)P-153

Fig. 1 (abstract P-151). Glycan analysis from modulating glycosylation with EfficientFeed C+ and GlycanTune C+.
Surface active agents (surfactants) are commonly used cell culture medium components for reducing shear stress in non-static suspension culture. Despite the preferred application of poloxamer 188, there is an ongoing discussion within the cell culture community about surfactant-related process deviations. Furthermore, surfactants have been shown to interact with polypellexes as well as polymer nanoparticles within various applications (e.g., transfection, encapsulation). Better understanding the related mechanisms of action will facilitate finding alternative components for progressive cell culture media formulations.

Materials and methods
HEK 293-F and CHO-K1 cell lines were cultivated in Xell’s chemically defined transfection media (HEK TF or CHO TF) in plain and baffled shake flasks to evaluate the impact of surfactants on shear stress. The surfactants were also evaluated regarding their impact on transient GFP expression via flow cytometry. The localisation of poloxamers in HEK 293-F culture was investigated using fluorescein-labeled Pluronic® F-68 and F-127, LysoTracker® Blue DND-22 (lysosomes) and CellMask™ Deep Red (cell membranes) in confocal microscopy. SEC and 1H-NMR measurements for structural analyses were performed at JCSM, Jena.

Results
Growth performance during precultures and batch curves in plain shaking flasks did not show any differences among tested surfactants or lots thereof, and cell densities reached 10-12·10^6 cells/mL (Fig. 1a and b). Experiments with HEK 293-F cells at elevated power input in baffled shaking flasks revealed distinct differences between Pluronic® F-68, F-127 and Kolliphor® P188, with F-127 showing the best performance. Peak viable cell densities reached with lots A and B of Pluronic® F-68 and F-127 were comparable to those in plain shaking flasks, while those for Kolliphor® P188 and lots C and D of Pluronic® F-68 were significantly lower. Peak viable cell densities were of 2 – 12·10^6 cells/mL (Fig. 1c). Similar transiently defined efficiency and mean fluorescence of transfected cells independent of applied surfactant and lot thereof indicated no major impact of respective poloxamer (Fig. 1d). Interestingly, experiments using fluorescein-labelled Pluronic® showed a time-dependent uptake into HEK cells. Visual tracking revealed an endocytic uptake of poloxamers by the cells (>10-fold increase in signal after 96 h) and its colocalisation with cell membrane and lysosomes. SEC (Fig. 1e) analyses showed differences between the tested poloxamers. Especially tested lots of Pluronic® F-68 revealed notable deviations in the low molecular weight fraction (peak 2, Fig. 1e), compared to the other poloxamers.

Conclusion
Cultures subjected to varying levels of shear stress showed distinct growth differences depending on used poloxamer. While experiments in plain shake flasks did not show any differences in growth, cultivations under elevated shear stress in baffled shake flasks resulted in lower peak viable cell densities with Kolliphor® P188 and some Pluronic® F-68 lots. It remains unclear whether this can be explained by different membrane protective activities alone, or if other mechanisms, occurring during and after cellular uptake, contribute to this effect. Especially for the tested lots of Pluronic® F-68, SEC of surfactants showed differences in the low molecular weight fraction. This fraction mainly represents polyethylene oxide (PEO) (revealed by NMR), which is likely to be a remnant from synthesis. These observations indicate that the use of different poloxamers and lots thereof should be carefully evaluated, especially under elevated shear stress. Further experiments will focus on investigating distinct SEC fractions of poloxamers.

Acknowledgements
We would like to thank the German Federal Ministry of Education & Research (BMBF # 031A5188B, Vectura) for funding.
in electroporation) were both found to negatively impact PEI-mediated transfection of CHO cells, while another tested polymer enhanced growth as well as transfection efficiency. The use of a strong chelator led to a high transfection efficiency, but impaired cell growth. Based on the results of the independent substance testings, the medium formulation was modified by the addition of a weak chelator and further components including vitamins. Different osmolalities between 280 mOsmol/kg and 340 mOsmol/kg were tested for the final formulation, but no major impact was seen neither on transfection efficiency nor on viability 2 days post-transfection.

The final CHO TF medium formulation supported high cell growth of finally tested CHO cell lines 2 and 3 with peak viable cell densities above 10^6 cells/ml in batch cultivations with an overall cultivation time of 7-8 days (Fig. 1). Transfection efficiency was above 90 % at 2-4 d post-transfection during transient GFP expression. Growth performance during transient mAb expression was similar with final mAb titers ranging from 70 mg/L reached with CHO cell line 2 and 110 mg/L achieved with CHO cell line 3.

Conclusions

As components such as ammonium iron(III) citrate, iron(III) chloride, iron(II) sulfate heptahydrate and ammonium iron(III) sulfate dodecahydrate reduce or completely prevent transfection, iron composition requires careful optimisation to support high transfection efficiency and sufficient growth of CHO cell lines. Similarly, composition and concentration of polymers and chelators have to be tested carefully in order to balance out opposing effects on transfection and cell growth. Finally, it was possible to successfully develop a high performing transfection medium, whereby it was possible to counterbalance some contrary effects of the presented substances. Further improvements of the process might be achieved by adapting the protocol, as the results shown are based on a simple pre-complexing of DNA-PEI. Moreover, product yields could potentially be increased by using feeds, temperature shifts or commonly used enhancers (e.g. valproic acids).

References

1. Eberhardy SR, Radziuk L, Liu Zhong: Iron (III) citrate inhibits transfection of CHO cells. BMC Proceedings 2018, 12(Suppl 1):P-161

P-161

Bioreactor scaling thought new – from 5 to 2000 L with utility functions

Sebastian Ruhl1, Adrian Stacey2, Ellen Lam3, Cécile Villemant4, Anil Kumar Rathod5, Anton Stefan6, Christian Zahnow1, Gregory Bremer7, Andrew Tait8, Jens Maruszczyk9, Ute Husemann10, Gerhard Greller11, Sartorius Stedim Biotech, Göttingen, Germany;2Sartorius Stedim Biotech, Royston, UK;3Sartorius Stedim North America, Bohemia, NY, USA;4Sartorius Stedim India, Bangalore, India;5Sartorius Stedim Cellca, Laupheim, Germany

Correspondence: Sebastian Ruhl (sebastian.ruhl@sartorius-stedim.com)

Introduction

Scaling of a cell culture process is an essential part in its development. In a typical approach scaling [1] is performed by keeping a (critical) process parameter constant throughout the complete bioreactor range. This can lead to non-beneficial results either on the high or the low end of the range. For instance, the specific power input (P/V) of 30 W/m³ might result in a good agitation in production scale whereas it leads to a non-turbulent mixing behavior in process development scale. To overcome this issue a new approach for an easy scaling procedure was developed. This Utility Function approach for agitation scaling is based on individual functions with a value-based mapping independent of bioreactor scale.

Material and methods

Process insight information (established either from DoE process investigation or existing experience with a process platform) is directly formalized into a set of mappings which transform bioprocess values into perceived benefits (0 to 1). At each bioreactor scale, parameters (e.g. stirring and gassing) are then chosen to maximize the product of resultant Utility Functions.

The model CHO fed-batch process in this trial comprised a CHO DG44 cell line that was transfected to produce a humanized antibody IgG1. A chemically defined media system was used. The process, including cell line, medium and feeding strategy was designed and developed by Sartorius Stedim Cellca.

The aim of the gassing scale-up was to achieve similar cell densities when the addition of pure oxygen starts. For all Flexsafe STR® bags oxygen was supplied via the micro sparger part of the combi sparger. All other systems used a ring sparger with holes face up.

The initial air flow rate was set to an oxygen transfer rate (kLa) of 8 1/h at the corresponding agitation rate and volume. All process engineering characterization parameters were determined according to DECHEMA guidelines [2].

With the use of the Utility Functions the discrete agitation rate was determined (Table 1).

Results and Discussion

The Utility Functions led to discrete agitation rates where not only homogeneous mixing but also a turbulent flow pattern and a suitable specific power input was guaranteed. The initial gassing rate of air supplied enough oxygen for 5 x 10⁶ cells/mL in all bioreactors.

Due to the used scaling methods the growth patterns in all bioreactor scales were comparable. Peak viable cell densities (VCD) of 20 – 26 x 10⁶ cells/mL were achieved and viability at the point of harvest was above 80 % in all scales.

The final product concentration was in an acceptable range of 2.9 – 3.6 g/L. Product quality attributes show comparability over the complete bioreactor range (Fig. 1).

The harvest criteria of 12 days gave a combination of viability and product concentration that made it easy to process the cell broth during cell removal and other downstream steps.

Conclusions

The process implementation of the CHO production System – Expressing mAb 2 was successfully performed with the use of Utility Functions. Cell growth, productivity and product quality is comparable over the complete bioreactor range.

References

1. Tai M., et al.: Efficient high-throughput biological process characterization. (2015) Biotechnology Progress DOI 10.1002/btpr.2142.
2. Zahnow C., et al.: Scale-up of a stirred single-use bioreactor family. (2017) Poster ESACT Meeting.
Initial gassing rate [%] 0.15 2.75 7.0 73.2
Agitation rate [rpm] 334 162 121 70

sis has to be well maintained. When H2O2, an oxidative stress in-
synthesis and quality control of the secreted proteins, ER homeosta-
the ER function [4]. Because ER has a responsibility on the protein
mitochondrial energy metabolism and protein synthesis can disturb
Oxidative stress that naturally accumulates in the ER as a result of
ER stress [2]. Prolonged ER stress induces apoptotic cell death [3].
Itosis, and thermal instability can disturb the ER functions, which triggers
of physiological conditions such as oxidative stress, hypoglycemia, acid-
protein folding, and early post-translational modifications [1]. A number
and resident proteins through the regulation of protein translocation,
in eukaryotic cells, is responsible for controlling the quality of secreted
Endoplasmic reticulum (ER), the central part of the secretory pathways
Background
BMC Proceedings
2018, 12(Suppl 1):P-174
Use of an antioxidant to improve monoclonal antibody production
and quality in CHO cells
Tae Kwang Ha1, Anders Holmgaard Hansen1, Stefan Kol1,
Helene Fastrup Kildegaard1, Gyun Min Lee1,2
Correspondence: Helene Fastrup Kildegaard (hefri@biosustain.dtu.dk);
Gyun Min Lee (gyunminlee@kaist.ac.kr)
BMC Proceedings 2018, 12(Suppl 1):P-174
Fig. 1 (abstract P-161), Product analysis from STR® and UniVessel®
Glass (performed by BioOutsource)

Table 1 (abstract P-161). Results of the scaling strategy
| Ratio | STR® | STR® | STR® |
|-------|------|------|------|
|       | 50   | 200  | 2000 |
| Agitation rate [rpm] | 334  | 162  | 121  | 70   |
| Initial gassing rate [Lpm] | 0.15 | 2.75 | 7.0  | 73.2 |

Fig. 1 (abstract P-174). Profiles of (a) cell growth, (b) viability, (c) mAb concentration, and (d) ROS level of a CS13-1.00 cell line producing mAb during shake flask cultures with baicalein addition.

P-174
Use of an antioxidant to improve monoclonal antibody production
and quality in CHO cells

Endoplasmic reticulum (ER), the central part of the secretory pathways
in eukaryotic cells, is responsible for controlling the quality of secreted
and resident proteins through the regulation of protein translocation,
protein folding, and early post-translational modifications [1]. A number
of physiological conditions such as oxidative stress, hypoglycemia, acid-
ossis, and thermal instability can disturb the ER functions, which triggers
ER stress [2]. Prolonged ER stress induces apoptotic cell death [3].
Oxidative stress that naturally accumulates in the ER as a result of
mitochondrial energy metabolism and protein synthesis can disturb
the ER function [4]. Because ER has a responsibility on the protein
synthesis and quality control of the secreted proteins, ER homeosta-
sis has to be well maintained. When H2O2, an oxidative stress in-
ducer, was added to recombinant Chinese hamster ovary (rCHO) cell
cultures, it reduced cell growth, monoclonal antibody (mAb) produc-
tion, and galactosylated form of mAb in a dose-dependent manner.
Antioxidants can reduce the oxidative stress level and suppress the
apoptotic cell death by scavenging oxygen free radicals, inhibiting
chain reaction of oxidation, and detoxifying peroxide [5]. However,
developed the potential of mass production of mAbs, studies on the
effect of antioxidants on the production and quality of mAbs in rCHO
cell cultures have not been fully substantiated.

Materials and methods
To find a more effective antioxidant in rCHO cell cultures, six differ-
ent antioxidants including baicalein, which have used widely in
mammalian cell cultures, were evaluated as chemical supplements
with two different rCHO cell lines producing the same mAb in 6-well
plates. Then, batch and fed-batch cultures were performed in shake
flasks with the supplementation of baicalein, which showed the best
effect on culture performance among the 6 antioxidants. The reactive
oxygen species (ROS) and ER stress levels were measured to study
the effect of baicalein on mAb production and quality.

Results
Among these antioxidants, baicalein showed the best mAb production
performance. Addition of baicalein significantly reduced the expression
level of BiP and CHOP along with reduced ROS level, suggesting oxida-
tive stress accumulated in the cells can be relieved using baicalein. As
a result, addition of baicalein in batch cultures resulted in 1.7 - 1.8-fold in-
crease in the maximum mAb concentration (MMC), while maintaining
the galactosylation of mAb (Fig. 1 and Table 1). Likewise, addition of
baicalein in fed-batch culture resulted in 1.6-fold increase in the MMC
while maintaining the galactosylation of mAb.

Conclusions
Oxidative stress negatively affected the production and galactosylation
of mAb in rCHO cell cultures. Among the various antioxidants tested in
this study, baicalein showed the best mAb production performance in
both batch and fed-batch cultures of rCHO cells. Baicalein addition sig-
ificantly enhanced mAb production while maintaining galactosylated
forms of mAB. Thus, baicalein is an effective antioxidant for use in rCHO
cell cultures for improved mAb production.

Acknowledgements
This research was supported by Danish Council for Independent Research –
Technology and Production Sciences (FTP), The Novo Nordisk Foundation,
and the Ministry of Science, ICT and Future Planning for Basic Core
Technology Development Program for the Oceans and the Polar Regions
of the NRF (NRF-2016M1A5A1901813).

References
1. Ruggiano A, Foresti O, Carvalho P: Quality control: ER-associated degrada-
tion: protein quality control and beyond. J Cell Biol 2014, 204(6), 869-879.
2. Schönhärl AH: Pharmacological targeting of endoplasmic reticulum stress
signalling in cancer. Biochem Pharmacol 2012, 85(5), 653-666.
3. Urra H, Dufey E, Lisboa F, Rojas-Rivera D, Hetz C: When ER stress reaches a
dead end. Biochim Biophys Acta 2013, 1833(12), 3507-3517.
4. Birben E, Sahiner UM, Sackesen C, Erzurum S, et al: Oxidative stress and
antioxidant defense. World Allergy Organ J 2012, 5(1), 9-19.
5. Shimazaki H, Watanabe K, Veeraraghavan PT, Harima M et al. The antioxidant
edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction
in rats with autoimmune myocarditis. Free Radic Res 2010, 44(9), 1082-1090.
Table 1 (abstract P-174). The μ, MVCC, qmAb, and MMC with or without baicalein addition during batch cultures. No baicalein (C), DMSO (C+), and 100 μM baicalein (T).

|        | MVCC (x 10^6 cells/mL) | qmAb (pg/cell/day) | MMC (μg/mL) |
|--------|------------------------|-------------------|-------------|
| C      | 2.62 ± 0.23            | 17.49 ± 1.37      | 520.1 ± 95  |
| C+     | 1.8 ± 0.19             | 25.05 ± 2.23      | 465.5 ± 93.9|
| T      | 2.35 ± 0.06            | 22.13 ± 2.20      | 901.3 ± 112.9|

P-175

Model-assisted cell culture control – unstructured, unsegregated models as a key element for adaptive seed train and fed-batch optimization
Tanja Hernández Rodríguez1, Susan Krull1, Volker C. Hass3, Johannes Möller2, Ralf Pörtner2, Björn Frahm4
1Biotechnology & Bioprocess Engineering, Ostwestfalen-Lippe University of Applied Sciences, Lemgo, D-32657, Germany; 2Institute of Bioproces and Biosystems Engineering, Hamburg University of Technology, Hamburg, D-21073, Germany; 3Hochschule Furtwangen University, Faculty of Medical and Life Sciences, Villingen-Schwenningen, D-78054, Germany
Correspondence: Björn Frahm (bjorn.frahm@hs-owl.de)
BMC Proceedings 2018, 12(Suppl 1):P-175

Background
The production of many biopharmaceuticals (e.g., antibodies & proteins for diagnostic and therapeutic purposes) requires the cultivation of mammalian cell lines, which is demanding with respect to various aspects such as complex cell metabolism, variabilities in cell behavior, scale dependencies, influences of changes in cultivation conditions, medium composition etc. Although an increasing number of measurement parameters is available, only a part of them is routinely utilized in industrial cell culture processes and their corresponding seed trains. Nevertheless, the data base grows, statistical investigation of data gains importance and process data are more easily accessible in the context of industry 4.0.

Cell cultivation has to consider these complex requirements, e.g., for fed-batch control and seed train design. Furthermore, cultivation strategies have to be adapted to new products, cell lines and clones as well as to different production plants when transferring processes. One approach to encounter the variabilities and to include actual information from the process and from data analysis is adaptive model-assisted control [1].

Methods
Two software tools enabling adaptive model-assisted control applying unstructured, unsegregated models have been developed and implemented using MATLAB®, WinErs and Fortran, one tool for fed-batch control and another one for seed train simulation and optimization.

Results
One key element of adaptive model-assisted control is the underlying process model. In order to provide an adaptive character, model parameters should be easily identifiable from routine cultivation data, which is available during seed train and fed-batch without additional sophisticated measurements. Therefore, the usage of unstructured, unsegregated models is recommended.

Conclusions
Process design and optimization, e.g., regarding seed train and fed-batch, is realized by adaptive model-assisted software tools using unstructured, unsegregated models. They enable feedback from the process via routine cultivation data and allow adaptation to diverse circumstances such as different cell lines, products, cultivation conditions, plant configurations etc.

References
1. Pörtner R et al.: Advanced Process and Control Strategies for Bioreactors. Book chapter, pp. 463-493, Current Developments in Biotechnology and Bioengineering: Bioprocesses, Bioreactors and Controls, Elsevier, ISBN 978-0-444-63663-8, 2016.
2. Kern S, Platas Barradas O, Pörtner R, Frahm B: Model-based strategy for cell culture seed train layout verified at lab scale. Cytotechnology, 2016 Aug68(4):1019-32. doi: 10.1007/s10616-015-9858-9. Epub 2015 Mar 21.
3. Frahm B: Seed train optimization for cell culture. Chapter, Animal Cell Biotechnology-Methods and Protocols, 3rd edition, edited by Pörtner R, Springer/Humana Press, ISBN 978-1-62703-732-7, ISBN 978-1-62703-733-4 (eBook), 2014.

a) Example of an unstructured, unsegregated cell culture model (for adaptive model-assisted control)
One example, describing cell growth, cell death, uptake of substrates and production of metabolites via a first order system of ordinary differential equations and Monod-type kinetics, is shown in Table 1. This mathematical model includes 13 cell specific model parameters [2].

b) Application examples
This contribution illustrates the usage of such a model for two applications: A controller for the calculation of fed-batch feed trajectories and a software tool for seed train design, analysis and optimization. The implementation is shown in each case concerning the structure and the open-loop control sequence in Fig. 1a fed-batch control and Fig. 1b seed train simulation & optimization. Both implementations are divided into two main parts, i) adaptation to cell line and ii) open-loop control sequence.

i) Adaptation to cell line: Based on a corresponding mathematical cell culture model, model parameters must be identified reflecting cell line and cell behaviour.

ii) Open-loop control sequence for fed-batch control: Based on model and a priori identified model parameters, the optimization cycle includes getting data from the running cultivation, automated adaption of model parameters, prediction of future process course, computation of optimal feed profiles and realization.
Table 1 (abstract P-175). Equations of balances and kinetics of an employed process model including \( X_v \) viable cell density, \( X_t \) total cell density, \( \mu \) cell-specific growth rate, \( \mu_a \) cell-specific death rate, \( t \) time, \( K_g \) and \( k \) Monod kinetic constant and Monod constant for uptake, \( K_{lim} \) Cell lysis constant, \( q \) cell-specific uptake rate or production rate, respectively, \( Y \) kinetic production constant, \( Glc \) glucose, \( Gln \) glutamine, \( Lac \) lactate, \( Amm \) ammonia, \( F \) feed rate, \( V \) volume.

### Balances with fed-batch terms

**Biophase**

\[
\frac{dx_v}{dt} = (\mu - \mu_a) \cdot x_v + \frac{F_{in}}{V} \cdot x_v
\]

**Cell growth & death**

\[
\mu = \frac{c_{Glc} \cdot k_{Glc}}{c_{Gln} \cdot k_{Gln}} \cdot \left( \frac{c_{Glc}}{c_{Gln}} \right)^{\frac{c_{Gln}}{c_{Glc}}} \cdot \mu_{max}
\]

**Liquid phase**

\[
\frac{dx_v}{dt} = -q_{Glc} \cdot x_v + \frac{F_{in}}{V} \cdot x_v
\]

**Substrate uptake & metabolite production**

\[
q_{Glc} = q_{Glc,\text{max}} \cdot \left( \frac{c_{Glc}}{c_{Glc}^{\text{cutoff}}} \right)^{H}
\]

\[
q_{Lac} = q_{Lac,\text{uptake}} + q_{Lac,\text{uptake,max}} \cdot \left( \frac{c_{Lac}}{c_{Lac}^{\text{cutoff}}} \right)
\]

\[
q_{Amm} = q_{Amm,\text{uptake}} + q_{Amm,\text{uptake,max}} \cdot \left( \frac{c_{Amm}}{c_{Amm}^{\text{cutoff}}} \right)
\]

### Kinetics

- \( \mu = \mu_{max} - \mu_{lim} \cdot \left( \frac{c_{Glc}}{c_{Glc}^{\text{cutoff}}} \right)^{H}
\)
- \( q_{Glc} = \frac{0.5 \cdot \mu_{max}}{c_{Glc}^{\text{cutoff}}}
\)
- \( q_{Lac,\text{uptake}} = Y_{Lac,\text{uptake}} \cdot \mu \)
- \( q_{Amm,\text{uptake}} = Y_{Amm,\text{uptake}} \cdot \mu \)
- \( c_{Glc} \geq 0.5 \cdot q_{Lac,\text{uptake}} \cdot c_{Lac}^{\text{cutoff}}
\)

Fig. 1 (abstract P-175). Scheme of adaptive model-assisted cell culture control. Example for a fed-batch control and b seed train simulation and optimization

P-183

Creating a suitable microenvironment for growing human primary T cells to high cell densities

Melanie Werner, Patrick Kaiser, Michael Hader, Valérie Jérome, Ruth Freitag

Chair for Process Biotechnology, University of Bayreuth, Bayreuth, 95447, Germany. Present address: GSK Vaccines GmbH, Marburg, Germany. 35043

Correspondence: Ruth Freitag (ruth.freitag@uni-bayreuth.de)

BMC Proceedings 2018, 12(Suppl 1):P-183

### Background

**Ex vivo** expansion of human primary T cells is of considerable scientific and medical interest, e.g. as for T cell therapy. Currently, this is time consuming and requires the addition of massive amounts of stimuli. Recently, we showed that human leukemia T cells (Jurkat cells) can be expanded to tissue like cell densities (>10^8 cells mL<sub>bead</sub>) in polyelectrolyte capsules. Significant advantages, such as great mechanical stability, good biocompatibility and good mass transfer properties characterized these capsules based on sodium cellulose sulfate/poly(diallyldimethyl) ammonium chloride (SCS/PDADMAC) [1, 2]. Here, we present the possibility to cultivate human T cells, freshly isolated from blood, to high densities in similar semipermeable polyelectrolyte microcapsules within less than 10 days.

Materials and methods

Cells were encapsulated in semipermeable SCS/PDADMAC polyelectrolyte microcapsules or confined in 1.5% alginate/poly-L-lysine (PLL) beads, a standard approach for cell immobilization. The permeability of the microcapsules was estimated using dextran-based molecular weight standards (10 and 20 kDa) and vitamin B12 (1.6 kDa). Gentle digestion with endocellulase allows an easy release of the cells out of the capsules. Cell growth, cytokines production and phenotype were measured in non-encapsulated and encapsulated cells grown under standard culture conditions. Moreover, we analyzed the interplay between the secreted cytokines and the SCS within the capsules and its putative influence on cell growth.

Results

Cells mixed in the cellulose sulfate solution under physiological conditions can be safely trapped within a liquid core during capsule formation. Encapsulated cells can reach cell densities ≤ 40 x 10^6 cells mL<sub>capsule</sub> whereas cells confined in alginate/PLL beads and non-encapsulated ones reached 11.3 x 10^6 cells mL<sub>bead</sub> and 2.4 x 10^6 cells mL, respectively. One major advantage of these polyelectrolyte microcapsules (<1 mm) is the low MWCO (<10 kDa) (Fig. 1a-b). This restricted permeability allows for a conditioning of the capsule core by autocrine factors, which in turn permits the use of basal cell culture medium instead of expensive T cell specialized media, hence does not necessitate high amounts of rhIL-2 and reduces the cultivation costs. Moreover, co-encapsulation of rhIL-2 had a beneficial effect on the growth kinetics in most cases (Fig. 1c). Some evidence is presented that the SCS used to form the polyelectrolyte microcapsules, specifically adsorbs IL-2 (Table 1) – A cytokine which provides an essential signal for T-cell proliferation and differentiation [3]. Therefore, we postulate that the SCS used for encapsulation has biomimetic properties, creating an artificial extracellular matrix mimicking heparin sulphate which in turn positively affect T cell proliferation via trans-presentation of IL-2 (Fig. 1d) [4].

Conclusions

Primary T lymphocytes can be expanded under appropriate conditions outside the body. In the latter, T cells grow/expand in specific environments where the cells are tightly packed, leading to multiple cell–cell contacts and manifold interactions with the extracellular matrix. Ex vivo suspension cultures of diluted cells cannot provide such a microenvironment. In the microcapsules-based cultivation system presented, the cells are suspended in a viscous SCS-solution. The low molecular weight cut off of the surrounding polyelectrolyte membrane assures that typical signaling molecules produced by the cells are retained thus facilitates the “conditioning” of the cellular microenvironment, while nutrients and metabolites can pass. Expensive additives, such as interleukin-2 (IL-2), can be co-encapsulated. Expansion then no longer requires specialized T-cell media. Moreover, the SCS seems to have biomimetic properties, representing an artificial extracellular matrix mimicking heparin sulphate. We consider that the described method may be an appropriate alternative to expand T cells while creating a local microenvironment mimicking in vivo conditions.
Acknowledgements
This research was supported by the DFG (Deutsche Forschungsgemeinschaft), grants BU 461/26-1 and FR 830/14-1.

References
1. Werner, M.; Schmoldt, D.; Hilbrig, F.; Jérôme, V.; Raup, A.; Zambrano, K.; Hübner, H.; Buchholz, R.; Freitag, R. High Cell Density Cultivation of Human Leukemia T Cells (Jurkat Cells) in Semipermeable Polyelectrolyte Microcapsules.
2. Kaiser, P.; Werner, M.; Schmoldt, D.; Hilbrig, F.; Jérôme, V.; Raup, A.; Zambrano, K.; Hübner, H.; Buchholz, R.; Freitag, R. Cell retention by encapsulation for the cultivation of Jurkat cells in fixed and fluidized bed reactors.
3. Boyman, O.; Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system.
4. Jérôme, V.; Werner, M.; Kaiser, P.; Freitag, R. Creating a Biomimetic Microenvironment for the Ex Vivo Expansion of Primary Human.

Fig. 1 (abstract P-183). Influence of the capsule material on the expansion of human primary T lymphocytes. a. Polyelectrolyte capsule (SCS/PDADMAC). b. Growth of T lymphocytes encapsulated in SCS/PDADMAC versus alginate/PLL. Growth kinetics of activated peripheral blood T cells, non-encapsulated (a) and encapsulated in SCS/PDADMAC (b) or alginate/Poly-L-Lysine (c). The cells were cultivated in fresh (solid lines) or conditioned (dotted lines) specialized T cells medium containing phytohemaglutinin (PHA) as activating substance. Starting on day 4, 35% of the growth medium was exchanged every second day. Data represent mean ± SD (n=3). D0: day of encapsulation. Right: Total number of cells produced in non-encapsulated (orange bars) and encapsulated (violet bars) systems and total amounts of additives (rhIL-2, PHA) required. d. Schematic representation of the putative influence of the capsule microenvironment on the T cells signalling after PHA activation. Left: Non-encapsulated T lymphocytes; right: T lymphocytes in SCS/PDADMAC capsules.

Table 1 (abstract P-183). Analysis of rhIL-2, rhIFNγ, and sCD25 recovery after incubation with SCS

| Time of incubation [h] | Recovery (%) |
|------------------------|-------------|
|                         | rhIL-2      | rhIFNγ    | sCD25     |
| 0                      | 100 ± 5.3   | 117 ± 3.8 | 103.7 ± 1.3 |
| 3                      | 74.0 ± 4    | 72.6 ± 1.0 | N.D.      |
| 6                      | 56.7 ± 0.3  | 106.5 ± 4.9 | N.D.      |
| 21                     | 10.9 ± 0.3  | 82.1 ± 2.1  | 93.6 ± 10.2 |

Prior to ELISA, the various proteins were incubated at 37°C in SCS prepared as for encapsulation. As control, the SCS was replaced by PBS. Shown are mean values ± SD, n = 3.

P-190
The new age of digital biomanufacturing
William Whitford1, Daniel Horbelt2
1GE Healthcare Bio-Sciences AB, Uppsala, Sweden, 75184; 2Insilico Biotechnology AG, Stuttgart, Germany, 70563
Correspondence: William Whitford (william.whitford@ge.com); Daniel Horbelt (daniel.horbelt@insilico-biotechnology.com)

Background
Digital manufacturing (DM) is heightening the productivity and robustness of existing processes and facilities. It also enables the efficient development of previously unmanageable products or processes and provided the basis for a wave of innovations. DM is a resident and on-line source of continuous optimization of process performance. It relies upon the comprehensive, real-time interfacing of both human and machine sourced information through one centralized system. More than legacy Distributed Control System (DCS) and supervisory control and data acquisition (SCADA), it is an integral interconnection of real-time access to divergent sources of information. As such, it can promise deep analysis and predictions leading to shortened product cycle and advanced process control. This comprehensive analysis is extending beyond operations performance data from the production floor to data driving such activities as raw materials security of supply (SoS) and business continuity management systems (BCMS).

Materials and methods
Digital Biomanufacturing (DB) can be viewed as yet another, larger, embodiment of digital biotechnology. DB is similar to digital manufacturing in that it promotes innovations in the manufacturing of biologicals by using such things as computer aided design, manufacture, verification and deep process analysis using software sensors (Fig. 1). However, the fact that there are living components (cells) involved in the processes puts a distinctly different flavor to the systems employed. It is desirable to use a distinct term here to distinguish it because, as in the terms bioproduction and biopharmacology, DB addresses many unique aspects of biologically-based activities.

Results
The reasons why the biotech and biopharma industry lags behind other sectors such as the automotive regarding the transformation to digital manufacturing are (i) the complexity and dissipative nature of biological systems, (ii) distributed heterogeneous data and (iii) limited at-line or on-line data sources. However, the costs of genomic sequencing, omics data generation, and computing resources are decreasing rapidly, and at the same time process analytical technologies, computational power and predictive modeling as well as data management infrastructures are greatly improving (Table 1). By removing roadblocks that used to limit approaches, these changes have paved the way to transforming the bioeconomy into an industry that is based on digital knowledge. Such new and optimized manufacturing technologies as continuous biomanufacturing and 3D bioprinting can actually demand the interfacing of many sources of information, deep data
analysis including software sensors for metabolic fluxes, and model-based predictions of digital biomanufacturing. The application of predictive models for bioprocess optimization greatly improves established platforms and finally leads to a massively increased mechanistic process understanding.

Conclusions

Four essential benefits result from the increased bioprocess understanding, development, and control of DB. First, personnel are relieved of many manual and repetitive tasks. Second, strategic planning and operational efficiency are improved. Third, we see real-time optimization of end-to-end manufacturing based on such high-value criteria as projected product quality and profitability. Fourth, it enables previously unmanageable operations and creates innovative solutions.

References

Whitford W: The Era of Digital Biomanufacturing. BioProcess International 2017 15(3):12–18

Fig. 1 (abstract P-190). Intelligent software applications support digital biomanufacturing process development and control. • Databases using data collected online, at-line, and offline from bioprocesses operating worldwide. • Process data are used to generate metabolic network models that represent a specific host cell line in a bioprocess. • Model-based computational simulations improve process understanding and reduce experimental efforts for media design, clone selection, and metabolic engineering. • Automated data import and processing allow for streamlined and standardized metabolic process analysis. • Identification of critical metabolic parameters is used for proactive steering and control of production processes.

Table 1 (abstract P-190). Enablers of digital biomanufacturing

| Information technology | Biotechnology |
|------------------------|--------------|
| Advanced interfacing, process analytics, and control algorithms | Advanced process engineering, analytics equipment, at-line assay |
| Big Data: effective management of large and complex data sets | New in-line (SU) probes and automated at-line (cell-free) sampling |
| Adaptive fuzzy expert system now employ artificial intelligence | Rapid at-line 2D - fluorescence; near/mid-IR; Raman spectroscopy |
| Flexible and affordable data storage and cloud hosting | Near-real time concentration measurements using CFCA methods |
| Laboratory information management systems (LIMS) | At-line surface plasmon resonance; specificity, kinetics, and affinity |
| Industrial internet of things (IoT) and cloud computing | Intriguing microfluidic platform-based at-line cell-condition analytics |
| FDA-regulated suitable software providing traceability/backup | Near real-time product CQA assessment and data accession |
| Analytical QbD (A2QbD) or QbD as applied to analytical methods | |

P-192

Monitoring between-batch behavior of real-time adjusted cell-culture parameters

Xavier Lories, Jean-François Michiels

Arlenda, Mont-Saint-Guibert, 1435, Belgium

Correspondence: Xavier Lories (xavier.lories@arlenda.com)

BMC Proceedings 2018, 12(Suppl 1):P-192

Background

Cell-culture parameters (CCP), such as pH, may be continuously measured online and subject to real-time automated adjustment (e.g. automated addition of a base to prevent the pH to drop too low). This is an efficient method to maintain the parameter within specified limits. This type of control constraint the variability within the predefined limits and does not provide any information on the between-batch variability of the process. Online measurements of CCP provide time-dependent curves presenting one or more transitions. Different types of transition can be observed:

- The process can shift from a state in which adjustment is needed to keep the CCP in range to a state in which it is not. Typically, the CCP drifts away from a limit.
- The process shifts from a state in which adjustment is not needed to one in which it is. For instance, a drifting CCP reaches the lower or upper limit of the accepted range.

The timepoints at which those transitions take place are here called changepoints. Those are aspects of the process and, as such, should be controlled.

In the multiple changepoints cases, the approach allows the early termination of runs showing very early or very late first changepoint.

Material and methods

The identification of the changepoints position is based on simple rules rather than complex statistical modeling to keep the identification methodology simple. Once the changepoint are identified, a multivariate Bayesian model is adjusted on the appropriately transformed data. Prediction regions are obtained and used as control limits [1].

Results

Results obtained for a 2-changepoint case are shown on Fig. 1. Points on the right-hand graph represent new batches. The red triangle represents a failed batch. It appears that the control strategy fails to identify the failed batch.

Two reasons can be considered:

- The limits of the prediction region have been established based on 9 points, such a small sample size is likely to be insufficient for the definition of such a control chart.
- The tested batches were produced out of set point. A control chart should be used on a stable process, ran in the same conditions, in order to be really relevant. This work was based on available historical data, which is never an ideal situation.

Conclusions

The suggested strategy offers a simple approach to the monitoring of between-batch behavior for cell-culture. Once the limits have been defined, the approach is quite straightforward and usable by non-statistician. However, such strategy, as any other of this type, must be based on a sufficient number of batches for the definition of the control limits in order to have a good estimation of the batch-to-batch variability.
Biotechnological Development Laboratory, FBCB, Universidad Nacional Del Litoral, Santa Fe, C.C. 242. (S3000ZAA), Argentina; 3Cell Culture Laboratory, FBCB, Universidad Nacional Del Litoral, Conicet, Santa Fe, C.C. 242. (S3000ZAA), Argentina; 2Biotechnological Development Laboratory, FBCB, Universidad Nacional Del Litoral, Santa Fe, C.C. 242. (S3000ZAA), Argentina; 4Cell Culture Laboratory, FBCB, Universidad Nacional Del Litoral, Conicet, Santa Fe, C.C. 242. (S3000ZAA), Argentina.

Correspondence: Diego Fontana (dfontana@fbcb.unl.edu.ar)

BMC Proceedings 2018, 12(Suppl 1):P-204

Optimization of the production process for a vlp-based rabies vaccine
Diego Fontana1,4, Federico Marsili2, Sebastián Antuña3, Marina Etcheverrigaray4, Ricardo Kratje6, Claudio Prieto2,3 1Biotechnological Development Laboratory, FBCB, Universidad Nacional Del Litoral, Conicet, Santa Fe, C.C. 242. (S3000ZAA), Argentina; 2Biotechnological Development Laboratory, FBCB, Universidad Nacional Del Litoral, Santa Fe, C.C. 242. (S3000ZAA), Argentina; 3Cell Culture Laboratory, FBCB, Universidad Nacional Del Litoral, Santa Fe, C.C. 242. (S3000ZAA), Argentina; 4Cell Culture Laboratory, FBCB, Universidad Nacional Del Litoral, Conicet, Santa Fe, C.C. 242. (S3000ZAA), Argentina.

Background
Rabies is a zoonotic viral disease with a mortality close to 100% [1]. As there is not an efficacious treatment available, post-exposure vaccination is recommended for individuals in contact with the virus. On the other hand, the most common source of virus transmission is saliva of infected animals, mostly dogs, whereby mass vaccination of pets is the most cost-effective way to reduce human infections. In this context, availability of both human and veterinary vaccines is critical [2,3].

Our group had previously developed an effective VLP-based rabies vaccine candidate produced in high density HEK293 cell cultures with serum free medium (SFM) [4,5]. One of the aims in vaccine production process is the achievement of a good productivity with a low cost per dose, mainly in the case of vaccines for animal use in which case the SFM is one of the principal expenses. In this work, we show the adaptation of the producer clone to a non-expensive in-house developed culture medium, in order to reduce the global cost of the process and therefore the price per dose.

Experimental approach
First, we compared a direct and a sequential adaptation protocol of our HEK293 RV-VLPs producer clone, from 100% of the commercial SFM (EX-CELL293, SAFC) to a new formulation with only 50% of the SFM and a minimum essential medium (P2G), developed in our laboratory specifically for RV-VLPs production. This new formulation was called RVPM (Rabies Vaccine Production Medium). The specific productivity of RV-VLPs in culture supernatants was measured by sandwich ELISA, using the 6th International Standard for rabies vaccine that quantify the glycoprotein content (NIBSC, expressed in ELISA Units per ml). Further, we evaluated both media for the production of the rabies vaccine, using stirred tank bioreactors operated in continuous mode (BIOSTAT QPlus, Sartorius). The production of the RV-VLPs was daily evaluated by ELISA and the obtained harvests analysed by the NIH potency test for rabies vaccine.

Results and discussion
After the adaptation process, suspension cultures without aggregates or clumps were obtained, with the same specific growth rate. A lower maximum cell density with the RVPM was reached, achieving 5x10⁶ cells.ml⁻¹, compared with the SFM that reach cell densities between 8 and 9x10⁶ cells.ml⁻¹ in batch mode. The specific RV-VLPs productivity per cell was maintained, obtaining values of 0.88 and 0.90 EU.10⁶cells⁻¹.day⁻¹ for the clone being cultured in SFM and RVPM, respectively.

Taking into account that this producer clone can be changed directly from one medium to the other without lag phase or cell damage, and that in RVPM the maximum cell density reached was lower, this medium was proposed to be analysed in high cell density in perfusion mode for a continuous culture in bioreactor.

Therefore, we performed two cultures in parallel to compare the efficacy of each media formulation in perfusion. As shown in Fig. 1, we obtained very similar culture performances in both bioreactors; 14.4 EU.ml⁻¹ and 16.1 EU.ml⁻¹ of RV-VLPs for the commercial SFM and RVPM, respectively. After that, the harvests were evaluated by the NIH potency test obtaining a rabies vaccine potency of 1.2 IU.ml⁻¹ for both cultures (being 1 IU.ml⁻¹ the minimum potency required for animal vaccine).

Thus, the results obtained represent an interesting advance in the optimization of this vaccine production process since the use of this new medium formulation represents a reduction of 40% of the total cost which will be reflected in a considerable reduction of the price of the vaccine dose.

References
1. Jackson A: Recovery from rabies: A call to arms. J. Neurol. Sci. 2014, 339:6-7.
2. Briggs D: The role of vaccination in rabies prevention. Curr. Opin. Virol. 2012, 2:309–314.
3. Meslin F, Briggs D: Eliminating canine rabies, the principal source of human infection: What will it take?. Antiviral Res. 2013, 98:291–296.
4. D. Fontana D, Kratje R, Etcheverrigaray M, Prieto C: Rabies virus-like particles expressed in HEK293 cells. Vaccine 2014, 32:2799-2804.
5. D. Fontana D, Kratje R, Etcheverrigaray M, Prieto C: Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate. Vaccine 2015, 33:4238-4246.
Manufacturing and distribution advancements, from centralized to distributed, foresee affordable treatments’ obtainability via supplying local populations with local production units.

Materials and methods

- Bench-scale fixed-bed bioreactor;
- Carriers made of 100% pure non-woven hydrophilized PET fibers;
- Vero cells grown in serum-free and serum containing media;
- Attenuated polio strains;
- Cell nuclei on carriers counted by the crystal violet method;
- Polio virus production estimated by Elisa assay (D-antigen content).

Results

Cultivation of Vero cells in medium with serum and in serum-free medium, was carried out in bench-scale compact fixed-bed bioreactors, to determine which culture conditions result in the highest growth rate, the highest cell biomass by carriers and virus production.

Cells were inoculated at 0.05x10^6 cells/cm^2 and infected during the mid-exponential phase, following a complete media exchange. Viral infection took place in serum-free media. In-line clarification and purification is targeted to be performed in only a few steps (maximum one of two) without intermediary diafiltration. In such configuration, we measured that Vero cells can reach a cell density of 300-350x10^3 cells/cm^2 with PDL/day of 1.0-1.2 in serum-containing media.

This new facility is expected to manufacture any type of viral vaccine at a very low cost and could be deployed at the site of the manufacturer in emerging countries, killing the two birds of cost of manufacturing and distribution with one stone. The presentation will feature the description of the engineering development, but also the preliminary results of cell growth, infections, and product quality, as well as a description of the COGS calculation.

Conclusion

Univercells developed a disruptive polio vaccine manufacturing technology exceeding expectations when compared to traditional methods – achieving a superior result via its all-in-one solution of a simple, scalable, and fully-disposable vaccine production platform resulting in long-term cost-effectiveness, flexibility and sustainability:

- All upstream, downstream and inactivation steps take place within a closed system with all the equipment contained in a low footprint isolator – creating a confined area for polio virus handling that facilitates the deployment of micro-facilities.
- This leads to a dramatic reduction in capital investment, time required for development and increases production capacity.
- In conclusion, this is a simple and elegant solution for the industrial production of human vaccines at a low cost in micro-facilities, making polio vaccines available to all.

Acknowledgements

Univercells has granted by the Bill and Melinda Gate foundation to Develop Breakthrough Vaccine Manufacturing Platform.

Fig. 1 (abstract P-213). Schematic representation of Univercells’ all-in-one manufacturing process

P-213

Disruptive vaccine manufacturing platform aiming to reach extra low production cost

J.-C. Drugmand, S. Dubois, A. Reniers, J. Forte, A. Deleau, D. Herbiniat, Y. Dohogne, J. Castillo

Univercells SA, Gosselies, Belgium

Correspondence: J.-C. Drugmand (jcdrugmand@univercells.com)

BMC Proceedings 2018, 12(Suppl 1):P-213

Background

Vaccines are one of the most powerful and effective health inventions ever developed – providing tremendous economic and societal value; yet several factors hinder comprehensive immunization coverage. Traditional methods of biologics production, based on stainless steel bioreactors, allow pharmaceutical companies to achieve economy of scale, but are limited by high capital expenditures. Such approaches stifle manufacturing innovation and lack long-term cost-effectiveness and sustainability.

Current innovations can cut biologics’ production costs to revolutionize the mainstream use of biologic treatments, focusing on developing fast, potent and cost-effective vaccine production. Univercells’ mission to make biologics affordable to all initiated a paradigm shift, targeting an innovative single-use manufacturing platform incorporating bioprocess into continuous operations. Univercells’ mission to make biologics affordable to all initiated a paradigm shift, targeting an innovative single-use manufacturing platform incorporating bioprocess into continuous operations. The objective is a down-scaled high-productivity process for a cost-effective manufacturing solution. The resulting micro-facilities are easily-deployable in developing countries, breaking entry barriers to biomanufacturing (Fig. 1).
Extensive rearrangements but high genomic stability in a biotechnologically advantageous derivative of modified vaccinia virus Ankara

Ingo Jordan1,2, Deborah Horn1, Kristin Höwing1,3, Lars Haag4, Volker Sandig1
1ProBioGen AG, 13086 Berlin, Germany; 2CureVac AG, 72076 Tübingen, Germany; 3Sartorius Stedim Cellca GmbH, 88471 Laupheim, Germany; 4Vironova AB, 113 30 Stockholm, Sweden

Background
Vectorised vaccines based on modified vaccinia virus Ankara (MVA) are reported to stably maintain large transgenes, and to be safe, immunogenic and tolerant to pre-existing immunity. MVA is usually produced on primary chicken embryo fibroblasts but continuous cell lines are being investigated as more versatile substrates.

We have previously reported development of a continuous suspension cell line (CR.pIX) derived from the muscovy duck and efficient production process for MVA in chemically defined media [1,2]. This process allowed isolation of an hitherto undescribed genotype (MVA-CR19) that induced fewer syncytia in adherent cultures and replicated to higher infectious titers in the extracellular volume of suspension cultures [3]. Replication of MVA-CR19 remained restricted predominantly to avian cells, an important property of MVA vectors.

Material and methods
Homologous recombination in CR.pIX cells was used to generate viruses with various expression cassettes in deletion site III [4] and combinations of the differentiating point mutations of MVA-CR19 in a backbone of wildtype virus. All recombinant viruses were plaque-purified. Successful introduction of the mutations was confirmed by sequencing and specifically designed restriction fragment length polymorphisms (RFLPs). Viruses were analyzed by serial passaging, diagnostic PCRs across deletion sites [4], replication kinetics, plaque phenotype and electron microscopy. The genome was further investigated by anchored PCR and long PCR.

Results
Efficiency of spread of recombinant viruses (Fig. 1a) could be mapped to a point mutation in one of the genes, A34R. However, although MVA-CR19 carries mutations in three structural proteins the most surprising result of our new study (Fig. 1c). This extensive rearrangement affects 15% of the viral genome and has also increased the area of complementarity between the two telomeres. The recombination site was precisely located and shown via analysis of earlier and subsequent passages to be a stable property of MVA-CR19.

Various viruses, including those with larger dual (DsRed1 and GFP) expression cassettes, were serially passaged at least 20-fold. Although the genotype of MVA-CR19 is advantageous for replication, all genotypic and genetic markers of wildtype and MVA-CR19 were stably maintained in all passages of the recombinant viruses, independent of wildtype or MVA-CR19 backbone.

Conclusions
We confirmed our previous results that suggested that MVA-CR19 replicates efficiently in single-cell suspensions and were able to connect this property with the D86Y mutation in A34, a structural protein on the surface of the virions. MVA-CR19 was also found to differ from wildtype MVA by a recombination between left and right viral telomere. Due to this event, several genes encoded at the left terminus have been deleted whereas the gene dosage of those originally encoded only at the right terminus may have increased. We do not currently know how much the various point mutations and changes in genomic structure combine to explain the improved replication of MVA-CR19. As several of the affected genes have been reported in the literature to impact interaction of MVA with the host we would expect that in vivo studies may reveal additional novel properties of MVA-CR19.

An extremely important distinction between our earlier study [3] and this one concerns the source of the viruses. Here, we investigated plaque-purified viruses and confirm the high genetic and genomic stability of MVA. Different expression cassettes inserted into deletion site III, all diagnostic RFLPs and PCRs over various sites of the genome and within the viral telomeres remained unchanged throughout at least 20 serial passages - independent of whether recombinant viruses with wildtype or CR19-derived backbones were characterized.

References
1. Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V: An avian cell line designed for production of highly attenuated viruses. Vaccine. 2009, 27: 748-756.
2. Jordan I, Northoff S, Thiele M, Hartmann S, Horn D, Höwing K, Bernhardt H, Oehmke S, von Horsten H, Rebeisi D, Hinrichsen L, Zelnik V, Mueller W, Sandig V: A chemically defined production process for highly attenuated poxviruses. Biol J Int Assoc. Biol Stand. 2011, 39: 50-58.
3. Jordan I, Horn D, John K, Sandig V: A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium. Viruses. 2013, 5: 321-339.
4. Kremer M, Volz A, Krejitz JHCM, Fux R, Lehmann MH, Sutter G. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol Biol Clifton NJ. 2012, 890: 59-92.
Optimized transfection efficiency for CHO-K1 suspension cells through combination of transfection and culture media

Abdalla A. Elsheereef, T. André Jochums, Antonina Lavrentieva, Janina Bahnemann, Dörte Solle, Thomas Schaeper

Institut für Technische Chemie, Leibniz Universität Hannover, Hannover, 30167, Germany; Pilot Plant Facility, National & Microbial Products, National Research Center, Cairo,12622, Egypt

Correspondence: Abdalla A. Elsheereef (elsheereef@iftc.uni-hannover.de)

BMC Proceedings 2018, 12(Suppl 1):P-227

Background

Transient gene expression systems using polyethylenimine (PEI) are considered to be fast, flexible and cost-efficient for recombinant protein production [1]. Transfection efficiency depends on different factors; one of them is the type of media. Production media support cell growth and protein production but not high transfection efficiency (TE) mediated by PEI [2]. Therefore, media were selected for transfection followed by feeding of production media [3] to improve TE and protein production. Two different transfection strategies are compared: conventional transfection by preparing polyplex of a plasmid (pDNA) and PEI interaction before transfection and insitu transfection by direct addition both of them to the cell suspension and the polyplex formed spontaneously [4].

Materials and methods

Cells were seeded 24 hr in CHOMACS CD media before transfection. At transfection time point an equal amount of cells were resuspended in each media type. Transfection was applied either insitu or conventional (polyplex prepared in 100 μL of 150 mM NaCl and incubated for 20 min., media addition was performed 5 hours post-transfection (hpt). Media type and transfection condition were illustrated in Table 1.

Results

Media screen result exhibits the highest transfection efficiency of around 50% transfected cells by Opti-MEM medium coming along with low cell growth and viability. To improve the transfection efficiency, basic parameters including cell density, pDNA, and PEI concentrations were varied and higher transfection efficiency was reached by reducing media or accordingly increasing cell density, PEI and pDNA concentration for transfection. Further optimization results show that the transfection of CHO-K1 cells in Opti-MEM (transfection medium) for 5 hours followed by addition of CHO-MACS CD (production medium) for further enhancing the transfection, cell count, and cell viability. The transfection efficiency (TE) increased up to 85 ± 2.6% coincide with increases in viable cell concentration (VCC) in comparison to transfected and cultivation in Opti-MEM media alone Fig. 1a. Both conventional and insitu methods are successfully transfected CHO-K1 to the same similar high TE as shown in fluorescence microscope images of Fig. 1b. Insitu transfection shows super-priority for suspension cell transfection concerning the reduction of handling steps (one step) compared to the conventional way (two steps). The insitu transfection avoiding the optimization step required for the incubation period to prepare transfection polyplex but require a higher amount of pDNA and PEI than conventional way as shown in Table 1.

Acknowledgements

I would like to thank DAAD for a PhD. grant and to thank (Institute of Technical Chemistry, Leibniz University of Hannover) for supporting me with all required facility.

References

1. Pham PL, Karen A, Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol. 2006;34(2):225-237. doi:10.1385/MB:34:2:225.
2. Meleady P. Heterologous Protein Production in CHO Cells. Vol 1603.; 2017. doi:10.1007/978-1-4939-6972-2.
3. Baldi L, Hacker DL, Adam M, Wurm FM. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett. 2007;29(5):677-684. doi:10.1007/s10529-006-9297-y.
4. Backliwal G, Hildinger M, Hasija V, Wurm FM. High density transfection with HEK 293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng. 2008;99(3):721-727. doi:10.1002/bit.

Table 1 (abstract P-227). Summary of transfection conditions

| Parameters | Media screen for GFP transfection | Optimize of GFP transfection | Comparison of transfection method |
|------------|----------------------------------|-----------------------------|----------------------------------|
| Media type | ProCHO5, Opti-MEM, CHOMACS CD, ProCHO4, UltraCHO, DMEM/F12 | Opti-MEM + CHOMACS CD | Opti-MEM + CHOMACS CD |
| Transfection volume (w/o w/media addition at 5 hpt) | 5 mL | 12.5 + 25 mL | 25 + 25 mL |
| Transfection protocol | Insitu | Insitu | Conventional |
| Cells amount | 10 x 10^6 | 62 x 10^6 | 10 x 10^6 |
| pGFP-N1 plasmid pDNA (μg) | 6 | 37.5 | 5 | 6 |
| Linear PEI 25 Kda (μg) | 30 | 187.5 | 15 | 30 |
| Scale | Spin tube®50 bioreactor | 25 mL Shake flask | Spin tube *50 bioreactor |

*Insitu without and w with

Transfection efficiency was monitored at 48 hpt by fluorescence microscope and flow cytometer. Cell count and viability were determined by Codey analyzer.

P-228

Regulation of recombinant protein expression during CHOBLR/rcTA pool generation increases productivity and stability

Adeline Pouliain, Alaka Mullick, Yves Durocher, Bernard Massie

Human Health Therapeutics Portfolio, National Research Council, Montreal, QC, Canada; Department of microbiology, infectiology and immunology, Université de Montreal, Montreal, QC, Canada;

Department of biochemistry, Université de Montreal, Montreal, QC, Canada;

Correspondence: Bernard Massie (bernard.massie@cnrc-nrc.gc.ca)

BMC Proceedings 2018, 12(Suppl 1):P-228

Background

In order to deal with the growing demand of large quantities of therapeutic proteins in a timely fashion, expression systems are being optimized to reduce the time of generation of stable clones as well as to increase the levels of protein secretion. This can be achieved by a combination of expression cassette optimization, cell engineering and selection process.

Materials and methods

We have previously developed the cumate gene-switch, which is a very efficient expression system for protein production [1].

Results

We have shown that the cumate-inducible promoter (CRS) was the strongest promoter we had tested so far in Chinese hamster ovary (CHO) cells. With this promoter, we were able to generate stable CHO pools capable of producing high levels of a Fc fusion protein (900 mg/L), outperforming by 3 to 4 fold those generated with CMV5 and hybrid EF1a-HTLV constitutive promoters. Besides the strength
of the CR5 promoter, we demonstrated that the ability to control both the time and the level of expression during pool generation and maintenance gave a real advantage to the inducible expression system. Indeed, we observed that keeping the expression OFF during selection enabled the generation of pools with superior productivity compared with the pools whose expression was maintained ON. Moreover, preliminary results suggest that keeping recombinant protein expression down increases the frequency of high producer clones [2].

Conclusions

Knowing that one of the main bottlenecks of the successful bioprocessing of recombinant proteins using CHO cells is the rapid isolation of a high producer, our data suggest that the cumate gene-switch system could be a valuable platform for the generation of stable clones.

Acknowledgements

This work was supported by the National Research Council Canada: Human Health Therapeutics portfolio.

References

1. Mullick, A., Y. Xu, R. Warren, M. Koutroumanis, C. Guilbault, S. Broussau, F. Malenfant, L. Bourget, L. Lamoureux and R. Lo: The cumate gene-switch: a system for regulated expression in mammalian cells. BMC Biotechnology 2006, 6(1): 43.
2. Poulain, A., S. Perret, F. Malenfant, A. Mullick, B. Massie and Y. Durocher: Rapid protein production from stable CHO cell pools using plasmid vector and the cumate gene-switch. Journal of Biotechnology 2017, 255: 16-27.

P-231

Generating monoclonal production cell lines with ≥ 99.9 % probability

Albert J. Paul, Verena Fischer, Christoph Zehe
Sartorius Stedim Cellca GmbH, 88471 Laupheim, Baden-Württemberg, Germany

Correspondence: Albert J. Paul (albert.paul@sartorius-stedim.com)

BMC Proceedings 2018, 12(Suppl 1):P-231

Background

The main regulatory authorities and organizations demand proof of monoclonality for biotechnological producer cells. With increasing pressure to shorten timelines and to improve drug safety, technologically advanced methods have to be established to ensure that production cell lines are derived from a single progenitor cell. Sartorius Stedim Cellca’s single cell cloning approach is based on one round of fluorescence-activated cell sorting (FACS) using Becton Dickinson (BD) FACSariaTM Fusion cell sorter combined with photodocumentation by SyntenTec Cellavista microscopic imaging system. For the approach, critical process parameters such as different cell lines, viability and cell aggregation levels were investigated separately to assess their contribution to the probability of monoclonality.

Materials and Methods

A variety of producer cell pools generated from Sartorius Stedim Cellca’s CHO DG44 host cell line were used for the evaluation of probability of monoclonality. Single cell cloning experiments were performed using FACSaria FusionTM (BD). Three to one day(s) prior to the experiments, cells were seeded at 3 x 10⁵ cells/mL. On day of the experiment, the cells were centrifuged and stained with DLight 650 conjugated Protein A. Subsequently, cells were washed, resuspended in PBS, filtered through a FACS tube with cell strainer cap and analyzed by flow cytometry. The top 3–5 % population with regard to DLight 650 fluorescence was selected and FACS droplets were sorted into 384-well flat bottom plates containing cloning medium. Doublet discrimination was done by using a FCS-W/FCS-H dot plot, and a SSC-W/SSC-H dot plot. Immediately after single cell cloning into 384-well plates (1 cell/well) the plates were centrifuged followed by imaging using the Cellavista (day 0). Further Cellavista images are taken on day 1, day 2 and on one day between day 5 and 7. Outgrowth was defined at day 14.

Results

8 cell lines expressing different recombinant products were investigated to calculate probability of having ≥ 2 cells/well after FACS sorting P(d), the apparent probability P(i) of having ghostcells (cells that are out-of-focus and, thus, are not visible during initial microscopic imaging), and the apparent probability P(k) of having ghostcells that outgrow the 384-well stage (Fig. 1). Using these results, the probability of obtaining a monoclonal cell by using Sartorius Stedim Cellca’s single cell cloning approach was determined (Table 1) by

Conservative examination: P(monoclonal, conservative) = 1 – (P(d) x P(i))

Realistic examination: P(monoclonal, realistic) = 1 – (P(d) x P(k))

Cell pools with low viability can theoretically impact the probability of monoclonality by e.g. diminishing microscopic imaging quality (cell debris). Therefore, pool cell line 1 with very low viability (≥36 %) was used to demonstrate, that the probability of monoclonality is still ≥ 99.9 % in case of low viability on day of sorting:

P(monoclonal, conservative) = P(d) x P(i) = ≥ 99.9 %
P(monoclonal, realistic) = P(d) x P(k) = > 99.9 %

Furthermore, cell pools with high aggregation levels can theoretically impact the probability of monoclonality by sticking together during FACS sorting and therefore increase the probability P(d) of having ≥ 2 cells/droplet. Therefore, pool cell line 8 with high aggregation levels (≥11.1 %) was used to demonstrate, that the probability of monoclonality is still ≥ 99.9 % in case of highly aggregated cell pools on day of sorting:

P(monoclonal, conservative) = P(d) x P(i) = > 99.9 %
P(monoclonal, realistic) = P(d) x P(k) = > 99.9 %

Conclusions

In summary, there is no obvious correlation between protein product type and the determined probabilities for monoclonality. Furthermore, pools with a viability as low as 36 % and pools with an aggregation level as high as 11.1 % can be used for SCC resulting in acceptable probabilities of monoclonality.
Table 1 (abstract P-231). Probability of monoclonality of eight different cell lines, each expressing a distinct protein product

| Recombinant antibody product | P(monoclonal, conservative): ≥ 95% | P(monoclonal, realistic): ≥ 99% |
|-----------------------------|----------------------------------|---------------------------------|
| Pool cell line 1 IgG4        | 99.9 %                           | 99.9 %                           |
| Pool cell line 2 IgG4        | 99.8 %                           | >99.9 %                          |
| Pool cell line 3 Complex protein | >99.9 %                       | >99.9 %                          |
| Pool cell line 4 IgG1        | >99.9 %                          | >99.9 %                          |
| Pool cell line 5 IgG1        | >99.9 %                          | >99.9 %                          |
| Pool cell line 6 IgG4        | >99.9 %                          | >99.9 %                          |
| Pool cell line 7 Complex protein | >99.9 %                       | >99.9 %                          |
| Pool cell line 8 IgG1        | >99.9 %                          | >99.9 %                          |

P-232
Legacy cloning methods in the modern world part 1: reassessing the capillary aided cell cloning technique
Alison Porter1, Ian Tedder2, John McGuire3, Andy Racher4
1Process Development Sciences, Lonza Biologics plc, 228 Bath Road, Slough, SL1 4DX, UK; 2Cell Culture Development, Lonza Biologics plc, 228 Bath Road, Slough, SL1 4DX, UK; 3European Regulatory Affairs–Mammalian, Lonza Biologics plc, 228 Bath Road, Slough, SL1 4DX, UK; 4Future Technologies, Lonza Biologics plc, 228 Bath Road, Slough, SL1 4DX, UK
Correspondence: Alison Porter (alison.porter@lonza.com)
BMC Proceedings 2018, 12(Suppl 1):P-232

Background
ICH guidance [1] requires that any cell line used to produce biopharmaceuticals originates from a single progenitor cell. Recently, there has been increased scrutiny of the method(s) used to achieve this requirement. Here, we review the suitability of the legacy capillary aided cell cloning (CACC) method in light of this changing landscape of expectations.

The CACC method is based on the ‘spotting’ technique [2] and relies on independent visual conformation by two scientists of the presence of a single cell in a 1 μL droplet. This method achieves a high probability of monoclonality in one cloning round. Although the method has since been replaced by FACS single cell deposition for routine use, it remains a viable cloning method.

Materials and methods
- Performed by trained scientists
- Dilute culture to 1500 ± 500 cells/mL with ≤2% doublets
- Draw cell suspension into pipette tip by capillary action; tap tip against the centre of the base of each well of a 48 well plate.
- Size of resulting droplet = ~1 μL (Fig. 1a)
- Two scientists independently view all wells using a microscope (initially use 40x magnification with the entire rim of the droplet visible within the field-of-view. Next, examine particles using 100x or 200x magnification to confirm they are cells) and individually record the number of cells present in each well’s droplet (Fig. 1b to d).
- Exclude droplet from further analysis if full visualisation is hindered (Fig. 1e to h).
- Add growth medium, and incubate plates. Record all wells containing colonies; only progress colonies from wells that both scientists agree contains only one cell.
- Data analysis:
  - Each scientist’s observations categorised as: 0 cells, 1 cell or >1 cell
  - Observed outcome for each well: growth or no growth
  - Probability of monoclonality estimated from data using a statistical model

Results
Advantages of the CACC Method Compared to Limiting Dilution Cloning (LDC)
Increased accuracy of P(monoclonality) with CACC
- LDC weakness: no visualisation after seeding (to check both well seeding and subsequent growth of colonies is well described by the Poisson distribution), potentially overestimating P(monoclonality)
- Addressed by CACC: Visual examination with colonies arising from wells seeded with 1 cell distinguished from those seeded with >1 cell
- Visualisation step further strengthened by: Using controls for exclusion of wells; measuring errors based on the presence or absence of colonies in wells where two scientists independently reported 0 cells; and formally analysing the data using a suitable statistical model

Decreased time and resource requirements with CACC
- High P(monoclonality) possible in single round as each well examined individually with only those containing a single cell progressed, and because the error rate for incorrect scoring is considered to be low

Frequency of Errors With CACC Method
Possible visual observation errors considered:
- two scientists miss a cell
- one cell sitting on top of another and the two thus appearing as one

An experiment was performed to estimate error frequency [3].

Conclusion
- Scientists miss a cell infrequently (in the range 0.4% to 1.3%, [3])
- Error frequency does not invalidate use of direct observation methods for cell cloning
- Single cell seen by both scientists is highly likely to be monoclonal

Summary of Strategies in Place to Control Errors
- During method development, strategies established to control potential sources of error (Table 1)

Conclusions
Use of a contemporaneous visualisation approach, a strict control strategy, and a suitable statistical model (which takes into account potential errors) results in:
- The CACC method being at least as robust as the LDC method
- The CACC method being a reliable, single-step method for cloning to achieve a high P(monoclonality)

Acknowledgements
R. Boraston for photographs in Fig. 1.

References
1. International Committee on Harmonisation (ICH) Q5D (1997). www.ich.org.
2. Clarke JB & Spier RE (1980). Arch. Virol, 63:1-9.
3. Onadipe OA, Metcalfe KM, Freeman PR & James C (2001). E. Lindner-Olsson et al (eds), Animal Cell Technology: From Target to Market, 72-74.
Potential Error | Impact | Control strategy
--- | --- | ---
Presence of doublets or clumps of cells | Doublets are unlikely to affect P(monoclonality) as wells with doublets containing these will not be recorded as containing a single cell and will therefore not be progressed. However, presence of a doublet could increase the chance of a cell being sat exactly on top of another and therefore being missed. It will also increase time and resource required to achieve a desired number of wells which both scientists have recorded as containing a single cell. As such, it is good practice to ensure proportion of doublets is low. | Ensure cell sample to be cloned contains ≤2% doublets.

Scientists hindered from visualising cells within a droplet | Scientists miss cells and P(monoclonality) is misleadingly high. | Procedure in place to exclude wells with droplets harbouring certain characteristics from further analysis and progression.
(i) Two independent scientists view the droplets.
(ii) Scientist fatigue is controlled by limiting the amount of time a scientist can spend cloning on any given day.
(iii) Statistical model takes into account potential errors.

An error is made in determining the number of cells a droplet contains | P(monoclonality) is misleadingly high or low. | Ensure cell sample to be cloned contains ≤2% doublets.
A novel siRNA aided method for CHO cell line selection

Andreas B. Diendorfer1, Vaibhav Jadhav1, Zach Wurz2, Frank Doyle3, Ted Eveleth2, Scott Tenenbaum3, Nicole Borth1, 4
1Austrian Center of Industrial Biotechnology, Vienna, Austria; 2HocusLocus LLC, Albany, NY, USA; 3State University of New York Polytechnic Institute, Albany, NY, USA; 4University of Natural Resources and Life Sciences, Vienna, Austria

Correspondence: Andreas B. Diendorfer
(andreas.diendorfer@boku.ac.at)

BMC Proceedings 2018, 12(Suppl 1):P-236

Background:

Traditional cell line engineering strategies mainly include an antibiotic resistance selection. In this process, cells are transfected with the GoI (gene of interest) together with an antibiotic resistance gene and those cells are selected that survive treatment with the respective antibiotic [1]. Although the gene responsible for the survival of the cell is transfected together with the GoI, resistance is not necessarily linked to high GoI expression. Thus, a significant proportion of resistant cells may not express the GoI at all, necessitating the search for alternative, more closely linked selection systems.

siRNAs (silencing inducing RNAs) are short, noncoding RNAs that can bind to complementary mRNA and inhibit their translation. This function has been used in many approaches to silence the expression of certain genes [2]. With their short length, siRNAs can be hidden in introns (non-translating regions) of genes, making it possible to couple the expression of a siRNA to a gene. This way a cell produces a correlating amount of siRNA when transcribing the gene, without adding any further translational burden on the cell.

The co-expression of the siRNA can be used as a selective marker by one of the following methods: (1) Knock-down of a suicide gene to enable a cell’s survival after suicide gene mRNA transfection, (2) down-regulation of a surface marker which is used in MACS (magnetic cell separation) to filter out wanted or unwanted cells, and (3) inhibition of a fluorophore marker for selection using FACS without product specific antibodies.

For siRNA based cell selection systems, siRNAs replace the commonly used antibiotics resistance as a marker. Cells that produce Gol will also produce the siRNA that protects the cell from a suicide gene. The selection protein (suicide genes, fluorophores, surface markers, etc.) is transfected as mRNA and is only expressed during selection.

Materials and methods:

The general process is outlined in Fig. 1. (A) The traditional antibiotic resistance marker is replaced by an siRNA, which is co-transcribed with the Gol. Unlike in antibiotic resistance, the marker here is not a protein, reducing the translational burden and providing more resources for Gol production [3]. (B) Transcription produces Gol mRNA together with either resistance gene or the spliced and processed siRNA. (C) Selection is done by the addition of antibiotics in the traditional approach or by transfecting a selective marker’s mRNA with a target site complementary to the product dependent siRNA. (D) Traditionally selected cells are selected based on the amount of antibiotic resistance they produce. siRNA knocks down a marker gene (suicide gene or a marker for MACS or FACS processing), but does not need an additional protein for selection. The genetic coupling of siRNA and Gol ensures selection based on Gol productivity.

Results:

Transfection with the suicide gene proved to be 100% lethal within 2 days, with no outgrowth over two weeks. Protection by expression of the siRNA was shown to be efficient. Currently a comparison of stable cell line development programs based on siRNA selection and neomycin selection is ongoing.

Conclusions:

The novel selection system should speed up cell line development, as the system kills rapidly and directly selects for cells transcribing the product gene on a high level. We expect to see more high producers earlier in the process, which will allow for an easier and faster selection in the following steps. siRNA based selection offers great opportunities. By directly selecting based on Gol transcription and not a proxy marker, we expect more relevant cells on a pool level. In addition, the elimination of an antibiotics resistance allows more cellular resources for Gol production. The system offers multiple ways of application; either by enriching wanted, or depleting unwanted cells.

Acknowledgements:

Austrian BMWFW, BMWIT, SFG, Standortagentur Tirol, Government of Lower Austria and Business Agency Vienna through the Austrian FFG-COMET-K2.

References:

1. Bandaranayake AD, Almo SC: Recent advances in mammalian protein production. FEBS letters 2008, 588:253-260.
2. Wilson RC, Doudna JA: Molecular mechanisms of RNA interference. Annual review of biophysics 2013, 42:217-239.
3. Kallehauge TB, Li S, Pedersen LE, Ha TK, Ley D, Andersen MR, Kildegaard HF, Lee GM, Lewis NE: Ribosome profiling-guided depletion of an mRNA increases cell growth rate and protein secretion. Scientific reports 2017, 7:40388.
Background
Single-cell cloning is an essential step used in the upstream development of transformed cell lines for therapeutic protein production. While single-cell clones are typically used to ensure product consistency, such low cell density cultures present a survival challenge; cells grow more slowly or may even not survive at low densities in protein-free media, costing the industry time and money and limiting the pool of candidate colonies for choice of production clones [1,2]. To address this problem, we aimed to develop a highly efficient serum-free medium suitable for optimizing single-cell cloning efficiency by studying a range of conditioned media (CM) samples isolated from different Chinese Hamster Ovary (CHO) cell lines.

Materials and methods
CHO-S, DG44 and CHO-K1 were adapted to CHO-S SFM-II (Gibco) medium for a minimum of three passages. Conditioned media was then collected when the cultures reached a cell density of 1x10^6 cells/ml (typically day 2-3 depending on the growth profiles of each cell line and whether they grew in suspension or attached conditions). Samples were then centrifuged twice to remove cell pellet/debris and stored at -20°C. The ability of conditioned media to support CHO colony formation was then assayed using 96-well plates, seeding the cells at low cell density (1-10 cells/well) by diluting down CHO cultures in media/conditioned media. After incubation at 37°C for 10 days, cloning efficiency was assayed using a standard XTT assay. Initial screening of the nine CM samples was performed using CHO-K1 cells due to their widespread use in industrial antibody production. Successful media candidates were subsequently screened using additional CHO cell lines.

Results
From the CHO-K1 tests, four conditioned media were identified as supporting improved cloning efficiency when compared to the unconditioned media results: SFM-II media (K1-SFMII-CM) conditioned by suspension CHO-K1; SFM-II media and Poly Vinyl Alcohol (PVA) (DG44-SFMIIPVA-CM) conditioned by suspension DG44; SFM-II media (CHOS-SFMII-CM) conditioned by suspension CHO-S and SFM-II media (ACHOS-SFMII-CM) conditioned by adherent CHO-S.

The highest CHO-K1 cloning efficiency was observed with the CHOS-SFMII-CM, displaying growth in 90% of the wells seeded. The DG44 SFM-II+PVA CM suspension cultures, also improved unconditioned media performance, displaying growth in 21 of the 96 wells seeded.

The K1-SFMII-CM and ACHOS-SFMII-CM are the most well characterized to date, having been tested on two other CHO cell lines: CHO-S and DG44. CM from CHO-S cells growing in SFM-II media adherent cultures (CHOS-SFM-II adherent CM) increased cell cloning efficiencies of several CHO cell lines when compared to SFM-II unconditioned media – (i) CHO-K1: 28-fold increase, (ii) CHO-S: 2-fold increase and (iii) DG44: 6% increase (Table 1). The K1-SFMII-CM product improved cell cloning efficiency for DG44 cells (avg. increase>1.5-fold) and CHO-S cells (avg. increase>3-fold) (Fig. 1) and also the adherent CHO-K1 cell line growing in ATCC +5%FBS.

Conclusions
The ability of conditioned media to support CHO growth in limiting-dilution conditions (1, 6 and 10 cells/ml) was investigated. From a range of nine conditioned media samples; four compelling products have been identified which improve low-cell density growth of CHO-K1 cells, compared to SFM-II control media. We feel that these early-stage conditioned media products may increase cloning efficiencies during upstream CHO cell line development, resulting in financial savings for industry and increasing the possibilities of identifying particularly high-performing transformed clones.

Acknowledgements
This research is supported by SFI Grant 13/IA/1841.

References
1. Ming Lim U., Gek Sim Yap M., Pin Lim Y., Goh L., and Kong Ng S.: Identification of autocrine growth factors secreted by CHO cells for applications in single-cell cloning media. J Proteome Res 2013, vol 12(7):3496-3510.
2. Zhu J., Wooh JW, Hou JJ, Hughes BS, Gray PP, Munro TP: Recombinant human albumin supports single cell cloning of CHO cells in chemically defined media. Biotechnol Prog 2012, vol 28(3): 887-891.
Table 1 (abstract P-246). Number of colonies observed in CHO-K1, DG44 and CHO-S limiting-dilution cultures in CHO-S SFM-II adherent conditioned media (ACHOS-SFMII-CM) compared to SFM-II unconditioned media (SFMII Ctl) and AGOS-SFMII-CM.

|        | SFMII Ctl | ACHOS-SFMII-CM | Fold change |
|--------|-----------|----------------|-------------|
| CHO-K1 | 1.5+/−0.71| 42+/−1.41      | 28          |
| DG44   | 31+/−3.06 | 33+/−0.24      | 1.06        |
| CHO-S  | 23+/−0.71 | 46+/−2.12      | 2           |

Fig. 1 (abstract P-246). Number of colonies observed in CHO-K1, DG44 and CHO-S limiting-dilution cultures in CHO-K1 SFM-II suspension conditioned media (K1-SFMII-CM) compared to SFM-II unconditioned media (SFMII Ctl). * p≤0.05, ** p≤0.01

P-247

Expediting upstream stages of protein biomanufacture through the use of Ubiquitous Chromatin Opening Elements – UCOE’s
Bethany McClosey1, Joe Orlando2, Kimberley Mann2, Michael Antoniou3
1:Department of Medical and Molecular Genetics, Kings College London, London SE1 9RT, UK; 2:MilliporeSigma, Process solutions, Bedford, MA, 01730, USA
Correspondence: Bethany McClosey (bethany.mccloskey@kcl.ac.uk)
BMC Proceedings 2018, 12(Suppl 1):P-247

Background
The main rate-limiting step in the upstream stages of protein biomanufacture is the isolation of stable, high producing cell clones. Ubiquitous Chromatin Opening Elements (UCOE’s) consist of at least one promoter region with associated methylation-free CpG island from housekeeping genes; they possess a dominant chromatin opening capability and thus confer stable transgene expression. UCOE-viral promoter (e.g. CMV) based plasmid vectors markedly reduce the time it takes to isolate high, stably producing cell clones. Although some UCOE-viral promoter combinations have been tested, they have not been thoroughly evaluated in Chinese hamster ovary (CHO) cells.

Material and method
Plasmid vectors containing combinations of either the human HNRPA2B1-CBX3 UCOE (A2UCOE) or murine Rps3 UCOE (Rps3 UCOE) linked to different viral promoters (hCMV, gpCMV, SFFV) driving expression of an eGFP reporter gene were functionally analysed by stable transfection into CHO-K1 cells and expression analysed by flow cytometry and qPCR to determine vector copy number.

Results and discussion
The results at 21 days post-transfection and selection clearly indicate that the Rps3 UCOE-gpCMV and -hCMV combinations give the highest transgene expression as shown in Fig. 1. The A2UCOE-hCMV/gpCMV constructs were the next efficacious but 2-fold lower than the Rps3 UCOE vectors. The SFFV promoter linked with either of the two UCOE’s was the least effective with expression levels 17-fold lower than the Rps3-CMV constructs. The Rps3 UCOE-gpCMV/hCMV constructs are now being further modified to include elements that will provide optimal post-transcriptional pre-mRNA processing (splicing, polyadenylation, transcription termination, mRNA stability) thereby maximising stable cytoplasmic transgene mRNA levels and protein production.

References
1. Neville JJ, Orlando J, Mann K, McCloskey B, Antoniou MN. (2017) Ubiquitous Chromatin-opening Elements (UCOE): Applications in biomanufacturing and gene therapy. Biotechnol Adv. 35: 557-564.
weeks and t=8 weeks. Altogether three different proteins of interest with six cell clones each were tested.

Results
We adapted our cell line development process by increasing the initial selection during the first selection phase, thereby allowing the omission of the 30 nM MTX amplification step. We observed that the capacity of amplifiability varied for different products. Cell lines with a protein titer ranging from >1 g/L to 1.5 g/L (DTE) in shake flask fed-batch showed to be more susceptible to increased initial MTX levels and were thus not amplifiable with 30 nM MTX. In contrast, cell lines with high protein titer >1.5 g/L were observed to adapt to 30 nM MTX easily and were amplifiable.

Finale shake flask fed-batch data with CLD 2.0 clones of high-expressing products showed comparable titers to clones from the standard approach. CLD 2.0 clone titers for DTE proteins revealed an average 2.0-fold increase compared to clones generated in the standard approach. Titors of top producing clones were in a range of 1.8 g/L to 2.7 g/L (Fig. 1). Furthermore, stability data of CLD2.0 cell clones from different DTE products showed a stable specific productivity in a range of +/- 15% over eight weeks cultivation. Fed-batch titer from t=2 weeks and t=8 weeks were in a normal range of +/-20% of the standard 30 nM projects.

Conclusions
Our results demonstrate that CLD 2.0 is a robust and reliable process for standard products (mAb) and DTE proteins. With our new process, we were able to increase titer of difficult-to-express proteins up to 200%. By omitting the amplification step (30 nM MTX) 96% of generated clones were stable over eight weeks cultivation time. Additionally using the CLD2.0 approach, the time line from DNA to RCB was reduced to 5 months.

Materials and Methods
To identify the high expression sites in the CHO cells, we employed NGS to analyze the integration sites of a high producing cell line (titer > 3g/L). The pair-end reads with one read mapped to the vector and the other read mapped to the CHO reference genome are extracted to identify the integration sites. To test the expression activity of the integration sites, we employed CRISPR/Cas9 to specifically integrate the antibody gene into CHO genome for expression.

Results
Our data showed 4 integration sites are in the high producing cell line. Among the 4 integration site, IS1 integration site was tested by CRISPR/Cas9 for target integration of antibody gene for expression. The IS1-target integrated cell pool present higher expression titer than cell pool generated by target integration into other integration sites (Fig. 1a). The single cell clones derived from IS1-target integrated cell pool had low copy number of GOI (Fig. 1b). After normalization with copy numbers, the single cell clones derived from IS1-target integrated cell pool showed high titer per copy (123 ~583 mg/L/copy) (Fig. 1c).

Conclusions
This study demonstrated the generation of high-producing cell lines by CRISPR/Cas9 mediated target integration. This approach will cost less time and labor than traditional method. The active integration site will serve as a platform like a cassette player for therapeutic antibody production.

Acknowledgements
This study is funded by Ministry of Economic Affairs of ROC.

References
1. Fischer S, Handrick R, Otte K. The art of CHO cell engineering: A comprehensive retrospect and future perspectives. Biotechnol Adv. 2015 Dec;33(8):1879-96.
2. Inniss MC, Bandara K, Jusak B, Lu TK, Weiss R, Wroblewska L, Zhang L. A novel Bxb1 integrase RMCE system for high fidelity site-specific integration of mAb expression cassette in CHO Cells. Biotechnol Bioeng. 2017 Aug;114(8):1837-1846.

Table 1 (abstract P-256). Integration sites of a high-producing cell line was determined by whole genome sequence with 15X coverage.

| Cell line | Titer | Integration sites | Location |
|-----------|-------|------------------|----------|
| 3G7       | 2.5 g/L (fed batch) | IS1         | promoter |
| 175 mg/L (batch) | IS2         | upstream(-4k) |
|            | IS3         | intron        |
|            | IS4         | promoter      |

Fig. 1 (abstract P-256). Productivity of target integrated cell pools (a), single cell clones (b), and titer per copy (c)

P-260
Coupling lipidomics and transcriptomics for characterization of mammalian cell lines
Yue Zhang1, Deniz Baycin2, Armit Kumar3, Joseph Priola4, Kristen Lekstrom5, Michael A. Bowen6, Michael J. Betenbaugh1
1 Chemical and Biomolecular Engineering Department, Johns Hopkins University, Baltimore, MD 21218, USA; 2Biotechnology Development Center, Turgut Ilaclari, Istanbul, Turkey; 3Antibody Discovery and Protein Engineering Department, Medimmune, LLC, Gaithersburg, MD, USA; 4Juno Therapeutics, Seattle, WA, USA

Correspondence: Michael J. Betenbaugh (beten@jhu.edu)

BMC Proceedings 2018, 12(Suppl 1):P-260
**Background**

CHO, HEK and SP2/0 are the dominant host cells for biologics drug production. Achieving high level of recombinant protein production by these cell lines still remains a challenge. In order to understand the potential roles of lipids in protein production, secretion, vesicular transport and energy metabolism, we coupled high-throughput transcriptomics and lipidomics technologies. Quantitative lipidomics is an emerging ‘omics technology which can help us understand the physiological limitations of each cell line. The two types of major lipid groups in cells are non-polar and polar lipids. Polar lipids such as glycerophospholipids (PLs) include phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylglycerol (PG), and phosphatidic acid (PA). In this study; we integrated two dimensional high performance thin layer chromatography (2D-HPTLC) and mass spectrometry (MS) lipid analysis of SP2/0, CHO, and HEK cell lines to understand the major differences in the lipid content of these hosts.

**Materials and methods**

Bligh-Dyer method was used to extract the lipids and extracts were analyzed by HP-TLC and MS. The polar lipids were separated into different categories by 2-D HP-TLC using a CHCl₃-MeOH-H₂O (71:25:2.5, v/v/v) solvent system in the first dimension and a CHCl₃-MeOH-Acetic acid-H₂O (76:9:12, v/v/v) solvent system in the second dimension. Non-polar lipids were separated by 1-D HPTLC using hexane-diethyl ether-acetic acid. 2,7-dichlorofluorescein dye was used to visualize both polar and non-polar lipids. Further detailed analysis was performed on a QqQ mass spectrometer (Thermo TSQ VANTAGE, San Jose, CA) using negative-ion and positive-ion ESI modes as well as negative-ion ESI mode in the presence of lithium hydroxide.

**Results**

In this study, quantitative lipidomics was coupled with transcriptomics to further understand the physiological pathways of HEK, CHO-M and SP2/0 cells. Initial HP-TLC analysis indicated that major lipids in these industrial cell lines were PE and PC. Other polar lipids such as PI, PS, PG, PA, and SM were lower compared to PC and PE in exponential and stationary phases of each cell line. Figure 1 represents 2D HP-TLC results of HEK with the relative quantitation of polar lipids. In order to investigate the lipid subgroups, shotgun MS analysis was conducted for both exponential and stationary growth phases of the three cell lines. MS analysis indicated that lysophosphatidylethanolamine (LPE) and lyso-phosphatidylcholine (LPC) amounts were 4 - 10 fold and 2-4 fold higher in HEK cells compared to SP2/0 and CHO cell lines. Sphingomyelin (SM) was another lipid subgroup that was shown to have a major difference between SP2/0 and other mammalian cell lines. SM was 30-65 fold lower in SP2/0 cell line compared to CHO and HEK. To understand these metabolic differences, transcriptomics analysis was performed using Illumina HighSeq and Gene Expression Omnibus was used to conduct these mammalian cells. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used to map the transcriptomics data to the lipid synthetic pathways. Transcriptomics data mapping to KEGG pathways demonstrated that differences in LPE and LPC pathways correlate with the expression profiles of secretory phospholipase A2 (sPLA2), lyso phosphatidylcholine acyltransferase (LPEAT), lysophosphatidylcholine acyltransferase (LPCAT), and lysophospholipase (LYPLA) [1].

**Conclusions**

The HP-TLC and LC/MS findings demonstrated that high levels of LPE and LPC existed in the HEK cell line and low levels of SM were observed in the SP2/0 cell line. Coupling lipidomics with transcriptomics provides us with an improved understanding of the physiological differences across SP2/0, CHO, and HEK cell lines that could be used to guide cell engineering efforts with the goal of increasing the recombinant protein expression capabilities of these three cell lines.

---

1. Zhang Y, Baycin Hizal D, Kumar A, Priola J, Bahni M, Heffner K, Wang M, Han X, Bowen M.A., and Benetenga M. J: High-troughput Lipidomic and Transcriptomic Analysis to Compare SP2/0, CHO, and HEK-293 Mammalian Cell Lines. Anal. Chem., 2016, 89(3):1477-1485.
Development of a transposon-mediated integration system to generate high yield producing cells with low copy number of integrated target antibody gene

Hsin-Lin Lu1, Han-Yuan Liu1, Bor-Shiun Chen1, Ying-Ju Chen1, Chien-I Lin1, Hsuan-Pu Chen2, Wei-Kuang Chi1
1Bioengineering Group, Institute of Biologics, Development Center for Biotechnology, New Taipei City, Taiwan; 2Fountain Biopharma Company, Taipei, Taiwan
Correspondence: Hsin-Lin Lu (hllu9999@dcb.org.tw); Wei-Kuang Chi (weikchi@dcb.org.tw)
BMC Proceedings 2018, 12(Suppl 1):P-268

Background
Productivity and stability are key factors for the selection of cell line in protein drugs production. Large amount of target gene integrated in cell genome could lead to the instability of production. Therefore, cells with low copies of target gene integrated in high yield sites could be an ideal production cells for manufacturing. It has been known that the transposon system can control the integrated copy number of target gene and can generate high yield producing cells, it could be a great approach to generate stable high yield producing cell lines carrying low copies of target gene through transposon system.

Materials and methods
We intended to develop a platform to generate high yield producing cell lines carrying 1-2 copy of the integrated target gene using transposon system. Two CHO cell lines, CHO-S cells and DXB11 cells, have been applied. Cells were co-transfected with transposon and target gene expression plasmids. After drug selection, the cell pool with highest productivity per target gene copy was applied to single cell cloning. The productivity and copy number of cell clones were determined, and the stability of cell clones was analysed after culture of about 60 generations.

Results
In the stable pools of CHO-S and DXB11 cells, the productivities per integrated target gene copy were about 11-13 mg/L/copy and 68-75 mg/L/copy in a batch culture, respectively. After single cell cloning, the integrated copy numbers in most cell clones were less than three copies per cell. In CHO-S and DXB11 cell clones, the productivities per integrated target gene copy were 20-60 mg/L/copy and 60-150 mg/L/copy in a batch culture, respectively. The productivity per integrated target-gene in cell clones developed by the transposon system was much higher than that in cell clones developed by random integration (Fig. 1a and b). To evaluate the productivity stability of cell clones developed by the transposon system, ten cell clones at generation 0, 30, 60, and 100 were applied in the analysis. Of interest, about 80% of cell clones were stable at generation 60, but lost the productivity at generation 100 (Fig. 1c), implying the most cell clones could maintain the stability within 2 months.

Conclusion
Using the optimized conditions of the transposon system to develop the stable gene expression cells, the productivity per integrated target gene was higher than random integration. These results suggested that our platform is capable to develop high yield producing cells with 1-2 copy of integrated target antibody gene and can be applied to identify high yield integration sites.

References
1. Rajendra Y, Peery RB, Barnard GC: Generation of stable Chinese hamster ovary pools yielding antibody titers of up to 7.6 g/L using the piggyBac transposon system. Biotechnol Prog. 2016, 32: 1301-1307
2. Balasubramanian S, Rajendra Y, Baldi L, Hacker DL, Wurm FM: Comparison of three transposons for the generation of highly productive recombinant CHO cell pools and cell lines. Biotechnol Bioeng. 2016, 113: 1234-1243.

Fig. 1 (abstract P-268). The productivity per integrated gene of interest (GOI) and the stability of cell clones developed by the transposon system. a Comparison of the integrated copy number of GOI and the productivity per integrated GOI copy between cell clones developed by random integration and transposon-mediated integration in CHO-S cells. b Comparison of the integrated copy number of GOI and the productivity per integrated GOI copy between cell clones developed by random integration and transposon-mediated integration in DXB11 cells. c The stability of antibody production in DXB-11 cell clones developed by the transposon system.
Comparison of glucose-lactate metabolism of three different mammalian cell lines using Flux Balance Analysis

Iván Martínez-Monge1, Pere Comas1, Joan Triquell1, Joan Albiol1, Carles Solà1, Antoni Casablanca1, Martí Lecina2, Carles Paredes1 and Jordi Joan Cairó3

1Department of Chemical, Biological and Environmental Engineering, Autonomous University of Barcelona, Bellaterra (Cerdanyola del Vallés), 08193, Spain; 2Bioengineering Department, IQS-Universitat Ramon Llull, Barcelona, 08017, Spain

Correspondence: Iván Martínez-Monge (ivan.martinez.monge@uab.cat)
BMC Proceedings 2018, 12(Suppl 1):P-272

Background
Mammalian cells show an inefficient metabolism characterized by high glucose uptake and the production of high amounts of lactate, a widely known growth inhibition by-product [1]. Recently, we have observed a different glucose-lactate metabolism in some cell lines. While some cell lines are unable to metabolize lactate, others can co-metabolize simultaneously glucose and lactate under certain culture conditions, even during the exponential growth phase [2]. These metabolic differences between different mammalian cell lines (CHO, HEK293 and hybridoma) have been studied by means of Flux Balance Analysis (FBA).

Materials and methods
Three different cell lines were cultured in a 2-liter bioreactor: CHO-S, HEK293SF and hybridoma KB-265. For the FBA, two adapted genome-scale metabolic models were used: a reconstruction of Mus musculus for CHO and hybridoma [3], and a reconstruction of Human metabolic model (Recon 2) for HEK293 [4].

Results
In cultures where pH was not controlled, two different metabolic phases were observed for CHO and HEK293 cells. During the first phase both cell lines produced large amounts of lactate as a consequence of the high glucose consumption rates. Interestingly, when pH dropped below 6.8, due to acid lactic secretion and accumulation, a second metabolic phase was identified, in which concomitant consumption of glucose and lactate was observed even during the exponential growth phase. Conversely, hybridoma cells were unable to co-consume lactate and glucose simultaneously even under non-controlled pH conditions. Therefore, the hybridoma physiological data used for the FBA corresponded to only phase 1 of pH-controlled cultures. A summary of the main cell growth and metabolic parameters obtained from the different experiments performed is presented in Table 1.

FBA shows (Fig. 1 for HEK293 cell culture) that lactate is produced in phase 1 because pyruvate has to be converted to lactate to fulfill the NADH regeneration in the cytoplasm and only a small amount of pyruvate can be transported into TCA through Acetyl-CoA. Cell metabolism in phase 1 is highly inefficient, as the majority of the carbon source is not used for the generation of energy nor biomass. In phase 2, in which mitochondrial LDH was considered, TCA fluxes could be maintained as in phase 1 at the maximal rate encountered; hence, the energy available for cells to grow was similar in both phases, obtaining similar growth rate.

Conclusions
Two different glucose and lactate metabolism behaviors have been observed in CHO and HEK293 cultures depending on the culture conditions: phase 1) glucose consumption and lactate production, and phase 2) glucose and lactate simultaneous consumption. In contrast, only phase 1 was observed in hybridoma cultures even when pH was non-controlled. FBA showed that TCA fluxes in phase 1 and phase 2 were similar, obtaining similar cell growth rate, but glucose uptake rate was much lower in phase 2 due to the lactate co-consumption. Some authors hypothesize that cells metabolize extracellular lactate as a strategy for pH detoxification [2]. Glucose and lactate co-metabolization resulted in a better-balanced cell metabolism, as can be seen from the metabolic fluxes calculated, with minor effects on cell growth. The observation of glucose and lactate co-consumption metabolic behavior and its deeper study and characterization could open the door of novel culturing strategies with the aim of increasing bioprocesses productivity.

Acknowledgements
The authors would like to mention that this research was supported by the FI-DGR (2017) from Spanish Government and the project was led by Prof. Jordi Joan Cairó Badillo.

References
1. Ozturk, S. S., Riley, M. R., & Palsson, B. O. (1991). Effects of ammonia and lactate on hybridoma growth, metabolism, and antibody production. Biotechnology and bioengineering, 39(4), 418-431.
2. Liste-Calleja, L., Lecina, M., Lopez-Repullo, J., Albiol, J., Solà, C., & Cairó, J. J. (2015). Lactate and glucose concomitant consumption as a self-regulated pH detoxification mechanism in HEK293 cell cultures. Applied microbiology and biotechnology, 99(23), 9951-9960.
3. Martínez, V. S., Dietmair, S., Quek, L. E., Hodson, M. P., Gray, P., & Nielsen, L. K. (2013). Flux balance analysis of CHO cells before and after a metabolic switch from lactate production to consumption. Biotechnology and bioengineering, 110(2), 660-666.
4. Quek, L. E., Dietmair, S., Hanscho, M., Martínez, V. S., Borth, N., & Nielsen, L. K. (2014). Reducing Recon 2 for steady-state flux analysis of HEK cell culture. Journal of biotechnology, 184, 172-178.

Table 1 (abstract P-272). Summary of the parameters related to cell physiology calculated for the different mammalian cell lines from experiments performed in a 2L-Bioreactor

| Parameter          | CHO-S | HEK293 | Hybridoma |
|--------------------|-------|--------|-----------|
| Phase 1            |       |        |           |
| x<sub>max</sub> (10^6cells·mL<sup>-1</sup>) | 4.1    | 8.5    | 14.0      |
| pH range           | 7.5-6.8| 6.8-7.3| 6.8-6.9   |
| q<sub>glucose</sub> (nmols·mgDW<sup>-1</sup>·h<sup>-1</sup>) | -343.120 | -77.573 | -354.000 |
| q<sub>lactate</sub> (nmols·mgDW<sup>-1</sup>·h<sup>-1</sup>) | 555.290 | -87.608 | 600.000   |

Fig. 1 (abstract P-272). Flux Balance Analysis performed in phase 1 (glucose consumption and lactate secretion) (a) and phase 2 (glucose and lactate simultaneous consumption) (b) for HEK293 cells. Only the relevant fluxes for the discussion are depicted. Fluxes units are in nmols·mgDW<sup>-1</sup>·h<sup>-1</sup>. The ATP generation was maximized in order to calculate the fluxes through the metabolic network.
P-274
Robust and reliable transient protein production with PEIpro®, a well characterized polyethylenimine optimized for transfection
Mathieu Porte, Valérie Moreau-Toussaint, Julien Depollier, Jonathan Havard, Valérie Kédingier, Géraldine Guérin-Peyrou, Cindy Croizier, Fabrice Stock, Alengo Nyama, Patrick Erbacher
Polyplus-transfection, Bioparc, 850 Boulevard S. Brant, 67400 Illkirch, France
Correspondence: Mathieu Porte (mporte@polyplus-transfection.com)
BMC Proceedings 2018, 12(Suppl 1):P-274

Background
Transient protein expression in mammalian cell lines has gained increasing relevance as it enables fast and flexible production of high-quality eukaryotic protein. Considerable efforts have thus been made to overcome existing limiting aspects of transient gene expression systems, in terms of cell lines, cell culture-based systems, and protein production in a cost-effective manner. Milligram amounts of protein per liter can be produced within several days, allowing a significant shortening of the bioproduction process in comparison to protein production from stable clones. To ensure the robustness of the process, it is essential to have a reliable and easy-to-use transfection method.

To palliate for the need of a reliable transfection reagent, we developed PEIpro®, the only commercially available PEI optimised for mid to large-scale transient protein production during process development. PEIpro® is a non-polydispers and fully-characterised polymer that has become the gold PEI standard due to its reliability, reproducibility in high DNA delivery efficiency and in ensuing high protein production yields.

Here, we present experimental data showing the benefits of using PEIpro® for protein production in comparison to other PEIs. We further demonstrate compatibility of using PEIpro® for recombinant protein production in most commonly used chemically-defined media.

Material and methods
Suspension HEK-293 and CHO cells were cultured in shaker flasks in various synthetic media, as listed in Table 1. HEK-293 and CHO cells were resuspended at 1×10⁶ cells/ml of serum-free medium, on the day before transfection. Cells were transfected with 0.5-1 mg of plasmid DNA encoding for the Luciferase gene reporter using PEIpro®, PEI "Max" and L-PEI 25 kDa (Polysciences, Warrington, PA) resuspended at 1 mg/ml according to the manufacturer’s recommendation. Luciferase expression was assayed 48 hours post-transfection using a conventional luciferase assay.

Results
Comparison of PEIpro® to other commercially available PEIs was achieved by transfecting suspension HEK-293 and CHO cells with plasmid DNA encoding for the luciferase gene reporter. Luciferase production yields obtained in HEK-293 and CHO cells were at least respectively 5-fold and 10-fold higher when using a similar amount of PEIpro in comparison to the other PEIs (Fig. 1). Conversely, at least 1 mg of plasmid DNA and 4-fold more of PEI "Max" and L-PEI 25 kDa were needed to obtain a similar Luciferase expression range in both HEK-293 and CHO cells.

We further assessed the compatibility and versatility of PEIpro® by measuring protein production yields obtained in most commonly used animal-free synthetic media. As shown in Fig. 2, PEIpro® leads to high protein production yields in several commercially available media formulations for HEK-293 and CHO cell lines.

Conclusion
PEIpro® is the only fully characterised PEI transfection reagent that is suitable for reliable and reproducible recombinant protein production, irrespective of the scale of production and of the type of adherent and suspension cell culture system.
Comparison of expression strategies based on bicistronic and tricistronic vectors for Trastuzumab and Trastuzumab-interferon-α2b production in CHO and HEK293 cells

Joan Miret, Ramon Romain, Aida Roura, Cristina Moreno, Guillelm Arboix, Merce Farrià, Daniela Cancelleri, Claudia Di Gesù, Antoni Casalblancas, Martí Lecina, Jordi Joan Cairò

1Department of Chemical, Biological and Environmental Engineering, Universitat Autònoma de Barcelona, Barcelona, 08193, Spain; 2Department of Biotechnology, Farmhispania SA, Montmeló, 08160, Spain; 3School of Medicine and Surgery, University of Palermo, Palermo, 90133, Italy; 4IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain

Correspondence: Joan Miret (joan.miret@uab.cat)

BMC Proceedings 2018, 12(Suppl 1):P-276

Background

Monoclonal antibodies (MAbs), which are widely used in anticancer therapies, are mainly produced by mammalian cell lines. MAb conjugation to biological molecules for enhancing their antitumor activity offers a new powerful tool for anticancer therapies. We have assessed the production of commercially approved anti-HER2 therapeutic antibody Trastuzumab (Tzmb) [1] and also its fusion with interferon-α2b (IFNα2b). Two cloning strategies consisting in transferring CHO-S and HEK293 cell lines with two bicistronic or with a single tricistronic plasmids have been assessed. The in vitro efficacy of both antibodies has been tested and compared side by side.

Materials and methods

Tzmb heavy and light chains were cloned in two bicistronic plasmids (pIRESpuro3 and pIRESneo3, Clontech) and in a tricistronic plasmid derived from pIRESpuro3. IFNα2b was spliced to Tzmb heavy chain by overlap extension PCR and the resulting Tzmb-IFNα2b fusion protein was also cloned in the expression vectors in the same way than non-modified Tzmb.

Selected cell pools were cultured in 125 ml shake flasks containing SFMTransf simultaneous 10% v/v of Cell Boost 5 (HyClone), 4 mM of GlutaMAX (Gibco) and 2 μg/ml of puromycin and also with 700 μg/ml of neomycin in the case of the cells transfected with pIRESneo3. Cells were cultivated in the same conditions as described elsewhere [2]. Purified products (using protein A chromatography (HiTrap MabSelect Sure, ÄKTA Avant 150)) were quantified by both ELISA and SDS-PAGE. Antigen binding test was performed in Sk-br-3 breast cancer cell line by means of flow cytometry analysis. The biological activity of the different candidates was tested with MTT assay.

Results

Both Tzmb and the fusion protein Tzmb-IFNα2b have been successfully expressed in CHO-S and HEK293, which use for heterologous protein expression have previously been optimized in prior works [3]. The tricistronic strategy resulted in the most efficient, showing a 3.5-fold increase in terms of productivity with respect to the bicistronic double-transfection for Tzmb in CHO-S cells and a 5-fold increase in HEK293 cells (Fig. 1a). In the case of Tzmb-IFNα2b, the tricistronic strategy also allowed to achieve higher productivities than the bicistronic one (Fig. 1b). Regarding the differences of specific productivity between both cell lines tested, HEK293 emerged as the best production host candidate, for the two tested strategies (tricistronic and bicistronic) and for the two produced proteins, showing a 1.5-fold increase in terms of productivity with respect to CHO-S cells for Tzmb using the tricistronic strategy.

Tzmb and Tzmb-IFNα2b were analysed in terms of their antigen binding capacity, and both were found to efficiently bind to HER2-expressing Sk-br-3 cells (Fig. 1c). Thus, the antibody affinity to HER2 antigen has not been affected when fused to INF-α2b. Finally, antiproliferative activity of Tzmb and Tzmb-IFNα2b were assessed on the same Sk-br-3 cells. At a concentration of 500 nM of Tzmb, and after a 72-hour incubation, Sk-br-3 cells presented a 83% growth with respect to the untreated control. However, no antiproliferative effect was observed for Tzmb-IFNα2b (Fig. 1d).

Conclusions

The tricistronic strategy provides higher productivity yields in HEK293 and CHO-S cell lines for both recombinant proteins (Trastuzumab and Tzmb-IFNα2b). Regarding which cell line is the best production host candidate, HEK293 achieved higher productivity than CHO-S cells for the two proteins tested. All constructions performed preserved the binding affinity to its antigen, Trastuzumab and Tzmb-IFNα2b bind efficiently to the HER2 antigen present in Sk-br-3 cells. Finally, Tzmb-IFNα2b does not present an improved antiproliferative effect with respect to Trastuzumab when compared by means of an in vitro assay.

References

1. Clifford A, Hudis MD: Trastuzumab – Mechanism of action and use in clinical practice. N Engl J Med 2007, 357: 39-51.
2. Liste-Calleja L, Lecina M, Cairò JJ: HEK293 cell culture media study towards bioprocess optimization: Animal derived component free and animal derived component containing platforms. J Biotech Bioeng 2014, 117(4): 471-477.
3. Román R, Miret J, Scaila F, Casalblancas A, Lecina M, Cairò JJ: Enhancing heterologous protein expression and secretion in HEK293 cells by means of combination of CMV promoter and IFNα2 signal peptide. J Biotechnol 2016, 239: 57-60.

Production of therapeutically relevant lentiviral vectors for clinical studies

Johann-Christoph Dettmann1, Martin Meyer1, Thomas Nol1

1Miltenyi Biotech GmbH, Bergisch Gladbach, Germany; 2Faculty of Technology/AG Zellkulturtechnik, University of Bielefeld, Bielefeld, Germany

Correspondence: Johann-Christoph Dettmann (johannd@miltenyibiotec.de)

BMC Proceedings 2018, 12(Suppl 1):P-279

Background

The genetic engineering of patient-specific T cells with lentiviral vectors (LVV) expressing chimeric antigen receptors (CAR) for late phase clinical trials requires the large-scale manufacture of high-titer vector stocks. The state-of-the-art production of LVV is based on 10- to 40-layer cell factories transiently transfected in the presence of serum. This manufacturing process is extremely limited by its labor intensity, open-system handling operations, its requirements for significant incubator space plus costs and patience risk due to presence of serum.

To circumvent these limitations, this study aims to develop a stable and serum-free process to produce LVV with PEI-mediated transfection. In addition, this study also focuses on the development of a
production system not only using a GFP marker but also a therapeutically relevant transgene (CD20-CAR) [1].

Materials and methods

Therefore, three different cell lines (HEK 293, 293T, 293FT) were investigated concerning their productivity of LVV and their growing behavior in the in-house serum-free medium TransMACS. As part of this, Design of Experiment was used to investigate the optimal conditions for PEI/DNA-transfection. Furthermore, this statistical approach was used focusing an ideal ratio between the 3rd generation plasmids (transfer plasmid CD20-CAR or GFP, envelope plasmid, packaging plasmids). In addition, different enhancers (sodium butyrate, lithium acetate, caffeine, trichostatin A, cholestrol, hydroxyurea, valproic acid) were investigated concerning their effects on productivity comparing HEK cultures producing LVV encoding for GFP-marker or CD20-CAR.

Results

Concerning productivity and growing behavior, HEK 293T was the favored cell line for our serum-free LVV manufacturing process. In addition, an additive screen revealed that sodium butyrate alone had the most promising effect on both GFP-LVV and CD20-CAR-LVV production. After PEI/DNA titration, we finally could increase LVV productivity by lowering PEI/DNA amount at higher cell densities referred to our standard transfection protocol. Furthermore, the titration for the optimal plasmid ration revealed, that for larger transfer constructs higher amounts of transfer plasmid are required than for smaller constructs to achieve a high productivity (Fig. 1).

Conclusion

The outcome of these experiments enabled the development of a robust HEK293T based process to produce clinical relevant LW under serum-free conditions. Furthermore, it provides an insight how therapeutic genes and the expression of its transgene can influence cell productivity.

References

1. Merten OW, et al. Production of lentiviral vectors. Mol Ther Methods Clin Dev. 2016;3:16017. doi: 10.1038/mtm.2016.17

Fig. 1 (abstract P-279). Figure shows response surface graphs for the GFP-transfer plasmid (a) and the CD20-CAR-transfer plasmid (b) at three different rev-plasmid concentrations (0.04, 0.2, and 0.4 μg/mL). Concentrations of the other plasmids decrease from the respective corner of the graphs towards the corresponding opposite line

Table 1 (abstract P-281). Phenotypic analysis of mixed populations

| Targeted miRNA | Phenotype |
|----------------|-----------|
| miR-23a        | Prolonged culture |
| miR-23b        | Prolonged culture, decreased productivity |
| miR-27a        | Decrease in growth |
| miR-27b        | Prolonged culture |
| miR-24         | Boost in growth and productivity |
Intracellular secretion analysis of recombinant therapeutic antibodies in engineered CHO cells aiming to establish high producer

Kohei Kaneyoshi1, Keiji Uchiyama2, Masayoshi Onitsuka3, 4, Noriko Yamano1, 4, Yuichi Koga3, Takeshi Omasa1,4

1Graduate School of Engineering, Osaka University, Suita, Osaka 5605871, Japan; 2The Institute for Enzyme Research, Tokushima University, Tokushima, Tokushima 7708503, Japan; 3Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Tokushima 7708513, Japan; 4Manufacturing Technology Association of Biologics, Kobe, Hyogo 6500047, Japan

Correspondence: Takeshi Omasa (omasa@bio.eng.osaka-u.ac.jp)

BMC Proceedings 2018, 12(Suppl 1):P-282

Background

Chinese hamster ovary (CHO) cells are the most widely used host cell line for the production of therapeutic antibodies. Pre- and post-translational modifications and optimization of culture methods contributed to increase the productivity, resulting in a very high titre [1, 2]. However, it has been pointed out that the intracellular secretion process is a bottleneck in the production of therapeutic antibodies [3]. In addition, the details of the process of secretion of humanized recombinant antibodies from CHO cells have not been well investigated. In this study, we thus analysed the detailed process of secretion of therapeutic antibodies using CHO cell lines, which have already been established as high producers, with the aim of obtaining information for the next target to improve productivity.

Materials and methods

We performed 1) chase assay, 2) immunofluorescent microscopy observation, and 3) size exclusion chromatography (SEC) analysis to investigate the duration of secretion, bottleneck position, and formation of recombinant IgG, respectively. High-producer CHO cells expressing humanized IgG1 [4] and IgG3 were used. For the chase assay, cells were cultivated in shake flasks with serum-free medium containing 50 μg/ml cycloheximide (CHX) to stop nascent peptide synthesis. The amounts of IgG both remaining in the cell and secreted into the medium at each time point were measured by quantitative western blotting. For immunofluorescent microscopy observation, cells were cultivated on coverslips with CHX for 4 h. Immunofluorescent staining against the recombinant IgG, endoplasmic reticulum (ER), and Golgi apparatus was performed after chemical fixation. For SEC, cells cultured with CHX were re-suspended in a buffer containing tritonX-100 and injected into a column. The amount of IgG in each fraction was measured by quantitative western blotting.

Results and discussion

The amount of IgG3 in the supernatant increased until 4–6 h after the inhibition of protein synthesis by CHX; however, it hardly changed thereafter (Fig. 1, upper panel). At this point in time, however, around 40% of IgG still remained in the cells (Fig. 1, lower panel), meaning that all of the synthesized IgG could not be secreted into the medium and remained in the cells for several hours. This result was almost the same as that of studies using IgG1-expressing cells [5, 6]. The localization of IgG in the cells was checked before and after the addition of CHX, with the results showing that IgG1 remained in the ER and was hardly seen in the Golgi apparatus [5–7]; IgG did not seem to be efficiently transported to the Golgi apparatus. The SEC experiment showed that most of the IgG1 remaining in the cell seemed to form full-sized antibodies [5, 6], but it could not be secreted despite this.

Conclusions

The high-producer cells could not secrete all of the synthesized IgG, and around 40% of IgG remained in the cells for several hours. This incomplete secretion is a common phenomenon among CHO cells producing different types of recombinant IgG. The IgG could not be transported from the ER to the Golgi despite its formation of full-sized antibodies. Solving this bottleneck in the transportation of IgG from the ER to the Golgi and/or achieving more efficient glycosylation of IgG after the formation of full-sized antibodies might be the next target to improve productivity.

Acknowledgements

This work was financially supported by the Project Focused on Developing Key Technology of Discovering and Manufacturing Drugs for Next-generation Treatment and Diagnosis from the Ministry of Economy, Trade and Industry of Japan and by Grants-in-aid for Scientific Research from the Japan Society for the Promotion of Science (USPS; JP26630433, JP26249125 and JP17H06157).

References

1. Wurm FM: Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004, 22(11):1393-1398.
2. Haredy AM, Nishizawa A, Honda K, Ohya T, Ohtake H, Omasa T: Improved antibody production in Chinese hamster ovary cells by ATF4 overexpression. Cytotechnology 2013, 65(6):993-1002.
3. Peng RW, Guett C, Tigges M, Fussenegger M: The vesicle-trafficking protein munc18b increases the secretory capacity of mammalian cells. Metab Eng 2010, 12(1):19-25.
4. Onitsuka M, Omasa T: Rapid evaluation of N-glycosylation status of antibodies with chemiluminescent lectin-binding assay. J Biosci Bioeng 2015, 120(1):107-110.
5. Kaneyoshi K, Uchiyama K, Onitsuka M, Yamano N, Koga Y, Omasa T: Intracellular secretion pathway analysis for constructing highly producible engineered CHO cells. 16th annual peptalk, San Diego, CA, USA, January 2017. Oral and Poster BC1101.
6. Kaneyoshi K, Uchiyama K, Onitsuka M, Yamano N, Koga Y, Omasa T: Intracellular secretion analysis of therapeutic antibodies in engineered high-producible CHO cells. Biochemical and Molecular Engineering XX, Newport beach, CA, USA, July 2017. Poster 41.
7. Kaneyoshi K, Uchiyama K, Onitsuka M, Yamano N, Koga Y, Omasa T: Analysis of intracellular recombinant IgG secretion in engineered CHO cells. The 29th annual and international meeting of the Japanese Association for animal cell technology (JAACT2016 Kobe), Kobe, Hyogo, Japan, November 2016. Oral O-1.

Fig. 1 (abstract P-281). Graphical workflow of targeting miRNAs in CHO cells and analysis of miRNA expression as well as indels.
Rational antibody humanization assisted by molecular dynamics simulations

Linda Schwaigerlehner1, Patrick Mayrhofer1, Maria Pechlaner2, Chris Oostenbrink2, Renate Kunert1
1Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria; 2Department of Material Sciences and Process Engineering, University of Natural Resources and Life Sciences, Vienna, Austria

Correspondence: Linda Schwaigerlehner (linda.schwaigerlehner@boku.ac.at)

Background

Humanized monoclonal antibodies (mAbs) are among the most promising drugs, but defined strategies for their modification are still not available. Our work deals with humanization of murine mAb2/3H6. The superhumanization approach leads to a loss of binding affinity which was partially restored by a single human-to-mouse backmutation (T98hR). [1] This residue was selected by synergistic combination of sequence analyses of antibody framework regions and structural information using novel in silico simulations. For structural stabilization, a conglomeration of tyrosine residues surrounding T98hR was identified, the so called “tyrosine cage”. [2] Analysis of the “tyrosine cage” was done by alanine scanning mutations with a double mutation variant T98hR + Y27hA (BM09) and a triple mutation variant T98hR + Y27hA + Y32hA (BM10). In a recent series of experiments we tried to enhance binding affinity by three new variants with backmutations in the variable light chain (VL). Originating from T98hR, residues in the VL were selected based on their spatial proximity to the CDR3 loop of the variable heavy chain. Affinity improvement of T98hR was evaluated by VL-double backmutation variants T98hR + F46lL (SU01) and T98hR + Q49lS (SU02) and a triple backmutation variant T98hR + F46lL + Q49lS (SU03).

Materials and methods

All five variants were expressed transiently in HEK293-6E cells and binding affinities were investigated in two individual settings with bio-layer interferometry. In the first approach concentrated cell culture supernatants were directly applied and mAbs were captured on protein A tips, blocked with 3D6scFv-Fc and the association and dissociation of 2F5 IgG was measured. For the second approach, the culture supernatants were purified and the affinity was determined with streptavidin biosensors. First, biotinylated 2F5 IgG was bound and then the association/dissociation of the purified 3H6 variants was measured.

Results

Affinity evaluation of concentrated culture supernatants with protein A sensor tips showed a decrease of binding affinity of BM09 and a loss of binding of BM10. The protein A measurement showed an increased binding strength of SU01, SU02 and SU03 compared to su3H6 and BM07. SU01 and SU03 result in a higher binding affinity compared to SU02. These results can be confirmed with purified variants by the streptavidin bio-assay (Fig. 1).

Conclusions

Alanine scanning of the tyrosine cage demonstrated a reduction of binding affinity (BM09) and a severe loss of binding (BM10), concluding that the tyrosine cage plays an important role for supporting a correct CDR loop conformation. Further affinity improvement of the single mutation variant T98hR could have been reached via mutations in the VL. It demonstrates the underestimated role of the VL for the interaction with its binding partner.

Acknowledgements

Financial support of the Austrian Science Fund (FWF; grant number P 25056) is gratefully acknowledged.

References

1. Mader A, Kunert R: Humanization strategies for an anti-idiotypic antibody mimicking HIV-I gp41. Protein Eng. Des. Sel. 2010, vol.23:947–954.
2. Margreitter C, Mayrhofer P, Kunert R, Oostenbrink C: Antibody humanization by molecular dynamics simulations-in-silico guided selection of critical backmutations. J. Mol. Recognit. 2016, vol.29:266–275.
P-288

MS-SILAC approach for phosphoproteomics of IGF signaling in producer CHO cells
Louise Brachtvogel1, Stefan Walter2, Thomas Noll1, Raimund Hoffrogge1
1Institute of Cell Culture Technology, CEBiTec, Bielefeld University, Bielefeld, Germany; 2University of Osnabrück, Osnabrück, Germany

Correspondence: Louise Brachtvogel (lbrachtvogel@uni-bielefeld.de)

BMC Proceedings 2018, 12(Suppl 1):P-288

Background
Although CHO cells are a major expression system for production of recombinant biopharmaceuticals, the molecular and cellular background characterizing a high producer is largely unknown. It has been observed that in producer cell lines important signaling pathways like the Akt-signaling are altered in characteristic ways. Thus analyzing according signaling events should lead to identification of key elements characterizing high producer cells. To investigate this, our emphasis lies on the phosphorylation status of involved proteins as reversible switches in all signaling pathways.

We aimed to establish a workflow for CHO-specific phosphoproteomics and focused on IGF signaling, as cell culture media often are supplemented with this growth factor. Two producer cell lines and the according parental cells were cultivated in a stable isotopic labeling with amino acids in cell culture (SILAC) experiment, followed by quantitative MS phosphoproteomic analysis including CHO-specific data evaluation.

Materials and methods
The chosen CHO cell lines were cultivated in triplicates in SILAC media containing isotopically-labeled lysine/arginine (hLys/hArg) and in parallel in identical standard media (lLys/lArg, TCX10D, Xell). Cell density, viability, metabolism and cell cycle distribution were monitored during 50 ml batch culture for 7-8 days. At day 3.25 IGF was added into hLys/hArg cultures. 5 min later a part of the cells was harvested. For MS analysis IGF-treated (hLys/hArg cultures) and control cultures (lLys/lArg cultures) were combined. The following MS sample preparation workflow included digestion of whole protein lysate and phosphopeptide enrichment via TIO2-beads. NanoLC-ESI-Orbitrap MS (Q Exactive Plus, Thermo Fisher Scientific) of phosphopeptides was executed with subsequent identification and quantification in MaxQuant [1]. In addition to SILAC quantification of H/L ratios for investigation of IGF effects, acquired data was also used to perform label-free quantification (LFQ) in MaxQuant [1] for comparison of cell lines. Statistical significance was calculated via t-test (p<0.05) or ANOVA (permutation-based FDR<0.05) in Perseus [2].

Results
IGF effects on growth and production
The IGF treatment resulted in a prolonged viability for all cell lines. However, an increased VCD was only observed for producer cell line 1, yielding in an enhanced integral of VCD (VCD). For the parental cells growth was inhibited by IGF, although S-phase cells were enriched at least temporary (Fig. 1a).

Regarding antibody production IGF led to a decreased qP and product titer, concomitantly with an increase in S-phase cells (Fig. 1a). This inverse correlation of proliferation and cell specific productivity is known from different productivity enhancing molecules, like butyrate [3].

MS investigation of signaling events
The phosphoproteomic experiment resulted in the identification of 10.485 class I-phosphorylation sites. Statistical evaluation of phosphopeptide abundances in Perseus showed up 144 significant differences between the cell lines and led to producer vs. parental classifications (Fig. 1b).

The quantitative evaluation via SILAC yielded in about 2.408 quantifiable phosphosites in at least 6 biological replicates. Rapid phosphorylation changes after growth factor treatment indicated signaling towards protein synthesis, cell cycle and regulation of actin cytoskeleton amongst others. For 201 phosphosites significantly different H/L ratios were calculated between the two groups parental vs. producer, four of them are listed (Table 1).

Conclusions
The workflow to study phosphorylation states revealed differences in the related cell lines and gave insights into signal transduction as a response on IGF. On the one hand, IGF-treatment resulted in a fast and widespread upregulation of phosphorylation sites within Akt- and MAPK-signaling. On the other hand, a different phosphorylation status for producer compared to parental cell lines uncovered distinctions in biological processes like RNA- and DNA-binding and regulation of cytoskeleton.

In sum, our successfully established phosphoproteomic approach allows to detect important signaling key players in CHO cells that subsequently can be targeted through cell engineering or small molecule treatment.

Acknowledgements
We would like to thank the Australian Institute for Bioengineering and Nanotechnology, University of Queensland-Brisbane, Australia (AIBN) for providing the CHO clones.

References
1. Cox, Mann: MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26:1367 – 1372.
2. Tyanova, Temu, Sintycyn, Carlton, Hein, Geiger, Mann, Cox: The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016, 13: 731–740.
3. Müller, Heinrich, Jabs, Kaspar-Schönefeld, Schmidt, Rodrigues de Carvalho, Albaum, Baessmann, Noll, Hoffrogge: Label-free protein quantification of sodium butyrate treated CHO cells by ESI-UHR-TOF-MS. J Biotechnol. 2017, 257:87-98.

Table 1 (abstract P-288). Selected differentially regulated phosphosites between both producer and parental cells following IGF treatment and SILAC-quantification

| Ratio H/L | Phosphosite | Protein Name (CHO) | UniProtAC |
|-----------|-------------|--------------------|-----------|
| 1.19      | Ser5        | DNA helicase       | G3H1V9    |
| 1.67      | Ser75 + Ser679 | Lethal (2) giant larvae protein-like 1 | G3OYH7 |
| 1.50      | Ser756      | Uncharacterized protein (Prune homology 2, human) | G3I7N4 |

Fig. 1 (abstract P-288). a Overview of growth, viability and cell cycle between parental (left) in comparison to one of the producer cell lines (right). b Hierarchical clustering of normalized, log-transformed and z-scored intensities as result of the LFQ-evaluation showing significant different phosphopeptide abundances between the cell lines.
Background
To improve antibody production in the CHO cell expression system, it seems to be useful to up- or downregulate gene expression including antibody folding, secretion, and cell metabolism. Many cell engineering approaches, including gene introduction, knockout and knockdown, have been employed to enhance recombinant antibody production [1]. However, identifying production enhancer genes is the rate-limiting step for CHO cell engineering, because the conventional method requires a series of experiments including genomic integration of the tested genes, selection of stable cell clones and cell culture experiments of several clones. In this study, we propose an approach for rapid evaluation of production enhancer genes based on an episomal expression system.

Materials and methods
Plasmid vector carrying the Epstein-Barr virus (EBV) encoded nuclear antigen 1 (EBNA1) was transfected into CHO cell line producing IgG1 antibody. After G418 selection and single colony isolation, EBNA1 expression was checked with capillary electrophoresis system Wes (ProteinSimple). EBV EBNA1-antibody (1EB12) was used for detection as the primary antibody. The expression vector for the gene of interest was prepared by inserting 1508 bp of an orIP DNA sequence into a plasmid vector carrying CAG promoter, resulting in the pOTC vector. PEI max (Polysciences, Inc.) and BalanCD Transfectory CHO (Irvine Scientific) were used for the transfection. The number of viable cells and GFP-positive cells were counted using Countess II FL Automated Cell Counter (Thermo Fisher Scientific). The transfected cells were cultured in CELLSTAR CELLreactor tubes. The tubes were incubated in a Climo-shaker ISF1-X (Kuhner). Antibody production was measured using biolayer interferometry with an Octet QK system (ForteBio).

Results
We constructed four CHO cell lines stably expressing EBNA1, termed IgG1-EB01 to EB04. In capillary electrophoresis analysis, we observed a clear peak corresponding to the EBNA1 expression by IgG1-EB01 cell lines. We tested the transfection efficiency by pOTC-GFP plasmids. In the best transfection condition, PEI/DNA in all four cell lines. We observed a clear peak corresponding to the EBNA1 expression including antibody folding, secretion, and cell metabolism. Many cell engineering approaches, including gene introduction, knockout and knockdown, have been employed to enhance recombinant antibody production [1]. However, identifying production enhancer genes is the rate-limiting step for CHO cell engineering, because the conventional method requires a series of experiments including genomic integration of the tested genes, selection of stable cell clones and cell culture experiments of several clones. In this study, we propose an approach for rapid evaluation of production enhancer genes based on an episomal expression system.

Materials and methods
Plasmid vector carrying the Epstein-Barr virus (EBV) encoded nuclear antigen 1 (EBNA1) was transfected into CHO cell line producing IgG1 antibody. After G418 selection and single colony isolation, EBNA1 expression was checked with capillary electrophoresis system Wes (ProteinSimple). EBV EBNA1-antibody (1EB12) was used for detection as the primary antibody. The expression vector for the gene of interest was prepared by inserting 1508 bp of an orIP DNA sequence into a plasmid vector carrying CAG promoter, resulting in the pOTC vector. PEI max (Polysciences, Inc.) and BalanCD Transfectory CHO (Irvine Scientific) were used for the transfection. The number of viable cells and GFP-positive cells were counted using Countess II FL Automated Cell Counter (Thermo Fisher Scientific). The transfected cells were cultured in CELLSTAR CELLreactor tubes. The tubes were incubated in a Climo-shaker ISF1-X (Kuhner). Antibody production was measured using biolayer interferometry with an Octet QK system (ForteBio).

Results
We constructed four CHO cell lines stably expressing EBNA1, termed IgG1-EB01 to EB04. In capillary electrophoresis analysis, we observed a clear peak corresponding to the EBNA1 expression by IgG1-EB01 cell lines. We tested the transfection efficiency by pOTC-GFP plasmids. In the best transfection condition, PEI/DNA ratio of 1/1, IgG1-EB01 cell showed the highest GFP-positive cell number (1.07×10⁷ cell/mL) and transfection efficiency (95%) among the four cell lines. Therefore, IgG1-EB01 cell lines were selected for further study. After the transfection, the number of GFP-positive cells continued to increase even after the passage (Fig. 1), suggesting that the pOTC-GFP plasmid was stably retained and replicated by EBNA1/orIP system in IgG1-EB01 cell lines. In preliminary experiments, we introduced three genes, MDH2, GSS and GCLM, into IgG1-EB01 cell lines. Cotransfection of these three genes led to an increase in IgG1 production from 287±18 mg/L (control) to 334±21 mg/L at day 8 (P<0.05, t-test, n=3). This result suggests that these three genes work as production enhancer genes. Conventional methods based on stable cells take up to 6 months to determine whether the gene of interest is beneficial for recombinant IgG1 production. In contrast, identification of production enhancer genes is achievable within 10 days by our proposed method based on EBNA1/orIP system.

Conclusions
The proposed method makes it possible to evaluate production enhancer genes in a rapid manner. The proposed method is a promising approach to identify genes enhancing recombinant antibody production.

Acknowledgements
This research is partially supported by the developing key technologies for discovering and manufacturing pharmaceuticals used for next-generation treatments and diagnoses both from METI and AMED, Japan.

References
1. Fischer S, Handrick R, Otte K: The art of CHO cell engineering: a comprehensive retrospect and future perspectives. Biotechnol Adv 2015, 33:1878-1896.
viable cell density after obtaining maximum viability and cultured for 9 days without feeding (batch). Expression of the target protein in cell culture supernatants of stable bulk pools was measured by ELISA.

Results

The three protein subunit genes were expressed from vectors with different selection markers. In the Reference constructs (without 2GUN), the α, β, and γ chains were expressed from vectors with marker genes for zeocin, blasticidin, and GS, respectively. A similar 3 vector combination was also generated with 2GUN elements integrated in each vector. In addition, 2 vectors with 2 subunits (γ-α and α-γ), each with a separate 2GUN element, promoter and polyadenylation signal, were generated with a GS marker gene. CHO GS-SC pools were transfected with the 4 appropriate vector combinations in equimolar ratios and selected in bulk in medium lacking glutamine and 1 or 2 antibiotics. The 2-vector transfected cell pools recovered first, due to the presence of only 1 antibiotic in the medium (Fig. 1a). The pools transfected with three 2GUN vectors recovered to maximum viability just a few days after the 2-vector 2GUN pools. Recovery of the Reference pools took up to a week longer than the 2GUN pools. Production of each pool was assessed in a batch production run in shaker flasks. All 2-vector 2GUN pools which recovered first produced titers around 0.1 g/L, which is almost 10-fold higher as compared to the production by Reference pools (Fig. 1b). The highest extant of 0.5 g/L were obtained in the 3-vector 2GUN pools. These data show that the 2G UNIC™ genetic elements can be successfully used to obtain a significant increase in the titer of difficult-to-express proteins. Similar results have been obtained with other DTE proteins, including fc-fusion proteins and bi-specific antibodies (not shown).

Conclusions

The expression of a large, glycosylated multimeric difficult to express protein can be increased more than ten-fold in CHO GS pools by application of 2G UNIC™ genetic elements. The highest expression of is obtained using a separate vector for each subunit.

Background

Chinese hamster ovary (CHO) cells are commonly used as host cells to produce biopharmaceuticals. However, the number of chromosomes in CHO cells varies. Previously, DG44-SC20 and DG44-SC39 cell lines with modal chromosome numbers of 20 and 39 were isolated from parental CHO-DG44 cells, from which IgG3-expressing cell lines named IgG3-SC20 and IgG3-SC39 were established, respectively. The IgG3-SC39 cell pool showed a higher specific IgG3 production rate than the IgG3-SC20 cell pool [1]. Even though all of the IgG3-SC20 clones and half of the IgG3-SC39 clones contained the same number of vector integration sites (single integration site), IgG3-SC39 cell clones produced more IgG3 following the culture of single-cell clones than any of the IgG3-SC20 clones [1]. In this study, we performed transcriptome analysis to investigate the characteristics of high-producer cells with chromosome aneuploidy.

Materials and methods

Transcriptome analyses using amplified fragment length polymorphism (AFLP)-based high-throughput expression profiling (HiCEP) and de novo mRNA-seq were performed on DG44-SC20, DG44-SC39, IgG3-SC20 and IgG3-SC39. To compare cell line with different numbers of chromosomes, transcriptome data from mRNA-seq were adjusted for cell number using RNA reference materials (NMIJ CRM 6204-a; National Institute of Advanced Industrial Science and Technology) mixed at equal amounts per cell. Pathways related to differentially expressed genes were searched using KeyMolNet (KM Data).

Results and discussion

High-chromosome-number CHO cells showed larger cell diameters, as determined by Vi-cell (Beckman Coulter) measurement. The predicted volume ratios, based on these diameters, are 2.24 (DG44-SC39:DG44-SC20) and 1.59 (IgG3-SC39:IgG3-SC20). The levels of β-actin and the products of most other genes that were detected by mRNA-seq differed by approximately 20% in the comparison between SC39 and SC20 (SC39 > SC20). Based on the analysis of gene expression levels per cell volume, approximately 90% of detected genes showed lower expression in both DG44-SC39 and IgG3-SC39 compared with the levels in DG44-SC20 and IgG3-SC20, respectively. In addition, the number of genes whose expression level was decreased in IgG3-SC39 compared with that in DG44-SC39 was larger than those showing the opposite pattern. The results of the comparisons between IgG3-SC20 and IgG3-SC39 indicate that differentially expressed genes were mainly related to cell growth (e.g. Myc, SMAD), apoptosis (e.g. Caspase), lipid metabolism (e.g. SREBP, PPARα) and epigenetic histone modification (e.g. BRCA, HAT) pathways. The mRNA levels of Myc, SMAD, Caspase, BRCA and HAT related genes were lower in IgG3-SC39, while those of SREBP and PPARα related genes were higher in IgG3-SC39. The effects of these pathways on antibody production should be examined in future.

Conclusions

In this study, we found that high-chromosome-number CHO cells have lower amounts of mRNA relative to their volume. A reduction per unit volume in the expression of genes that are required for survival might generate additional energy for recombinant protein production in high-chromosome-number cells. From an evolutionary perspective, an increased set of chromosomes underlies rapid evolutionary adaptation. Although there are issues to be considered, such as stability, there may also be advantages to using high-chromosome-number aneuploid CHO cells as a production host cells of recombinant proteins.

Acknowledgements

This work was funded partly by the Ministry of Economy, Trade and Industry of Japan (METI) and the Japan Agency for Medical Research and Development (AMED) for the Project Focused on Developing Key Technology of Discovering and Manufacturing Drugs for Next-generation Treatment and Diagnosis and partly by KAKENHI grants from the Japan Society for the Promotion of Science (JSPS; JP26630433, JP16H06157).

References

1. Yamano N., Takahashi M., Haghparast S. M. A., Onitsuka M. Kumamoto T. Frank J. Omasa T.: Increased recombinant protein production owing to expanded opportunities for vector integration in high chromosome number Chinese hamster ovary cells. Journal of Bioscience and Bioengineering 2016, 122: 226-231.

P-302

Characterization of antibody-producing CHO cells with chromosome aneuploidy

Noriko Yamano1,2, Sho Tanaka1, Norichika Ogata3, Masayoshi Onitsuka4, Yuichi Koga5, Takeshi Omasa1,2 1Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan; 2Manufacturing Technology Association of Biologics, 7-1-49 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; 3Nihon BioData Corporation, 3-2-1 Sakado, Takatsu-ku, Kawasaki, Kanagawa 213-0012, Japan; 4Graduate School of Technology, Industrial and Social Sciences, Tokushima University, 2-1 Minamijosanjima-cho, Tokushima, Tokushima 770-8513, Japan

Correspondence: Noriko Yamano (yamamori@bio.mls.eng.osaka-u.ac.jp)

BMC Proceedings 2018, 1(2Suppl 1):3

Page 64 of 78
Investigation of factors influencing recombinant human BMP2 expression in mammalian cells

Valérie Jérôme1, Lena Thoring2, Alexander Raup1, Denise Salzig1, 3, Sören Blum1, Florian Gruber1, Jennifer Nack1, Stefan Kubick2, Ruth Freitag1
1Chair for Process Biotechnology, University of Bayreuth, Bayreuth, 95447, Germany; 2Department of Cell-free and Cell-based Bioproduction, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses Potsdam-Golm (IZI-BB), Leipzig, Germany; 3Present address: University of Applied Sciences Mittelhessen, Institute of Bioprocess Engineering and Pharmaceutical Technology, Wiesenstrasse 14, 35390 Giessen, Germany
Correspondence: Ruth Freitag (ruth.freitag@uni-bayreuth.de)
BMC Proceedings 2018, 12(Suppl 1):P-317

Background
Human growth factors have an enormous therapeutic potential. Among them, the bone morphogenetic protein-2 (BMP-2) can induce de novo bone formation endowing the protein a high therapeutic potential. However, finding a suitable recombinant production system for such a protein still remains a challenge.

Materials and methods
Recombinant expression of hBMP2 was investigated in transiently transfected HEK-293 cells and in stable clones established in CHO-K1 cells cultivated in ExCell and Pro-CHO5 medium, respectively. Protein stability and interaction of the hBMP2 with the producer cells were investigated in vitro using commercially available rhBMP2. In addition, we investigated a cell-free protein synthesis system harboring translationaly active microsomal structures, hence having the potential to perform post-translational modifications, as an alternative production method.

Results
We showed that growth rates and viabilities of the rhBMP2-producing cells were similar to those of the parent cell line, while entry into the death phase was delayed in case of the recombinant cells. The maximum rhBMP2 concentration detected in the culture supernatant was low for stable clones but can be greatly improved by using recombinant CHO cell lysates containing endogenous microsomes for post-translational processing, may eventually present an attractive alternative. In consequence, the production of a recombinant protein is neither inhibited by its accumulation nor by any interaction with the cells, e.g. through the activation of inhibitory signaling pathways.

References
1. Brödel, A. K.; Sonnabend, A.; Roberts, L. O.; Stech, M.; Wüstenhagen, D. A.; Kubick, S., IRES-mediated translation of membrane proteins and glycoproteins in eukaryotic cell-free systems. PLoS ONE 2013, 8, (12), e82234.
2. Brödel, A. K.; Sonnabend, A.; Kubick, S., Cell-free protein expression based on extracts from CHO cells. Biotechnol Bioeng 2014, 111, (1), 25–36.
3. Jérôme, V.; Thoring, L.; Salzig, D.; Kubick, S.; Freitag, R.: Comparison of cell-based vs. cell-free mammalian systems for the production of a recombinant human bone morphogenic growth factor. Eng. Life Sci. 2017, DOI: 10.1002/elsc.201700005.

Table 1 (abstract P-317). Comparative analysis of the three production systems in term of yield and specific productivity

| Production system | Total amount produced [μg] | Time to peak hBMP2 titer (h) | Peak hBMP2 titer [ng/mL] | Specific productivity [ng/mL h] |
|-------------------|---------------------------|-----------------------------|-------------------------|-------------------------------|
| Recombinant cell line (CHO) | 0.015 | 120 | 0.15 | 0.0013 |
| Transient production (HEK-293) | 25 | 120 | 274.9 | 2.3 |
| Cell-free system (CHO) | 0.75 | 3 | 3700 | 12333.3 |

Conclusion
Human growth factors are complex molecules, which make their production in mammalian cells desirable. However, low product titers caused by a variety of both cell and process related effects may hinder the development of highly productive processes. In such cases, cell-free protein production using CHO cell lysates containing endogenous microsomes for post-translational processing, may eventually present an attractive alternative. In particular since these lysates can be used under tightly controlled conditions assuring a higher degree of reproducibility, than, e.g. transient transfection systems. Cell-free systems are known to circumvent typical bottlenecks of cell-based ones, e.g. metabolic regulation and cell maintenance mechanisms. In consequence, the production of a recombinant protein is neither inhibited by its accumulation nor by any interaction with the cells, e.g. through the activation of inhibitory signaling pathways.

Fig. 1 (abstract P-317). In vitro stability and interaction of rhBMP2 with the producer cells. a Stability of recombinant hBMP2. rhBMP2 produced in E.coli (white bars) and in CHO cells (black bars), duration: 120h. Fresh (dotted bars) and end-of-culture (solid bars) ExCell medium. b Binding of hBMP2 to CHO and HEK-293 cells: rhBMP2 produced in E.coli (●, ▲) and in CHO cells (●, ■), rhBMP2 produced in E.coli (●, ▲) and in CHO cells (●, ■): 3 x 106 CHO cells mL-1 in ProCHO5 medium (solid line), rhBMP2 produced in CHO (solid line), rhBMP2 incubated in the respective medium without cells (dashed lines), rhBMP2: 5 ng mL-1, incubation temperature 37°C.
**P-318**

**Systematic investigation of PDMAEMA-functionalized magnetic nanoparticles for their utilization in biotechnology**

Ullrich Stahlschmidt, Alexander P. Majewski, Valérie Jérôme, Axel H.E. Müller, Ruth Freitag

Chair for Process Biotechnology, University of Bayreuth, Bayreuth, 95447, Germany; Evonik Resource Efficiency GmbH, Marl, Germany, 45772; Institute for Organic Chemistry, Johannes-Gutenberg-University of Mainz, Mainz, 55128, Germany

**Correspondence:** Ruth Freitag (ruth.freitag@uni-bayreuth.de)

**BMC Proceedings 2018, 12(Suppl 1):P-318**

**Background**

In the recent years, the development of novel non-viral vectors for gene delivery into mammalian cells has increasingly become of focus. Recently, we reported on novel PDMAEMA-based nano-stars based on a superparamagnetic maghemite nanoparticles (γ-Fe₂O₃) core. Preliminary studies showed that the corresponding polyplexes, but also some of the cells that came into contact with them, became magnetic and were manageable by magnetic fields [1-3]. Here, we present a characterization of the influence of structure and composition on the function of these polymers using a library of highly homogeneous, paramagnetic nano-stars with varied arm lengths and densities [4].

**Materials and methods**

The paramagnetic nano-stars library was synthesized by coating maghemite nanoparticles (γ-Fe₂O₃) with a thin silica-shell functionalized with an atomic transfer radical polymerization (ATRP) initiator. PDMAEMA arms were grown from the core particles via ATRP. In one case, the PDMAEMA arm was end-capped with PDEGMA blocks produced during a second ATRP step. All nano-stars were characterized by size exclusion chromatography and thermogravimetry to calculate number and length of the PDMAEMA arms. The core diameter was determined by transmission electron microscopy and dynamic light scattering (DLS). The different variants (Table 1) were analyzed for their ability to complex pDNA (pEGFP-N1) using various physicochemical methods (DLS, Zeta sizer). Transfection efficiency/cytotoxicity in CHO-K1 cells were determined by flow cytometry. Transfected cells were placed in a magnetic field and the influence of the polymer architecture on the magnetic separation was investigated. Non-parametric Spearman analysis was used to correlate between arm length/arm densities, magnetic properties of the cells and transfection efficiency.

**Results**

Based on the hydrodynamic radii of the polyplexes, the investigated nano-stars could be divided into three subgroups (Table 1). Middle, but also high arm density nano-stars formed smaller polyplexes with hydrodynamic radii ≤ 300 nm, a size that is considered suitable for endocytosis and transfection.

Transfection efficiencies and cytotoxicities varied systematically with the nano-stars architecture, with viability showing a more pronounced dependency on the characteristics of the transfection agent than the transfection efficiency itself. The arm density was particularly important, with values of approximately 0.06 arms/nm² yielding the best results (Fig. 1a). The end-capping the polymer arms with PDEGMA significantly improved the serum compatibility (Fig. 1b).

The gene delivery potential of a given nano-star and its ability to render the cells magnetic did not correlate. Although, compared to the non-separated cells, EGFP-expressing cells were consistently more frequent in the magnetic cell fraction, while the non-magnetic fraction was slightly depleted. When the EGFP-expressing cells were further divided into low, middle and high producers, a statistically significant shift towards the high producers was observed in the magnetic cell fraction (Fig. 1c).

A nonparametric Spearman correlation analysis was used to statistically evaluate possible links between the molecular characteristics of the nano-stars, the physicochemical properties of the corresponding polyplexes, the transfection conditions, and the cellular reactions. The resulting correlogram is shown in Fig. 1d.

**Conclusions**

Transfection agents with magnetic properties enlarge the toolbox for studying non-viral gene delivery, since cellular magnetism is added as a new parameter. This allows, inter alia, a distinction between mere cellular interaction and actual uptake, which is otherwise difficult. Viability showed a much more pronounced dependency on the characteristics of the transfection agent/polyplex than the transfection efficiency itself, which should be taken into account during method optimization. End-capping the polymeric PDMAEMA-arms with PDEGMA-blocks improved the comparability of the polycationic nano-stars with serum components. In future optimized, blood-compatible, nano-stars, which can be retained/directed by magnetic fields, could become options for non-viral gene delivery in vivo.

**Acknowledgements**

This research was supported by the Upper Franconian Trust, grant P-Nr: 03847.

**References**

1. Majewski, A. P.; Schallon, A.; Jérôme, V.; Freitag, R.; Müller, A. H.; Schmalz, H. Dual-responsive magnetic core-shell nanoparticles for nonviral gene delivery and cell separation. Biomacromolecules 2012, 13, 857-866.

2. Majewski, A. P.; Stahlschmidt, U.; Jérôme, V.; Freitag, R.; Müller, A. H. E.; Schmalz, H.: PDMAEMA-grafted core-shell-corona particles for nonviral gene delivery and magnetic cell separation. Biomacromolecules 2013, 14, 3081-3090.

3. Raup, A.; Stahlschmidt, U.; Jérôme, V.; Synatschke, C. V.; Müller, A. H. E.; Freitag, R. Influence of polyplex formation on the performance of star-shaped polycationic transfection agents for mammalian cells. Polymers 2016, 8: 224-240.

4. Stahlschmidt, U.; Jérôme, V.; Majewski, A.; Müller, A.; Freitag, R. Systematic Study of a Library of PDMAEMA-Based, Superparamagnetic Nano-Stars for the Transfection of CHO-K1 Cells. Polymers 2017, 9, 156-175.

| Table 1 (abstract P-318). Molecular characteristics of the nano-stars used in this study | Designation | Name | Grafting density (arms/mm²) | Mn Polymer/Particle (kg/mol) | PDI Subgroup |
|---------------------------------------------|-------------|-----------|-----------------------------|-------------------------------|--------------|
| P3100_5 | NP@PDMAE AMA3000 | 0.006 | 235 | 1.2 | I |
| P242_9  | NP@PDMAE AMA2429 | 0.011 | 342 | 1.2 | I |
| P528_20 | NP@PDMAE AMA5280 | 0.024 | 1660 | 1.3 | I |
| P1100-4350_98 | NP@PDMAE AMA1100-4350 | 0.038 | 297500 | 1.6 | n.a. |
| P1037_46 | NP@PDMAE AMA1037 | 0.054 | 7498 | 1.6 | II |
| P1470_54 | NP@PDMAE AMA1470 | 0.064 | 12470 | 1.4 | II |
| P312_337 | NP@PDMAE AMA312337 | 0.149 | 16513 | 1.4 | III |
| P477_411 | NP@PDMAE AMA477411 | 0.182 | 30825 | 1.5 | III |
| P1240_653 | NP@PDMAE AMA1240653 | 0.289 | 127335 | 1.5 | III |
| P439_657 | NP@PDMAE AMA439657 | 0.291 | 45333 | 1.4 | III |
| P1661_679 | NP@PDMAE AMA1661679 | 0.300 | 172466 | 1.3 | III |

**PDMAEMA:** poly(dimethylaminoethyl methacrylate). PDEGMA: poly(diethylene glycol methyl ether methacrylate). PDI: polydispersity index (Mw/Mn). α: NP@PDMAEMA Block length/number of arms. b: The classification of the variants in the subgroups is based on the arm density and on the hydrodynamic radii (Rh) of the corresponding polyplexes covering a wide range of NP-ratios and analyzed for size by DLS after a 30 min incubation: I: low arm density, 300 < Rh (nm) ≤ 100; II: middle arm density, 50 < Rh (nm) ≤ 200; III: high arm density, 50 < Rh (nm) ≤ 300; n.a.: not available.
alternative approach to enhance productivity of current industrial cell lines. In summary, this study demonstrates an increase in protein folding capacity while preventing induction of apoptosis.

Materials and methods

Anti-rhesus IgG-secreting CHO cells [2] were cultured in SF-CDM in 125 mL shake flasks. The cells were treated with varying concentrations (30-500 ng/mL) of tunicamycin in a batch culture. Further, the effect of treatment with tunicamycin for short periods of time (24 hrs) was also evaluated. IgG titers and mRNA expression levels were quantified using ELISA and qRT-PCR (illumina), respectively.

Results

CHO cells were treated with different concentrations of tunicamycin and cultured in a batch for 8 days (referred as Continuous treatment/CTE). Figure 1a presents the maximum VCD and % drop in viability under treatment. A dose-dependent inhibitory effect is observed on growth and viability of cells in CTE-cultures, with minimal inhibition as lower concentrations. Contrastingly, IgG titers (Fig. 1b) were higher in treated cultures w.r.t. control in initial phase of the cultures at all the concentrations of tunicamycin. The per-cell productivity (Fig. 1c) also showed a significant increase w.r.t control at all the concentrations of tunicamycin. However, the increased productivity due to tunicamycin was not sustained and levels become similar to control after day 3 (data not shown).

To prevent loss of viability due to tunicamycin, the effect of short-term treatment (STE) with tunicamycin was explored. Cells treated with tunicamycin for 24 hours were harvested (corresponding to day 2 of CTE cultures) and inoculated in fresh media. The STE-cultures showed improved viability and higher maximum VCD as compared to CTE-cultures (Fig. 1a). The fold increase in IgG titers was not sustained beyond day 1-2 in STE-cultures (Fig. 1d) but significant increase in productivity was seen in the initial phase (Fig. 1e). Further, the cells were adapted over 25 continuous generations under 30ng/mL tunicamycin. The adapted cells had overall 1.3-fold higher productivity, as compared to control (Fig. 1f), in a batch culture.

To understand the molecular basis of increase in productivity, mRNA expression level of key genes was determined. XBP1s is a transcription factor involved in activation of chaperones (like Grp78, Calreticulin) and apoptotic genes (such as CHOP). Significant increase in the levels of calreticulin was seen on treatment with tunicamycin (Fig. 1g). Both XBP1s and Grp78 were marginally induced when treated with 30ng/mL of tunicamycin in both CTE-and STE-cultures (Fig. 1h), and significantly up-regulated when treated with 500ng/mL of tunicamycin. The CHOP mRNA levels also increase with increasing tunicamycin concentrations, with levels in STE-cultures lower than CTE-cultures (Fig. 1h). The results suggest that UPR induction may be important to increase productivity in these CTE/STE-cultures. Note that, tunicamycin had no effect on the expression levels of IgG heavy-chain, thus eliminating the involvement of IgGHC-mRNA in increasing productivity (Fig. 1i).

Conclusions

Tunicamycin induced ER-stress increased productivity in the initial phase of the culture and enhanced UPR-mediated folding capacity can be attributed as one of the reasons for it. At lower concentrations of tunicamycin, a fine balance between optimum UPR induction and apoptosis can be achieved, as seen in 30ng/mL tunicamycin STE-cultures. In summary, this study demonstrates an alternate approach to enhance productivity of current industrial cell lines.

Acknowledgements

This work was partially funded by DBT, Govt. of India. VC acknowledges UGC for his fellowship.

References

1. Segar, K.P., V. Chandrawanshi, and S. Mehra, Systems biology of unfolded protein response in recombinant CHO cells. BMC Proceedings, 2013. 7(Suppl 6): p. P67-P67.

2. Prashad, K. and S. Mehta, Dynamics of unfolded protein response in recombinant CHO cells. Cytotechnology, 2015. 67(2): p. 237-254.
Fig. 1 (abstract P-325). a Growth characteristics of CTE-and STE-cultures: comparison of maximum viable cell density achieved when rCHO cells are treated with varying concentrations of tunicamycin. Note, the maximum VCD was obtained on day 6. The % drop in viability at day 6 from time point of inoculation is also plotted. White bars denote VCD of CTE-cultures, Grey bars denote VCD of STE-cultures. White solid circle with dotted lines denote Viability of STE-cultures. Grey solid circle with dotted lines denote Viability of CTE-cultures. b Fold change in CTE IgG titers: fold change of IgG titers in CTE cultures. The IgG titers of day 2 (grey bars) and day 3 (black bars) were normalized w.r.t control day 1 levels. White bars denote day 1, grey bars denote day 2 and black bars denote day 3 qP levels. c Fold change in STE IgG titers: fold change of IgG titers in STE cultures. Ratios are calculated w.r.t control day 1 levels. White bars denote day 1, Grey bars denote day 2, Black bars denote day 3 fold-change. d IgG productivity profile of CTE-culture: comparison of per-cell productivity in pg/cell-day of CTE-cultures treated with varying concentrations of tunicamycin (30 – 500 ng/mL). White bars denote day 1, grey bars denote day 2 and black bars denote day 3 qP levels. d Fold change in STE IgG titers: fold change of IgG titers in STE cultures. e UPR mRNA (XBP1s, Grp78, CHOP) fold change. f Fold change in CTE IgG titers: fold change of IgG titers in CTE cultures when treated with tunicamycin (30 ng/mL – 500 ng/mL). White bars denote qP at day 1, grey bars at day 2 and black bars at day 3. f Productivity profile of CTE-cultures: comparison of productivity profile of control and long term tunicamycin adapted cultures in a batch mode. These long term adapted cells were obtained by culturing CHO cells in presence of 30 ng/mL tunicamycin for over 25 passages. Solid white circle with black line denote control productivity of control cultures and solid black squares with black line denote qP of tunicamycin adapted cells. g Calreticulin/CRT mRNA fold change: comparison of Calreticulin mRNA fold change w.r.t respective control for CTE- and STE-cultures when treated with 30 and 500 ng/mL of tunicamycin. White bars denote CTE-cultures harvested post 24 hrs of tunicamycin treatment. Black bars denote STE-cultures harvested post 24 hrs culturing in fresh media. h UPR mRNA (XBP1s, Grp78, CHOP) fold change: Comparison of XBP1s, Grp78 and CHOP mRNA fold change w.r.t respective control for CTE- and STE-cultures at 30 and 500 ng/mL of tunicamycin. White solid bars denote XBP1s levels of CTE-cultures, Grey solid bars denote Grp78 levels of CTE-cultures, Grey solid bars with black horizontal lines denote Grp78 levels of STE-cultures, White solid bars with black bubble pattern denote CHOP levels of CTE-cultures, Grey solid bars with black bubble pattern denote CHOP levels of STE-cultures. i IgG Heavy Chain mRNA fold change: comparison of IgG Heavy Chain mRNA fold change w.r.t respective control for CTE- and STE-cultures at 30 and 500 ng/mL. White bars denote CTE-cultures harvested post 24 hrs of tunicamycin treatment. Black bars denote STE-cultures harvested post 24 hrs culturing in fresh media.
integration. All cell pools constructed by gene targeting showed lower copy numbers of heavy chain and light chain in genomic DNA than those in the cell pool constructed by random integration, despite showing high productivity.

Conclusion

Our results indicate that high productivity of the cells constructed by gene targeting of chromosome 1 does not depend on the increase of the antibody copy number, and that the environments around these target regions are suitable for exogenous gene expression. The approach of using gene targeting to chromosome 1 may be promising for constructing antibody-producing cells.

Acknowledgements

This work was partially supported by the Project Focused on Developing Key Technology of Discovering and Manufacturing Drugs for Next-generation Treatment and Diagnosis from the Ministry of Economy, Trade and Industry, Japan (METI), and by Grants-in-aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS; JP26630433, JP26249125 and JP17H06157).

References

1. Wurm FM: Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004, 22 (11): 1393-1398.
2. Wilson C, Bellen HJ, Gehring WJ: Position effects on eukaryotic gene expression. Annu Rev Cell Biol 1990, 6: 679-714.
3. Omasa T, Cao Y, Park JY, Takagi Y, Kimura S, Yano H, Honda K, Asakawa S, Shimizu N, Ohtake H: Bacterial artificial chromosome library for genome-wide analysis of Chinese hamster ovary cells. Biotechnol Bioeng 2009, 104 (5): 986-994.
4. Cao Y, Kimura S, Inao T, Honda K, Ohtake H, Omasa T: Construction of BAC-based physical map and analysis of chromosome rearrangement in Chinese hamster ovary cell lines. Biotechnol Bioeng 2012, 109 (6): 1357-1367.

P-327

Development of retroviral vectors capable of site-specific gene insertion together with protein delivery

Yoshinori Kawabe1, Takuya Shimomura, Shuhao Huang2, Suguru Imanishi3, Akira Ito4, Masamichi Kamihira
1Department of Chemical Engineering, Faculty of Engineering, Kyushu University, Fukuoka, 819-0395, Japan; 2Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, 819-0395, Japan
Correspondence: Masamichi Kamihira (kamihira@chem-eng.kyushu-u.ac.jp)

Background

Retroviral vectors have been widely used as gene delivery tools in various biotechnology fields. However, the random integration feature of retroviral vectors seems to cause problems such as insertional mutagenesis and gene silencing. We previously demonstrated Cre-mediated retroviral transgene insertion into a pre-determined site of the founder cells using integrase-defective retroviral vectors (IDRVs), where a Cre expression plasmid was transfected into the cells prior to retroviral transduction [1]. Recently, we reported novel hybrid IDRVs (Cre-IDRVs) incorporating bioactive Cre recombinase protein, and validated site-specific gene integration of an scFv-Fc antibody expression unit into the Chinese hamster ovary (CHO) cell genome [2]. We also developed an accumulative site-specific gene integration system, which enables repeated integration of multiple transgenes into a pre-determined locus of the cell genome [3]. Here, we attempted repeated integration of transgenes using Cre-IDRVs.

Materials and methods

A viral vector plasmid (pQMSCV/HD[scFv-Fc]) encoding reporter genes and an scFv-Fc expression unit flanked with wild-type mutant loxPs was constructed for the production of IDRVs. Cre-IDRVs were produced described previously [2]. CHO cells (CHO/NE[scFv-Fc]×1 #2) introducing reporter genes (ATG-deleted-Neo/IRES/EGFP) and an scFv-Fc expression unit flanked with a compatible pair of loxPs were used as founder cells for second round of site-specific integration. Viral solution (8.0 × 10^{10} copies/well, MSCV/HD[scFv-Fc]) was infected to CHO/NE[scFv-Fc]×1 cells (2.5 × 10^5 cells/well). The cells were screened for 7–10 days in the presence of 200 μg/mL hygromycin B. Formed colonies were observed under a fluorescence microscope. Clones were isolated by the colony picking method. Genomic DNA extracted from cells was subjected to genomic PCR analysis.

Results and discussion

Figure 1a shows a schematic drawing of each round of targeted transgene integration using Cre-IDRVs harboring an scFv-Fc expression unit. We previously established recombinant CHO cells (CHO/NE[scFv-Fc]×1) expressing recombinant scFv-Fc proteins using Cre-IDRV produced by pQMSCV/NE[scFv-Fc] [2]. For the second Cre-RMCE reaction, we constructed a viral vector plasmid (pQMSCV/HD[scFv-Fc]) encoding marker genes (ATG-deleted Hyg/IRES/DsRed) and an scFv-Fc expression unit flanked with corresponding loxP sites. After the second round of Cre-mediated integration between circular retroviral DNA derived from IDRV and CHO/NE[scFv-Fc]×1 cell genome, Neo expression was expected, and red fluorescent protein was expressed in the cells. The expected structures of the transgene after Cre-RMCE reaction between IDRV and cell genome are also shown in Fig. 1a. After Cre/NE[scFv-Fc]×1 cells were infected with Cre-IDRV produced using pQMSCV/HD[scFv-Fc], two cell colonies were isolated using hygromycin screening (CHO/HD(scFv-Fc)x2). The cells expressed the reporter proteins (Fig. 1b). DNA from the cells subjected to PCR using specific primer pairs α and β, and γ and δ to confirm site-specific integration. DNA fragments with expected sizes were amplified in each cell clone (Fig. 1c). These results indicate that site-specific repeated integration was achieved using Cre-IDRVs. In contrast, scFv-Fc productivity in CHO/HD(scFv-Fc)x2 cells was slightly decreased compared with that of CHO/NE[scFv-Fc]×1 (data not shown). Although the reason remains unclear, repeat-induced gene silencing might occur due to tandem repeat structure of expression units. We reported improved recombinant antibody production using a production enhancer element [4]. Such a cis-regulatory element might be a feasible approach to enhance the productivity.

Conclusions

We demonstrated site-specific repeated transgene integration into a pre-determined chromosomal locus using Cre-IDRVs for the production of an scFv-Fc antibody.

Acknowledgements

This work was supported in part by grants for developing key technologies for discovering and manufacturing pharmaceuticals used for next-generation treatment and diagnoses, both from the Ministry of Economy, Trade and Industry (METI), Japan and from the Japan Agency for Medical Research and Developments (AMED).

References

1. Huang S, Kawabe Y, Ito A, Kamihira M: Cre recombinase-mediated site-specific modification of a cellular genome using an integrase-defective retroviral vector. Biotechnol Bioeng 2010, 107:717–729.
2. Kawabe Y, Shimomura T, Huang S, Imanishi S, Ito A, Kamihira M: Targeted transgene insertion into the CHO cell genome using Cre recombinase-incorporating integrase-defective retroviral vectors. Biotechnol Bioeng 2016, 113:1600–1610.
3. Kameyama Y, Kawabe Y, Ito A, Kamihira M: An accumulative site-specific gene integration system using Cre recombinase-mediated cassette exchange. Biotechnol Bioeng 2017, 113:1666–1677.
4. Kawabe Y, Inao T, Komatsu S, Huang S, Ito A, Omasa T, Kamihira M: Improved recombinant antibody production by CHO cells using a production enhancer DNA element with repeated transgene integration at a predetermined chromosomal site. J Biosci Bioeng 2017, 123:390–397.
Lipidomics: challenges, techniques, and futures possibilities for mammalian cell culture
Andréa McCann, Gregory Mathy, Laetitia Malphettes
UCB pharma, Braine l’Alleud, Belgium
Correspondence: Andréa McCann (andrea.mccann2@ucb.com)
BMC Proceedings 2018, 12(Suppl 1):P-330-B

Background
If lipids role in the cell have been reduced for a long time to cell membrane formation, it is now understood that lipids plays also a role into energy metabolism, vesicular transport, membrane structure, dynamics and signaling. However, the exact mechanism of how compositional complexity affects cell homeostasis remains unclear. Thanks to recent advances in mass spectrometry, it is now possible to study a wide range of lipids, providing a better understanding of lipid homeostasis in high performance cell culture processes.

Materials and methods
The purpose of this work was to develop a robust lipidomics method applied to mammalian cell cultures in a three step method: extraction, separation and detection (Fig. 1). Both Matyash [1] and Folch [2] extraction method were performed on our cells to reach the highest yield. Two separation techniques were also tested: hydrophilic interaction liquid chromatography (HILIC) and reverse phase chromatography. Finally lipid classes identification was achieved by tandem mass spectrometry analysis thanks to structure-specific fragmentation ions.

Results
The yield obtained with Matyash extraction method was higher than with Folch method for each lipid class tested. Besides, Matyash method presents also the advantage to be less toxic and suitable for high throughput analysis since the organic layer is above the aqueous layer.

Conclusion
This method was optimized in a stepwise process to ensure a sensitive and selective measurement of the lipids. Lipids were extracted by Matyash method, separated by HILIC and detected by tandem mass spectrometry. This method is suitable for both in process sample lipid analysis providing information on the cell lipid content, and for harvest samples, enabling to follow the lipid release during the different harvest steps.

This non-targeted lipidomic quantitation method will enable us to better control lipid synthesis during biopharmaceutical fed batch production through clone selection, metabolomics studies and harvest development.

Acknowledgments
Many thanks Stefanos Grammatikos for his support and to the whole Upstream Process Sciences team.

References
1. Matyash V, Liebisch G, Kurzhalia T V, Shevchenko A, Schwudke D: Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res. 2008, 49(5):1137-46.
2. Folch, J, Lees M, Sloane Stanley G H: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957, 226(1): 497-509.

Fig. 1 (abstract P-330-B). Lipid detection method workflow

P-339
Using Baculovirus as a gene shuttle in hMSC: optimization of transduction efficacy
Gundula Sprick1, Tobias Weidner2, Peter Czermak1,2,3,4
1Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstr. 14, 35390 Giessen, Germany; 2Fraunhofer Institute for Molecular Biology and Applied Ecology (IMF), Project group Bioresources, Winchester Str. 2, 35394 Giessen, Germany; 3Faculty of Biology and Chemistry, Justus Liebig University, Ludwigstr. 23, 35390 Giessen, Germany; 4Department of Chemical Engineering, Kansas State University, 1005 Durland Hall, Manhattan, KS 66506, USA

Fig. 1 (abstract P-339). Site-specific repeated transgene integration for CHO cells using Cre-IDRVs. a Schematic drawing of Cre-RMCE using Cre-IDRVs. b Fluorescent microscope images. Scale bars; 100 μm. c Genomic PCR analysis. Lanes 1 and 2, established clones; Lane 3, CHO/NE[scFv-Fc]×1; Lane W, H2O; Lane M, molecular weight standard markers (mix of λ-HindIII and ΦX174-HindII digests)
Correspondence: Gundula Sprick
BMC Proceedings 2018, 12(Suppl 1):3-P339

Background
Human mesenchymal/stromal cells (hMSC) can easily be isolated from e.g. bone marrow, fat tissue or umbilical cord blood and are therefore a central player in regenerative medicine, gene therapy and cell therapy [1–3]. The necessary gene shuttle is mainly provided by viruses associated with diseases, like retrovirus or adenovirus [4–7]. These possible pathogen viruses demand for high safety standards. Also, they are prone to genomic alterations and there is the possibility of virus inactivation, triggered due to pre-existing immunity in the patient [8–10].

In this context, the Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) is a safe alternative. The virus replication is host-specific for insects [11], but it is known since the mid-90s, that a temporary transduction of mammalian cells is possible [12]. Some modifications of the virus increased the applicability in stem cells. Pseudotyping the virus with the vesicular stomatitis glycoprotein (VSV-G) led to an expansion of the transducable cell [13,14] and the integration of the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) prolonged the recombinant protein expression [15,16].

For achieving a baculovirus-induced differentiation of hMSCs, the promoter and the expression strength of the recombinant protein are crucial factors. Still, there are still few comparative promoter studies [17,18]. However, a successful virus uptake is the prerequisite for a successful protein expression. We therefore investigated factors significantly influencing the transduction process by applying design of experiments (s. Fig. 1a).

Materials and methods
The experimental design comprises a two level factorial screening, set-up using Design Expert V9. For the transduction 60,000 c/cm² were seeded in 24-well plates with DMEM + 10% FCS and incubated overnight at 37°C, 8% CO₂ and humidified atmosphere. The recombinant baculovirus using an integrated EF1α promoter to control GFP expression, described elsewhere [18], was diluted to the respective concentrations in the different surrounding fluids. After discarding the cultivation medium of the hMSC-TERT, 1 mL of virus containing solution was added to the cells. The following incubation was varied in duration before replacing the virus solution with growth medium and an incubation overnight. 24 h post transduction (hpt) the cells were washed with PBS, trypsinized with 100 μL Trypsin/EDTA and incubated for 5 min at 37°C. Trypsination was then stopped applying 100 μL soybean trypsin inhibitor and the cells were analyzed using flow cytometry.

Results
As shown in Fig. 1a, the virus concentration and incubation time exert the highest influence on the transduction efficiency. Obviously, a higher concentration of viral particles and longer incubation of cells with virus increases the probability for hits between cells and virus particles. Additionally, the surrounding fluid can have a negative impact on the transduction. This is due to the interaction of medium components with the baculovirus. Therefore, PBS containing Ca²⁺ & Mg²⁺ is recommended as surrounding fluid for transduction experiments. In Fig. 1b, the transduction conditions resulting in the highest percentage of GFP⁺ cells are displayed: 150 virus particles per cell (PPC) and an incubation time of 5 h with hMSC-TERT.

Conclusion
The experiments show, that especially the virus concentration and the incubation time of cells with virus influence the transduction efficiency. Based on the results of the screening, further optimization of the transduction conditions will be done using a face centered central composite design with PBS containing Ca²⁺ & Mg²⁺ as surrounding fluid and at an incubation temperature of 37°C.

Acknowledgements
The authors thank the Hessen State Ministry of Higher Education, Research and the Arts within the Hessen initiative for scientific and economic excellence (LOEWE Program) for the financial support.

References
1. Kim N, Cho S-G. Clinical applications of mesenchymal stem cells. Korean J Intern Med 2013;28:387–402. doi:10.3904/kjim.2013.28.4.387.
2. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 2011;29:10. doi:10.1002/stem.556.
3. McGrail JP, Smith JR, Divine CL, Zuniga M, Weiss ML, Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals (Basel) 2015;8:196–220. doi:10.3390/ph8020196.
4. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005;74:711–38. doi:10.1146/annurev.biochem.74.050304.091637.
5. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011;12:316–28. doi:10.1038/nrg2917.
6. Vannucci I, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 2013;36:1–22.
7. Balakrishnan B, Jayandharan G. Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy. Curr Gene Ther 2014;14:86–100. doi:10.2174/1566523214666140302193709.
8. Rothe M, Modlich U, Schambach A. Biosafety challenges for use of lentiviral vectors in gene therapy. Curr Gene Ther 2013;13:453–68. doi:10.2174/15665232136661305260006.
9. Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamnan N, et al. Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther 2014;14:1241–57. doi:10.1517/17425292.2014.915307.
10. Merten O-W, Schweizer M, Chahal P, Kamen AA. Manufacturing of viral vectors for gene therapy: part I. Upstream processing. Pharm Bioprocess 2014;2:183–203. doi:10.4155/pbp.14.16.
11. Ayres MD, Howard SC, Kuzio J, Lopez-Ferber M, Posse RD. The complete DNA sequence of Autographa californica nuclear polyhedrosis virus. Virology 1994;202:586–605. doi:10.1006/viro.1994.1380.
12. Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A 1995;92:10099–1013.
13. Barsoum J, Brown R, McKee M, Boyce FM. Efficient Transduction of Mammalian Cells by a Recombinant Baculovirus Having the Vesicular Stomatitis Virus G Glycoprotein. Hum Gene Ther 1997;8:2011–22. doi:10.1089/hum.1997.8.17-221.
14. Kost T a, Condraey JP. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 2002;20:173–80.
15. Mähönen AJ, Airenne KJ, Purola S, Peltomaa E, Kaikkonen MU, Riekkinen MS, et al. Post-transcriptional regulatory element boosts baculovirus-mediated gene expression in vertebrate cells. J Biotechnol 2007;131:1–8. doi:10.1016/j.jbiotec.2007.05.022.
16. Zeng J, Du J, Zhao Y, Palanisamy N, Wang S. Baculovirus Vector-Mediated Transient and Stable Transgene Expression in Human Embryonic Stem Cells. Stem Cells 2007;25:1055–61. doi:10.1634/stemcells.2006-0616.
17. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren B-Z, et al. Systematic comparative analysis of constitutive promoters and the doxycycline-inducible promoter. PLoS One 2015;10:e016111. doi:10.1371/journal.pone.0016111.
18. Spick G, Weidner T, Salzig D, Czermak P. Baculovirus-induced recombinant protein expression in human mesenchymal stromal stem cells: A promoter study. J Biotechnol 2017. doi:10.1016/j.jbiotec.2017.08.006.

Table 1 (abstract P-339). Factors, their type and the range used to identify factors significantly influencing the transduction of hMSC-TERT with pseudotyped Baculoviruses

| Factor                  | Type   | Range          |
|-------------------------|--------|----------------|
| Virus concentration     | Numeric| 10 – 150 PPC   |
| Incubation time         | Numeric| 1 – 5 h        |
| Incubation temperature  | Categoric| 27°C, 37°C   |
| Surrounding fluid       | Categoric| PBS with Ca²⁺ & Mg²⁺, DMEM |
scFv clones was evaluated by phage display. The human scFv phage display Tomlinson I+J library was isolated from culture media by Protein-A affinity and size exclusion chromatography. Recombinant proteins were purified from HEK293E6 cells. Notch receptor (DLL1-EGF3), were cloned into pFUSE-Fc1-IgG1, and a truncated version, containing the minimal binding region to the DNA of human DLL1 full length extracellular domain (DLL1-ECD) and its ligands in several types of cancers, such as breast cancer (TNBC included), where it contributes to its development, progression and drug resistance [3], [4], [5]. Our aim is to generate a function blocking antibody against the Notch Delta-like-1 (DLL1) ligand with therapeutic efficacy against breast cancer.

**Materials and methods**

DNA of human DLL1 full length extracellular domain (DLL1-ECOD) and a truncated version, containing the minimal binding region to the Notch receptor (DLL1-EGF3), were cloned into pFUSE-Fc1-IgG1, and expressed in HEK293E6 cells. Recombinant proteins were purified from culture media by Protein-A affinity and size exclusion chromatography. The human scFv phage display Tomlinson I+J library was used to select specific scFv against peptides targeting DLL1 binding regions to Notch. The binding ability and specificity of the selected scFv clones was evaluated by scFv-on-Phage ELISA.

**Results**

Our strategy allowed us to obtain 20 mg of pure (>95%) and stable DLL1-ECOD-FC as confirmed by SDS PAGE and thermofluor assay. DLL1-EGF3-FC yield was very low and buffer screenings are ongoing to optimize protein stability. Functional studies performed in human breast cancer MCF7 cells showed that both ligands are biologically active as they increased the expression of the Notch-dependent genes HES-1, HEY-L and HEY-1. Recombinant DLL1 and peptides were used to select for monoclonal antibodies by Phage Display. After three rounds of panning with DLL1 peptides we identified 13 scFv positive clones, 2 of which presented high affinity to DLL1-ECOD-FC. Currently we are performing more phage display selections to increase the number of positive clones, scFv with higher affinities will be reformatted into IgGs and their ability to inhibit the Notch pathway will be evaluated. The anti-oncogenic effects of anti-DLL1 IgGs will be assessed in breast cancer cells in viability/apoptosis, proliferation, migration, and invasion assays.

**Conclusions**

An anti-DLL1 IgG with therapeutic efficacy against breast cancer will demonstrate that targeting DLL1 could be one of the key factors for successfully targeting breast cancer.

**Acknowledgements**

iBET, INOVA4Health (LSBDA-01-0145-FEDER-007344); FCT: PTDC/SAUONC/ 121670/2010, PTDC/BBB-BMD/4497/2014, PO/BD/113987/2015

**References**

1. Hudis CA and Gianni L. Triple-Negative Breast Cancer: An Unmet Medical Need. Oncologist. 2011. 16(Suppl 1): p. 1-11
2. Ecker DM, Jones SQ, Levine HL. The therapeutic monoclonal antibody market. mabs, 2015. 7(1): p. 9-14
3. Sharma A, Paranjape AN, Rangarajan A, Dighe RR. A monoclonal Antibody against Human Notch1 Ligand-Binding Domain Depletes Sub-population of Putative Breast Cancer Stem-like Cells. Mol Cancer Ther. 2011. 11(1): p. 77-86
4. Bolós V, Mira E, Martínez-Poveda B, Luxán G, Cañamero M, Martínez-A C, Mañes S, de la Pompa JL. Notch activation stimulates migration of breast cancer cells and promotes tumor growth. Breast Cancer Res. 2013. 15(4): p. R54.
5. Lamy M, Ferreira A, Dias JS, Braga S, Silva G, Babas A. Notch-out for breast cancer therapies. N Biotechnol. 2017 Epub ahead of print.

**P-349**

**AAV production in suspension: evaluation of different cell culture media and scale-up potential**

Rebecca C. Feiner, Kathrin Teschner, Irina Schierbaum, Julian Teschner, Kristian M. Müller

Cellular and Molecular Biotechnology, Bielefeld University, 33602 Bielefeld, Germany

**Correspondence:** Kristian M. Müller (kristian@symbio.net)

**BMC Proceedings** 2018, 12(Suppl 1):P-349

**Background**

Recombinant adeno-associated virus (rAAV) approaches have an outstanding reputation in gene therapy and are evaluated for cancer therapy [1]. Advantages include long-term gene expression, targeting of dividing and non-dividing cells, and low immunogenicity. Established rAAV production utilizes triple transfection of adherent HEK 293 cells, which hardly meets product yield requirements for clinical applications. We transferred the AAV production system to HEK 293-F suspension cells. This process is scalable and uses serum-free media streamlining downstream procedures. After optimization of transfection efficiencies and shaker cultivations, we produced titers of 1x10^13 viral genomes per cell in a 2 l bioreactor.

**Materials and methods**

The suspension adapted HEK-FreeStyle 293-F cell line was used for the experiments in chemically defined animal component free media (HEK-TF, HEK-GM (Xell AG), Freestyle F17 (Thermo Fisher Scientific)). Samples for viable cell density and viabilities were taken daily and analyzed using an automated cell counting system (Cedex, Roche Diagnostics). Transient transfection of 3x10^9 cells/ml was carried out with polyethylenimine Max in a 1:4 DNA-PEI ratio (w/w) with 2 μg DNA. Three plasmids (pGOI, pRepCap, pHelper) were applied in a molar 1:1:1 ratio (Fig. 1a). Pretests were performed in orbital shaking tube spin bioreactors. For scale-up, batch processes were carried out in 125 ml shake flasks as well as in 2 l stirred bioreactors at 30% air saturation and pH 7.1. Transfection efficiencies and rAAV production were quantified by flow cytometry using a GOI coding for a fluorescent protein and qPCR of genomic copies, respectively.

**Results**

By optimizing the DNA amount for transfection of 293-F cells more than 90 % of the cells were reproducibly transfected. Batch cultivations in shaker flasks revealed that rAAV were produced in the first 24-96 h after transfection. Figure 1b shows viable cell densities and viabilities in relation to the genomic titer. Genomic titers were determined from raw cell extracts and up to 10^11 copies/ml were repetitively achievable. A decrease in viability marked the decline in genomic copies per ml showing that a proliferation of the process
e.g. by addition of a feed would probably not increase yield. In a first scale-up, the rAAV production was transferred to a 2 L bioreactor (Fig. 1c). Transfection efficiencies in bioreactors of up to 55% were comparable to that obtained in a simultaneous shaker flask experiment. Transfection efficiencies were lower compared to prior experiments due to controlled conditions in the bioreactor. Nonetheless the titer with up to 1×10^5 genomic copies per cell was elevated compared to that of shaker flasks.

Conclusions
First experiments with 293-F cells in HEK TF medium showed promising results of transferring rAAV production from the adherent system to suspension. After improvement of transfections by the adjustment of DNA amounts in small scale experiments, AAV production was analyzed in shaker flasks. The batch process showed an expected increase in cell density with low variability between biological replicates (Fig. 1b). The genomic titer increased according to the viable cell density until day four where a sudden drop started. This observation was made for AAV productions in HEK-TF, HEK-GM and Freestyle F17 medium. For optimization of the bioreactor cultivation resulted in lower overall viable cell densities but in higher genomic copies per cell compared to shaker flasks (Fig. 1c). These results are comparable to already published data (Fig. 1). Up to 500 m² of surface area is available in a compact bioreactor measuring 88 mm in diameter in a total volume of 75 L with pH, DO and temperature control. A key feature of the iCellis bioreactor is that it scales by increasing the diameter of the fixed-bed while keeping the height constant with no change in aspect ratios. The height of the fixed-bed can be varied (2, 4 and 10 cm) as well as density of carrier packing (96 gm/L or 144 gm/L). The iCellis system comes in two formats, the iCellis Nano bioreactor (0.5-3.4 m²) and the iCellis 500 bioreactor (66-500 m²). Processes developed in the benchtop iCellis Nano bioreactor can be directly transferred to the corresponding iCellis 500 system. The iCellis Nano bioreactor enables an efficient platform for process optimization.

Materials and methods

Materials
- HEK-293 cells (Genethon).
- iCellis Nano bioreactors 0.8 m² (Pall, Part 810040NS) and 4 m² (Pall, Part 810042NS).
- Growth medium: FreeStyle F17 Expression medium (Thermo Fisher, Part A13835-02) supplemented with 4 mM GlutaMAX* Supplement (Thermo Fisher, Part 35050-083).
- Transfection reagents: PeiPRO® transfection reagent (PolyPlus, Part 115-100) and mix of proprietary plasmid constructions: pGFP, pRep2Cap8 and pHelper (Genethon).
- Production medium: Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher, Part 31053-028 supplemented with 4 mM GlutaMAX Supplement, Thermo Fisher, Part 35050-083).
- Lysis buffer: Triton X-100 solution (Merck Millipore, Part 1086432500) and NaCl solution (Sigma Aldrich, Part 59888), pH adjusted with NaOH 0.5 M (Merck Millipore 1.09137.2500).

Methods
The Genethon rAAV-8 process was transferred to an iCellis Nano bioreactor 0.8 m² (2 cm bed height, 144 gm/L density) bioreactor using FreeStyle media. The initial iCellis Nano process was established as (1) seed on Day 1, (2) transfect at Day 5, (3) harvest at Day 8 and yielded <1x 10^5 vp/cm^3. Media exchange, cell density at transfection, pDNA/cell ratio, and lysis method were then changed to determine the effect on productivity. The modified process was then scaled from 0.8 m² to 4.0 m² (10 cm bed height, 144 gm/L density) iCellis Nano bioreactor.

Results
- Media: A media exchange at 5 hours post transfection with DMEM substituted for FreeStyle medium resulted in an 8x increase in specific productivity.
Cell density at transfection: Cells were seeded at 6,000 cells/cm² and reached 200,000 cells/cm² at Day 5 which was determined to be the optimal cell density for transfection.

pDNA/cell ratio: Reducing pDNA by 50% had no significant effect on productivity.

Lysis: Use of Trion x-100 at 0.5% with 100 mM NaCl at pH 8 resulted in >100% virus recovery compared to sampled carriers.

Scaling: Specific productivity was maintained as the system was scaled from 0.8 m² to 4.0 m².

Overall, an average yield of 4x10¹⁵ VG/m² was achieved.

Conclusions

The iCELLis technology is being adopted widely for viral vector production. Transferring a process to the iCELLis Nano bioreactor can be easily achieved and once in place can be optimized to provide significant productivity increases and cost savings such as reduced pDNA. The iCELLis Nano bioreactor is an efficient bench-top system the results of which can be readily scaled to the iCELLis 500 system.

Fig. 1 (abstract P-353). a-d Immunostaining of representative cardiomyocyte spheroids. e Channel structure of 2-Organ-Chip. f Cardiomyocyte spheroids cultivated under dynamic conditions in 2-Organ-Chip over 7 days. g-h Characterization of cardiomyocyte spheroids by FACS analysis for g myosin heavy chain and h cardiac troponin T.

P-353

iPSC derived cardiomyocytes development for Multi-Organ-Chip cultivation

Anja Ramme¹, Eva Dehne¹, Anna Krebs¹, Roland Lauster², Uwe Marx¹
¹ TissUse GmbH, Oudenarder Str. 16, 13347 Berlin, Germany; ² Technische Universität Berlin, Medizinische Biotechnologie, Gustav-Meyer-Allee 25, 13355 Berlin, Germany

Correspondence: Anja Ramme (anja.ramme@tissuse.com)
BMC Proceedings 2018, 12(Suppl 1):P-353

Background

TissUse Multi-Organ-Chip (MOC) platform contributes to the ongoing advancement in systemic substance testing in vitro. Current in vitro and animal tests for drug development are failing to emulate the systemic organ complexity of the human body and, therefore, often do not accurately predict drug toxicity. Especially, cardiotoxicity is one of the main reasons why new compounds are failing in clinical trials. Therefore, we aimed to establish an autologous dynamic multi-organ-device integrating cardiomyocytes for substance testing.

Results

Generic 2D monolayer and 3D suspension iPSC derived cardiomyocytes differentiation protocols were established. Beating cardiomyocytes were first seen on day 8 in monolayer as well as in spheroid culture. Cardiomyocytes show up to 64% cardiac troponin T positive cells and 44% myosin heavy chain positive cells by flow cytometry (Fig. 1g, h). Myosin II heavy chain, α-actinin, myosin 9/10, myosin 11 and caldesmon expression was shown by immunohistochemistry (Fig. 1a-d). Due to the exclusion of a lactate enrichment of cardiomyocytes, cardiac fibroblasts are also expressed in the spheroids shown by vimentin staining. Those cardiac fibroblasts lead to a physiological heterologous cell population similar to the human heart. Beating spheroids were cultivated for 7 days under dynamic culture conditions in the Multi-Organ-Chip. The integrated on-chip micropump provides physiological-like pulsatile circulation at a microliter scale and leads to better nutrition and oxygen supply.

Conclusions

The next significant step is to combine multiple autologous 3D organ equivalents in our Multi-Organ-Chip using iPSC differentiation technology. Differentiating all cell types from one iPSC donor is crucial to overcome source and rejection problems. Combining our Multi-Organ-Chip platform with iPSC differentiation technology will eventually lead to a personalized system for drug and substance testing.

P-365

Lab as a service - automated cell-based assays

Lena Schober, Moritz Walter, Andrea Traube
Laboratory Automation and Biomanufacturing Engineering, Fraunhofer IPA, Stuttgart, Germany

Correspondence: Lena Schober (lena.schober@ipa.fraunhofer.de)
BMC Proceedings 2018, 12(Suppl 1):P-365

Background

The use of cell-based assays in pharmaceutical industry and academic research is a growing trend that is a driving force to reduce costs for drug development. Academic research is gaining information about intracellular targets or functional mechanisms through the variety of different assays. These benefits can be used in preclinical studies and furthermore costly late-stage drug failures may be reduced by the use of cell-based assays. The use of automated systems is also in great demand and will change the testing of substances and research activities. Nevertheless, there are a lot of barriers at the moment limiting the successful application of automated systems in this field. By the lack of flexibility and the demand for skilled computer scientists & engineers just the two main aspects stated by experts shall be mentioned.

Our strong background on automated cell culture technologies and expertise, gained in several projects, let us rethink the overall process chain and overcome established principles. A new service oriented platform for the execution of cell-based assays that are commonly used will be introduced. The main idea is to give access to automated infrastructure for academic research or spin-offs which cannot afford the special infrastructure.
Material and methods

The infrastructure which was modularly built up, consists of automated liquid handling robots, plate and tube handling robots as well as incubators, refrigerator and analysis systems as for example an imaging system. The aim is to address the need on reproducibility and reliability of results and to offer access to a maximal controlled and automated environment. With the help of a web-based configurator assay selection as well as parameterization of the assays can be done in an easy way. After the order process, test items can be shipped to the lab. Assays will be executed on the fully automated platform. By capturing in process data as well as environmental conditions, a real complete data set is leading to comprehensively results. As soon as results are available during the process, the view and analysing can be done in a secure cloud.

Results and conclusion

The service can be used for single experiments in low throughput applications and is therefore a benefit for labs which cannot afford automated infrastructure or the staff for the maintenance for such platforms. Extensive monitoring and data capturing during the run leads to a gapless data trail and the possibility of detailed result analysis. Due to automated processing the reproducibility is increased associated with direct reduction of costs and time. The centralized service paired with specific know-how allows up-scaling of processes at any time. The web-based interface provides a flexible guidance for the user and the online order gives 24/7 access on the infrastructure, leading to a fast reliable result generation. Furthermore the secure interaction with additional services e.g. other specific data analysis tool is possible. This dynamic access to automation offers high flexibility for low throughput experiments and will push high quality research and drug development in early stage.

References

1. Thoring L, Wüstenhagen D A, Borowiak M, Stech M, Sonnabend A, Kubick S: Cell-Free Systems Based on CHO Cell Lysates: Optimization Strategies, Synthesis of “Difficult-to-Express” Proteins and Future Perspectives. PLOs ONE, 11(9).

2. Brödel A K, Sonnabend A, Kubick S: Cell-Free protein expression based on extracts from CHO cells. Biotechnol. Bioeng. (Biotechnology and Bioengineering), 1: 25–3.

3. Jerome V, Thoring L, Salzig D, Kubick S, Freitag R: Comparison of cell-based vs. cell-free mammalian systems for the production of a recombinant human bone morphogenic growth factor. Engineering in Life Sciences.

4. Brödel A K, Sonnabend A, Robert L O, Stech M, Wüstenhagen D A, Kubick S: IRES-Mediated Translation of Membrane Proteins and Glycoproteins in Eukaryotic Cell-Free Systems PLOs ONE, 8(12).
a stable FVII production with an average of 8,03 IU/mL of FVII, 83%}

Results

ity chromatography using VIISelect (GE) column. After purification the activity using the Prothrombin Time (PT) assay. rFVII purification by affin-

ELISA assay, western blot, gene expression quantification and biological

gene expression quantification and biological

GFP selection marker gene. A master cell bank and a work cell bank

bicistronic lentiviral vector, 1054-GFP, containing a FVII gene and the

We have been using the Sk-Hep-1 human cell line for the production of

modifications in a cell line not yet used [8

to produce recombinant proteins with complex posttranslational

genic epitopes [5 - 7]. In this context, becomes extremely important

as well as the others coagulation factors, it may contain immuno-

hemophilia patients with inhibitory antibodies. However recombinant

factor VII (FVIIa) is an attractive candidate for hemostasis, independ-

dent of FVII/FIX, making this coagulation factor an alternative for

hemophilia patients with inhibitory antibodies. However recombinant

factor VII is produced in BHK-21 cells (Baby hamster kidney cells) and

as well as the others coagulation factors, it may contain immuno-

genic epitopes [5 - 7]. In this context, becomes extremely important

to produce recombinant proteins with complex posttranslational

modifications in a cell line not yet used [8 – 10].

Materials and methods

We have been using the Sk-Hep-1 human cell line for the production of recombinant FVII. To generate the recombinant cell line we have used a bicistronic lentiviral vector, 1054-GFP, containing a FVII gene and the GFP selection marker gene. A master cell bank and a work cell bank were generated in GMP conditions. The rFVII analyses were made by ELISA assay, western blot, gene expression quantification and biological activity using the Prothrombin Time (PT) assay. rFVII purification by affinity chromatography using VIISelect (GE) column. After purification the rFVII was formulated and dry froze to be used in in vivo experiments.

Results

In static conditions Sk-Hep-1 cells showed, for a period of 6 months, a stable FVII production with an average of 8,03 IU/mL of FVII, 83% of cell viability and 77% of cells expressing the GFP gene. After purifi-
cation with VIISelect column it was possible observe a recover of 65% of the purified protein with 95% degree of purity (Fig. 1). This recombinant purified FVII is being used in in vivo experiments to de-
termine the pharmacokinetics parameters and to evaluate the post-

a

b

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60
Soft biocompatible microcarriers for adipose-derived mesenchymal stem cells expansion
Dominique Gallo1, Elisabeth Bodo1, Catherine Saint-Hubert1, Alain Dunieu1, Ruben Werquin1, John Werenne1, Serge Lowagie4
1Institut de recherches microbiologiques Wiame, Brussels, Belgium; 2Meurice R&D, Brussels, Belgium; 3Biocelan, Université Libre de Bruxelles, Brussels, Belgium; 4Oh-Cell, Belloei, Belgium, 7970
Correspondence: Serge Lowagie (serge.lowagie@skynet.be)
BMC Proceedings 2018, 12(Suppl 1):P-376

Material and methods
Our expertise in the field of microbeads design using jetcutting technology [4] enabled us to engineer +/- 200 μm alginate beads of various G/M monomer ratio. We used jetcutter (geniaLab GmbH) with 100 μm nozzle at max speed 12000 rpm. Alginate solutions with concentrations 2% to 4% were gelified in 2% CaCl2 - EtOH 50% solution. Alginates with estimated viscosity (@1%) from 30 to 720 mPa were tested. A further surface treatment with gelatine (0,1%, 1%) and poly-L-lysine (0,1%) was carried out to reach an optimal cell anchoring of human adipose-derived mesenchymal stem cells (ATCC-PSC-500-011) in MesemPro RS medium (Gibco).

Results and conclusions
Jetcutter technology allowed us to obtain alginate microcarriers with a good homogeneity in size around 200 μm and sphericity comparable to commercial carriers (Table 1). Best adhesion of human adipose-derived mesenchymal stem cells was obtained on 0,1% gelatine coated alginate carriers (Fig. 1). We observed limited apoptosis and human adipose-derived mesenchymal stem cells stemness was conserved after 14 days in culture (data not shown).

References
1. Jean-Paul Prieels et al. Mastering industrialization of cell therapy products. Bioprocess International 2012 10(3).
2. Dennis E. Discher et al. Tissue cells feel and respond to the stiffness of their substrate. Science 2005 310.
3. Adam J. Engler et al. Matrix elasticity directs stem cell Lineage specification. Cell 2006 126 : 677-689.
4. Nedovic VA et al. Continuous cider fermentation with co-immobilized yeast and Leuconostoc oenos cells. Enzyme Microb. Technology 2000 26 (9-10): 834-839.

Table 1 (abstract P-376). Alginate microcarriers characterization

| Alginate | Mean size (μm) | Distribution factor (μm) | Sphericity | Surface (μm²) |
|----------|----------------|--------------------------|------------|--------------|
| A2 (3%)  | 193            | 19                       | 0.96       | 0.117        |
| Cytodex3 | 227            | 22                       | 0.94       | 0.164        |

*Alginate with estimated viscosity 50-150 mPa %G/M ratio 35-65
viability was analyzed by a Propidium iodide (PI) and Calcein AM staining. To improve spheroid functionality spheroids were cultivated with huOB Differentiation Medium (InSCREENeX, Germany). “Mini bone” tissue functionality and thus mineralization was analyzed by an alkaline phosphatase (alkaline phosphatase activity) and an alizarin red S Staining (Ca²⁺ deposits).

Results
The combination of CI-huOB cells with the magnetic 3D bioprinting technology enabled the establishment of reproducible and consistent 3D spheroids. Single spheroids per well were formed independent of the amount of cells (1,000-50,000 cells) (Fig. 1a). Formed spheroids were stable for a culture period of up to 50 days (Fig. 1b). Neither cell death nor cell proliferation were observed in the bioprinted spheroids which is indicated by the stable size of the spheroids throughout the cultivation (Fig. 1c). After treatment with a differentiation stimulus the 3D bioprinted spheroids became fully functional “mini bones”. This was highlighted by the alkaline phosphatase activity and the Ca²⁺ deposits within the 3D bioprinted spheroids (Fig. 1d,e).

Conclusion
Taken together, these results demonstrated that the functional immortalization technology provides physiologically relevant cells in sufficient numbers and that the magnetic 3D Bioprinting technology enabled a fast, consistent cell aggregation and the formation of stable uniform spheroids. Importantly, these immortalized cells are capable to differentiate when a suitable stimulus is provided. For differentiation into mini bones, 3D spheroid cultivation and additional stimulation by small molecules are required. The combination of physiologically relevant cell systems with three dimensional culturing will help to generate in vitro test systems which closely resemble the in vivo physiology and thereby supporting future drug discovery approaches.

Acknowledgements
This work was supported by grants from the Niedersächsisches Ministerium für Wissenschaft und Kultur (80029155) and the German Ministry for Economic Affairs and Energy (IGF 16153 N).

References
1. Lipps C, May T, Hauser H, Wirth D. Eternity and functionality - rational access to physiologically relevant cell lines. Biol Chem. Dec (2013);394 (12):1637-48.
2. Pérez-Campo FM, May T, Zauers J, Sañudo C, Delgado-Calle J, Arozamena J, Berciano MT, Lafarga M, Riancho JA. Generation and characterization of two immortalized human osteoblastic cell lines useful for epigenetic studies. J Bone Miner Metab. 2017 Mar;35(2):150-160. doi: 10.1007/s00774-016-0753-2.
3. n3D Biosciences and Geiner Bio-One, Biocompatibility of NanoShuttleTM and the magnetic field in magnetic 3D bioprinting, 2014. (Online), Available: http://www.n3dbio.com/wp-content/uploads/2014/05/Nanoshuttle-Biocompatibility-App-Note.pdf. [Accessed: 28.08.2017]

Fig. 1 (abstract P-381). Characterization of spheroid “mini bones”.

- **a** Different number (1,000-50,000 cells) of CI-huOB cells were printed into spheroids.
- **b** 20,000 CI-huOBs were printed into spheroids and cultivated for indicated time points.
- **c** For analyzing spheroid sizes, pictures were taken and quantified by ImageJ. (D/E) 20,000 CI-huOB cells were printed into spheroids and cultivated with (huOB Differentiation Medium) or without a differentiation stimulus for two weeks. Afterwards, bioprinted spheroids were sectioned by a cryo microtome and **d** stained for Ca²⁺ deposits (Alizarin Red S) or **e** stained for alkaline phosphatase activity.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.